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Prostate cancer is the most common cancer among men in the UK and is 
characterised by large biological and clinical heterogeneity. There is an urgent 
need for better-personalised patient stratification, for example in accurately 
identifying patients with regional lymph node metastasis. Nodal involvement 
negatively impacts on patient survival outcomes and the current pre-operative 
staging tools to determine the need for extended pelvic lymph node dissection at 
time of radical prostatectomy are far from precise. The primary tumour immune 
microenvironment influences tumour immune editing and therefore disease 
progression. The primary aim of this research was to investigate the in situ 
phenotype of prostate cancer tumour infiltrating immune cells and determine 
their potential as biomarkers for regional lymph node invovlement and further 
explore possible underlying mechanisms for their distribution.   
The discovery tissue microarray comprised of index lesions from 94 patients 
undergoing radical prostatectomy and pelvic node dissection (50 with and 44 
without histologic evidence of pelvic nodal disease respectively, referred to as 
LN+ and LN- thereafter). Two multiplex immunofluorescence panels were 
optimised to comprehensively characterise the immune microenvironment: (1) 
The macrophage and B cell panel includes CD68, CD163, CD20, AE1/3 (PanCK) and 
DAPI and (2) The T lymphocytic panel assays for CD4, CD8, FoxP3, PD-1, AE1/3 
and DAPI. The macrophage (CD68, CD163+), T (CD8+, CD4+) and B (CD20+) cell 
immune cell subpopulations within the malignant epithelium and associated 
stroma were measured and correlated to the nodal status.  Stromal infiltration by 
M1-like macrophages (CD68+CD163-) (p=0.047), CD8 effector (CD8+FoxP3-PD-1-) 
(p=0.008) and CD4 effector (CD4+FoxP3-PD-1-) T cells (p=0.0003, Mann Whitney 
test) were lower in LN+ patients. Stromal CD4 effector immune cell density 
remained a statistically significant independent predictor of lymph node spread in 
multivariate regression analysis (OR= 0.15, p=0.004). Additionally, in an 
independent validation cohort of 184 radical prostatectomy specimens, stromal 
CD4 effector immune cell density predicted the presence of nodal metastasis 
(OR=0.26, p=0.0004). Addition of stromal CD4 effector T cell density to currently 
used clinicopathological factors, namely T stage, PSA level, Gleason score and 
percentage of tumour positive cores, improved the predictive accuracy of current 
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nomograms (from 63.5% to 76.8%, p<0.0001). Tumour infiltrating immune cells did 
not however correlate with common molecular alterations of prostate cancer such 
as ERG overexpression and PTEN deletion. 
Transcriptomic analysis (by HTG EdgeSeq) of the tumour microenvironment was 
performed to assay 1,041 host immune response related genes. Surprisingly, I did 
not observe significant differences in the expression levels of adhesion 
molecules or chemokines (common regulators of immune cell migration) 
between LN+ and LN- cases. Instead, there was significant upregulation (FC>1.5, 
adj p value <0.05) of extracellular matrix components (collagen I, collagen III, 
fibronectin 1) in LN+ tumours, suggesting increased extracellular matrix fibrosis 
to be associated with reduced T lymphocytic infiltration and tumour immune 
evasion. Increased collagen III and fibronectin 1 protein expression were 
confirmed in LN+ patients. Collagen I had increased density score (by second 
generation harmonic), but not overall abundance, in LN+ patients, eluding to a 
disorganised stroma with increased cross-linking and elongated fibres. 
B7-H3 is a newly discovered member of the B7 family of immune checkpoint 
molecules with both immune and non-immune functions. I investigated the 
relationship of B7-H3 to the tumour microenvironment as well as its non-immune 
functions in prostate cancer. Contrast to PD-1, high B7-H3 expression correlated 
with worse clinicopathological patient features: higher T stage (p<0.0001), 
perineural invasion (p=0.01) and lymph node spread (p=0.0006). Furthermore, 
there was significant decrease in migration and invasion in vitro following 
suppressed B7-H3 expression in multiple human prostate cancer cell lines. RNA 
sequencing identified extracellular space chemotactic cytokines and their 
receptors to be highly downregulated genes in PC3M cells with B7-H3 knocked 
out. Future experiments will investigate the mechanistic downstream pathways 
of this phenotype and further evaluate the role of B7-H3 in metastasis in vivo. 
Data presented in this thesis reveal differences in the immune infiltrates, 
particularly CD4 effector (CD4+FoxP3-PD-1-) T cells between LN+ and LN- 
patients. Prospective clinical studies are needed to test the predictive value of 
stromal CD4 effector T cell density in diagnostic prostatic biopsies for regional 
nodal disease. The role of increased extracellular matrix components in 
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Chapter 1 Introduction 
1.1 Prostate cancer 
1.1.1 Prostate pathology 
The prostate gland is part of the male reproductive system. Histologically, it 
comprises of prostatic glands and connective tissue, ensheathed by a 
fibromuscular layer referred to as capsule (1). The glandular component is 
composed of ducts and acini of luminal cells overlying basal epithelial cells and 
scant scattered neuroendocrine cells (1). The luminal cells contribute to a wide 
variety of secretions for the seminal fluid, including prostatic-specific antigen 
(PSA) (1, 2). The connective tissue is composed of stromal fibroblasts, immune 
cells, nerves, vascular and lymphatic vessels and muscle fibres. All those 
components can give rise to malignancy but the majority of cancers arising in 
the prostate are prostatic acinar adenocarcinomas, commonly referred to as 
prostate cancer (1, 2).  
The precursor lesion of prostate cancer is prostatic intraepithelial neoplasia 
(PIN), which consists of cytologically atypical and abnormally proliferating 
luminal epithelial cells that retain an underlying layer of basal cells (2). Prostate 
cancers have a wide spectrum of histological appearances, ranging from poorly 
differentiated tumours without glandular architecture to well differentiated 
tumours, morphologically similar to benign glands (1, 2). The key feature is the 
loss of basal cell layer underlying the luminal cells. The vast majority of patients 
have multifocal disease, with multiple tumour foci across the entire prostate 
gland (1). Apart from architectural changes, prostate cancer cells also exhibit 
cytological abnormalities, such as nuclear enlargement, prominent nucleoli and 
mitoses (1), which along with immunohistochemical stains are used by 
pathologists for prostate cancer diagnosis.  
1.1.2 Prostate cancer epidemiology 
Prostate cancer (PCa) is the most common cancer in males in the UK, with 
approximately 48,600 new diagnoses each year (3). Currently, one in six males 
will be diagnosed with prostate cancer in their lifetime (4), and the incident 
rate is projected to rise even more by 2035 (3). This rise in diagnoses can be at 
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least partly attributed to advancing population age and increasing PSA testing 
(2, 5). Prostate cancer is also the second most frequent cause of cancer death in 
males the UK, with around 12,000 deaths in 2017 (6). The incidence and 
mortality rates of PCa are similar in other developed countries, including the 
United States (5).  
The most decisive factor for patient prognosis and survival is how advanced the 
tumour is, i.e. the stage of PCa at diagnosis. Patients with stages I and II have 
prostate tumours confined within the prostate gland, whereas patients with 
stage III have prostate tumours that have spread beyond the prostate (2). Stage 
IV prostate tumours have spread to organs outside the prostate (and seminal 
vesicles) and/or have regional nodal and/or distant metastatic deposits (2). In 
the UK, more prostate cancer patients are diagnosed at an early stage (up to 63% 
diagnosed at stage I or II), in which their tumour is still localised in the prostate 
(4). However, this is lower in Scotland, where only 56% of new diagnoses are at 
an early stage, the rest 44% of newly diagnosed patients have locally advanced 
(stage III) or metastatic disease (stage IV) (4). Advancing age, race and a family 
history of PCa are the only established risk factors for PCa, there is no clear link 
to any modifiable risk factors that could aid prevention of the disease (2, 4). 
1.1.3 Prostate cancer progression and clinical management 
PCa is characterised by clinical heterogeneity, ranging from indolent disease 
that can safely be observed to an aggressive, lethal course (5, 7). Key to the 
effective management of this heterogeneous disease is early risk stratification 
(8). Newly diagnosed PCa is assessed using a combination of radiological cancer 
staging (cTNM stage), PSA level and histological characteristics of prostatic 
biopsies including Gleason score (2, 8). The Gleason scoring system is based on 
the tumour architecture, assigning a primary pattern for the most prevalent 
grade and a secondary pattern for the second most prevalent grade. These 
grades range from 1 to 5, 1 being well‐differentiated glands with nodular 
circumscription and 5 being very poorly differentiated tumours with a non-
glandular pattern (2). The Gleason score derives from the addition of those two 
grades. Additional histological markers currently used to predict tumour 
behaviour include perineural invasion and percentage of tumour in biopsy cores 
(tumour quantification) (2).  
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For organ confined or locally advanced disease at the time of diagnosis, there 
are guidelines on patient management according to low (PSA<10 ng/ml and 
Gleason score <7 and cT1-T2a), intermediate (PSA 10-20 ng/ml or Gleason score 
=7 or cT2b) and high risk status (PSA 20 ng/ml or Gleason score >7 or cT2c-T4) 
(2, 8). In men diagnosed with lower risk, treatment options include active 
surveillance, radical prostatectomy (RP) or radiation therapy (2, 8). Patients 
with higher risk disease can be offered RP with or without extended lymph node 
dissection, radiation therapy as well as androgen deprivation therapy (ADT) (2, 
8).  
Some patients are diagnosed with advanced/metastatic disease or subsequently 
develop disease relapse following primary treatment with ADT (4, 7). ADT and 
chemotherapy are standard therapies for metastatic PCa. Suppression of the 
androgen receptor pathway has evolved from the traditional surgical or 
pharmacological castration to newer pharmacological agents, such as 
enzalutamide  and abiraterone acetate, which target the androgen receptor or 
androgen enzymatic biosynthesis respectively (2). Chemotherapy with docetaxel 
or carbazitaxel (with significant risks of toxicities) can extend the life 
expectancy of PCa patients but only by a few months (2, 7).  Patients inevitably 
develop resistant disease despite treatments and metastatic castration resistant 
PCa (mCRPC) remains an incurable disease.  
1.1.4 Prostate cancer clinical challenges 
Even though prostate cancer mortality rates are falling over the last decade (6), 
there are two main clinical areas in need of improvement. Firstly, there is an 
urgent need for better patient stratification in order to prevent over- or under-
treatment of PCa patients (7). Gleason scoring, PSA levels and tumour 
quantification are valuable tools for deciding disease management but they 
cannot adequately distinguish indolent from aggressive tumours. Additional 
prognostic markers are urgently needed to more effectively guide clinical 
decision making, for example in accurately stratifying patients that would 
benefit from extended lymph node dissection at the time of radical 
prostatectomy.  
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The second clinical unmet need is the paucity of therapeutic options for late 
stage mCRPC (2, 7). In other cancer types there has been significant 
advancement in cancer immunotherapy, which harnesses the body’s intrinsic 
immune responses against the tumour (9). Sipuleucel-T, an autologous 
personalised immunotherapy focused on patient’s own dendritic cell maturation 
against specific antigens, was the first immunotherapy agent approved for 
mCRPC (9). However the high cost and modest survival benefits have prevented 
its widespread adaptation to the clinic (9). Other immunotherapy approaches, 
such as immune checkpoint inhibitors, have so far been disappointing in PCa. It 
is possible that better patient selection and understanding of the key 
mechanisms that promote immunosuppression in prostate cancer would improve 
the efficacy of immunotherapy.  
1.1.5 Radical prostatectomy and extended lymph node dissection 
Radical prostatectomy (open, laparoscopic or robotic) is an established curative 
option for patients with early PCa (8). It involves the removal of the entire 
prostate gland and seminal vesicles alongside sufficient surrounding tissue in 
order to obtain a negative surgical margin (2, 8). This procedure can be 
accompanied by an extended pelvic lymphadenectomy in higher risk patients (2, 
8). This includes removal of more than 10 regional lymph nodes overlying the 
external and common iliac artery and vein, medial and lateral to the internal 
iliac artery, and within the obturator fossa (2, 10, 11). Even though extended 
lymph node dissection is necessary for accurate staging and therapeutic benefit 
(12) it does not come without patient complications and economic burden 
associated with extended operation time and hospitalisation (10). Approximately 
20% of patients develop such complications, which include lymphocele, deep 
vein thrombosis, pelvic haematoma, fever, acute urinary retention, pulmonary 
embolism and ureteral injury (10, 13).  
It is challenging for urological surgeons to make personalised patient decisions 
regarding extended lymph node dissection due to the heterogeneity of high-risk 
patients (7, 11). Currently preoperative nomograms based on clinical and 
histological parameters are used, the most popular being the Briganti nomogram 
(11). This is based on pre-operative PSA level, clinical stage, biopsy Gleason 
score and the percentage of positive cores (11). Even though this is considered 
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relatively accurate, it undeniably results in a significant portion of patients 
unnecessarily undergoing nodal dissection (2, 11). The prevalence of 
pathological confirmation of lymph node metastasis in patients undergoing nodal 
dissection ranges from 1 to 26% (10-13). Since extended pelvic lymph node 
dissection is considered for each patient with intermediate or high-risk disease 
undergoing radical prostatectomy, it is evident that better prognostic 
biomarkers for this procedure are urgently needed.  
1.1.6 Molecular Taxonomy of Prostate cancer 
During the past decade, the understanding of PCa genomics has progressed 
substantially (14).  It is increasingly recognised that the clinical heterogeneity 
observed in patients can be attributed to the wide array of genomic aberrations 
observed in PCa. About 50% of primary prostate cancer are characterised by 
juxtaposition of androgen regulated gene TMPRSS2 and ETS family genes (15). 
The most commonly involved member of the ETS family is the transcription 
factor ERG (46%), but also ETV1 (8%), ETV4 (4%) and FLI1 (1%) (15). These fusions 
of androgen regulated gene promoters and oncogenes are collectively the most 
common genetic alterations in PCa and are mostly mutually exclusive (14, 15). 
Whole genome sequencing revealed that these fusions are caused by a complex 
genetic rearrangement called ‘chromoplexy’, in which multiple chromosome 
segments are randomly severed and re-joined with frequent DNA deletions at 
their junction points (2).  
Tumours that lack ETS fusions commonly have mutually exclusive mutations of 
SPOP (11%), FOXA1 (3%) and IDH (1%) genes (15). The 26% of remaining PCa 
tumours were genomically heterogeneous and are driven by yet unknown 
specific genetic or epigenetic aberrations (15). These mutations of primary PCa, 
alongside ETS fusions and are both clonal, early events in PCa oncogenesis (14, 
15). They are followed by a wide array of subclonal changes that provides 
survival benefit and proliferative advantage to the cancer cells. Phosphatase and 
tensin homolog (PTEN) genomic inactivation acts as a negative regulator of the 
PI3K-AKT pathway and occurs in up to 40% of CRPC (16). PTEN loss has been 
repeatedly associated with worse clinical outcome and metastatic disease (17, 
18). PI3K-AKT pathway aberrations are frequently attributed to PTEN 
inactivation and occur in up to 40% of primary tumours (1) and 49% of CRPC (16). 
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They contribute to PCa progression by activating target genes that promote 
cancer cell growth and proliferation (19). Somatic aberrations of DNA repair 
genes occur in approximately 12% of CRPC and include genes involved in 
homologous recombination, such as BRCA1/2 and mismatch repair (16, 20). The 
incidence of mutations affecting cell cycle genes varies significantly between 
primary (5%) (21) and advanced CRPC (21-55%) (16, 20) and include deletions of 
tumour suppressor genes p53, RB1, CDKN1, CDKN2A/B, and CDKN2C, and 
amplifications of oncogenes CDK4 and CCND1. Lastly, in CRPC, the most frequent 
aberrations were found in the androgen receptor (AR) pathway (71%), implying 
that these tumours still depend on AR signalling (20).  
Summarising, there is a refined classification of PCa subtypes based on genetic 
alterations. Interestingly, different genetic backgrounds of PCa have been shown 
to influence the immune composition of the tumour microenvironment in vivo 
via different chemokine expression patterns (22) and inactivation of mismatch 
repair genes have been strongly associated with increased CD8 T cell infiltration 
in patient tumours (23). Also, pro-inflammatory cytokines produced by immune 
cells result in oxidative stress which has be linked to TMPRSS2-ETS gene fusions 
via DNA breaks (24). However, the overall reciprocal interactions between 
different genetic alterations and tumoural immune cell composition is far from 
clear. Better understanding of these relationships would potentially contribute 
to the identifications of novel prognostic as well as predictive biomarkers for 
personalised immunotherapies. 
1.1.7 Stratification of prostate cancer molecular subtypes using 
immunohistochemistry 
The commonest genetic alteration of PCa is the juxtaposition of TMPRSS2 and 
the transcription factor ERG by chromoplexy (15). As a result of this 
translocation, the expression of ERG becomes regulated by androgens and is 
therefore overexpressed in prostatic epithelium. ERG overexpression assessed by 
immunohistochemistry (IHC) has been successfully validated as a surrogate for 
TMPRSS-ERG translocation, with concordance between ERG IHC and Fluorescence 
in situ hybridisation (FISH) or quantitative polymerase chain reaction (PCR) 
above 95% (17, 25-27). Using IHC for detection of genetic alterations is less 
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expensive and time-consuming than FISH as well as more easily transferable into 
the current clinical pathology workflow setting.  
PTEN inactivation is a subclonal event that occurs frequently in PCa and has 
been repeatedly associated with worse clinical outcome and metastatic disease 
(17, 28-30). Interestingly, it is more frequently concomitant with ERG fusion 
cancers (19). Detection of PTEN loss by immunohistochemistry has been well 
established in previous reports and is comparable to the previously gold standard 
FISH detection (17, 18, 31). Even though PTEN is most frequently lost by large 
gene deletions that are detected by FISH (16, 32), less frequent genomic 
alterations, such as gene mutations, small insertions/deletions and epigenetic 
silencing (16, 32) can be detected with IHC only. Also, because PTEN loss is 
commonly heterogeneous in primary prostate tumours (18) using FISH detection 
for gene deletion can be technically challenging and screening for focal loss with 
IHC can be advantageous. Therefore, assessing PTEN expression by IHC is a 
robust and advantageous approach. 
1.2 Tumour microenvironment 
 
1.2.1 Tumour stromal microenvironment 
In cancer, the growth of tumour cells is driven by activation of oncogenic drivers 
and inactivation of tumour suppressors (33).  However, these aberrantly 
proliferating epithelial cells are not in isolation. They depend on reciprocal 
interactions with their surrounding stromal compartment, the tumour 
microenvironment (TME) (33, 34). The TME comprises of several different non-
malignant cells, such as fibroblasts, endothelial cells, pericytes and immune 
cells situated within extracellular matrix (ECM) (34). Crosstalk between cancer 
cells and TME can enhance or inhibit tumourigenesis, invasion and metastasis 
(34).  
 
1.2.2 Tumour immune microenvironment 
Tumour immune microenvironment is a decisive factor in tumour initiation and 
progression. Immune cells can provide tumour promoting as well as tumour 
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suppressive signals on epithelial cells via cell contact or secreted molecules (35, 
36). The interaction between cancer and immune cells is called cancer 
immunoediting and encompasses the consecutive phases of tumour elimination, 
equilibrium and tumour escape (36). During tumour elimination the host immune 
system successfully eradicates developing tumours. If tumour cells survive the 
elimination process they enter into an equilibrium phase, in which the immune 
system continues to contain tumour cells without fully eliminating them. Escape 
is signified by the expansion of tumour cells, overcoming the immune system 
(36). The balance between the effectiveness of the immune response and the 
mechanisms adopted by tumours to evade immune recognition and destruction 
determines the overall results (35).   
All solid tumours, including prostate cancer, contain different types of 
infiltrating immune cells that operate in conflicting ways, antagonising as well as 
promoting cancer progression (33). There are currently three main tumour 
immune microenvironment phenotypes that are driven by different biological 
mechanisms and are clinically relevant (35, 37). Firstly, the immune inflamed 
phenotype, also known as ‘hot’ tumours, are characterised by increased immune 
cell infiltration within tumour epithelial cells and surrounding stroma. These 
include immune suppressive cells, such as CD4 T regulatory cells and myeloid-
derived suppressor cells as well as CD4 and CD8 effector cells expressing 
exhaustion markers, such as programmed cell death 1 (PD-1) (35). This profile 
suggests the presence of a pre-existing anti-tumour immune response that has 
been halted, most likely due to immunosuppression within the TME (35, 37).  
Secondly, the immune excluded phenotype is also characterised by immune cell 
infiltration, however these do not penetrate the epithelial cells but are instead 
retained within the tumour-associated stroma (35, 37). This phenotype suggests 
a pre-existing anti-tumour response that has become ineffective due to the 
retention of immune cells away from the target epithelial cells. The limited 
immune cell migration through the tumour stroma can be attributed to altered 
chemokine milieu or mechanical barriers and is responsible for this immune 
phenotype’s tumour eradication failure (35, 37). Lastly, the immune dessert 
phenotype is characterised by a paucity of immune cell infiltration within the 
tumour parenchyma and surrounding stroma. This is the result of absence of pre-
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existing tumour immunity, with a lack of generation of anti-tumour specific T 
cells. The immune excluded and immune desert phenotypes are also known as 
‘cold’ tumours (35, 37). 
All immune cell types may be found within the tumour immune 
microenvironment. These include macrophages, myeloid derived suppressor cells 
(MDSCs), dendritic cells (DCs), B cells, CD4 helper and CD8 T lymphocytes being 
the most commonly encountered. These immune cells can be located within the 
tumour parenchyma, stroma or in organised tertiary lymphoid structures (37, 
38). Innate immune cells (macrophages, MDSCs, DCs) are the first line of defence 
against tumour antigens, and can also exert immune suppressive functions in 
order to maintain tissue homeostasis. DCs are key players that take up antigens 
and migrate to lymphoid organs where they present their antigens to T 
lymphocytes, functioning as a link between innate and adaptive immunity (39). 
Following priming and activation, these lymphocytes can produce an efficient 
antigen specific response against tumour cells. However, there are also effector 
lymphocytes with immune suppressive abilities such as regulatory T cells (39).  
1.2.2.1 Macrophages and myeloid derived suppressor cells 
Macrophages are abundant immune cells of the TME, characterised by high 
plasticity that allows them to shape their phenotype in response to the 
surrounding environmental cues (38). On the one end of the spectrum, tumour 
associated macrophages (TAM) can be M1-like or ‘classical’ TAMs that secrete 
pro-inflammatory cytokines, can present tumour antigens and have a pro-
inflammatory and tumouricidal role. On the other end, M2-like or ‘alternative’ 
TAMs can secrete anti-inflammatory cytokines ( IL‑4, IL-10, and TGFβ) playing an 
immunosuppresive role, promoting angiogenesis and favouring tumour 
progression (38). In reality, TAMs comprise different populations that often share 
features of both those two phenotypes which can change as tumour progresses 
(40).  
Myeloid derived suppressor cells are a heterogeneous population of myeloid 
lineage cells that can be immunosuppressive within the tumour 
microenvironment (38, 39). They consist of monocytes, granulocytes and 
immature myeloid cells which suppress T cytotoxic cells (39, 40).  
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1.2.2.2 Dendritic cells 
DCs are professional antigen presenting cells that are necessary for lymphocyte 
priming and activation. Tissue resident DCs capture antigens, process them and 
transfer them to draining lymph nodes, where they present them to lymphocytes 
(38). Alternatively, soluble antigens are transferred to the lymph node resident 
DCs via lymph fluid and are captured there (38). DCs present the captured 
antigens on major histocompatibility complex (MHCI and MHCII) molecules to T 
cells, resulting in the priming and activation of naive T cell responses against the 
cancer-specific antigens. Finally, the now activated effector T cells leave the 
regional lymph node and migrate to the tumour site (41). In cancer patients, this 
process is perturbed as tumour antigens may not be detected as foreign, 
effector T cells can be inhibited from infiltrating the tumour or factors within 
the TME can suppress the effector cells that are produced (41).  
1.2.2.3 Lymphocytes 
T and B lymphocytes are adaptive immune cells that can exert cell-mediated 
and humoral antigen specific immunity respectively (39). T cells mainly comprise 
of CD8 and CD4 helper T cells. Both subtypes are initially naïve T cells that 
differentiate into effector T cells in secondary lymphoid organs (38). CD8 T 
effector cells are largely cytotoxic CD8 T cells in the TME. They contain 
cytotoxic granules with perforin and granzyme B, which are released on 
interaction with target cells leading to their destruction by direct lysis (42). CD8 
regulatory T cells are also encountered with much lower frequency. CD8 as well 
as CD4 regulatory T cells inhibit anti-tumour immune response by cell contact 
dependent mechanisms and  producing immunosuppressive cytokines (IL-10 and 
TGFβ) (38). They are characterised by expression of nuclear forkhead box P3 
(FoxP3) (43). 
CD4 helper T cells comprise of a constantly expanding list of Th (T helper)  
subsets according to their transcriptional profiles, cytokine secretion and 
biological function (43). Apart from regulatory T cells, Th1 and Th2 polarised 
CD4 T cells play key roles in cancer immunoediting. CD4 Th1 T cells secrete 
inflammatory cytokines, such as IL2 and INFγ, promoting CD8 cytotoxic and 
innate immune cell cytotoxicity as well as antigen presentation (43, 44). In 
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contrast, Th2 CD4 T cells secrete immunosuppressive cytokines, such as IL4 and 
enhance T cell anergy and the tumour promoting activity of M2-like macrophages 
(44, 45). The functional orientation of CD4 helper T cells within the tumour 
microenvironment can favour a pro- or anti-tumourigenic immune response. 
Lastly, B cells are critical for humoral immunity, produce immunoglobulins and 
paracrine factors that can influence neighbouring immune cells (43). 
1.2.2.4 Immune checkpoints 
The adaptive immune system is able to recognise and respond to a variety of 
antigens. To ensure a tight balance is maintained between eradicating harmful 
pathogens and maintaining self-tolerance, T cell activation is finely tuned by 
two independent signals. The first signal is provided by the binding of T cell 
receptor (TCR) to the MHC upon recognition of an antigen. The second one, 
which is antigen independent, is provided by members of the B7 superfamily 
that are expressed on antigen presenting cells (APCs), which bind to their 
receptors on T cells and regulate immune responses by either co-stimulating or 
co-inhibiting them (44). 
Programmed death 1 (PD-1) is a transmembrane glycoprotein expressed on 
lymphocytes, DCs and activated monocytes that generates inhibitory signals and 
supresses activity of T cells upon binding with its programmed death ligands, PD-
L1 or PD-L2 (35). PD-L1 is expressed on a variety of cell types, including tumour 
cells and immune cells whereas PD-L2 is expressed mainly on dendritic cells in 
normal tissues (35).  PD-L1 can by autonomously expressed by tumour cells 
under the influence of oncogenic signalling pathways, known as ‘innate immune 
resistance’ (46). Alternatively, PD-L1 upregulation can be a result of ‘adaptive 
immune resistance’ in response to pro-inflammatory cytokines in order to 
protect tumour cells from CD8 cytotoxic T cell lysis and escape 
immunosurveillance (46) . 
1.2.2.5 Tumour immune microenvironment as a prognostic and predictive 
biomarker 
There is evidence that the immune reaction taking place at the primary tumour 
site has a significant impact on the course of the disease (38, 47). In colorectal 
cancer patients, increased CD8 T cell infiltration at the tumour invasive margin 
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has reproducibly been associated with improved clinical outcome, 
supplementing, if not superseding, the conventional TNM staging (48-51).  These 
observations have been expanded to gene expression analyses of human samples 
and in vivo models in order to investigate the functional relationships of 
different immune cell types in colorectal cancer, highlighting CD4 follicular 
helper and B cells as key players collaborating in the adaptive immune cell 
defence against tumour progression, via specific mediators such as CXCL13 (52).  
In renal cancer, higher percentage of infiltrating natural killer (NK) cells and CD4 
T cells with Th1 orientation were associated with better survival (53). In another 
renal cancer study using multiplex immunofluoresnce (mIF) panels, increased 
CD4 regulatory T cells and PD-1 expressing CD8 T cells within the tumour centre 
and invasive margin respectively were associated with worse survival (54).  In a 
large diffuse large B cell lymphoma study, low CD3 T cell infiltration was 
associated with a lower anti-tumour response expression signature and had an 
unfavourable prognostic impact. Also, tumour cells expressing PD-L1 and PD-1 
expressing T cells had adverse prognostic impact only in patients with high T-cell 
infiltration in close proximity to each other, suggesting a possible exhausted 
anti-tumour immune reaction in those patient (55).  
The importance of immune contexture is underscored not only by the abundance 
of immune infiltrates but also by its spatial context. In pancreatic ductal 
adenocarcinoma (PDAC), the spatial distribution of cytotoxic CD8 T cells in 
proximity to cancer cells correlated with improved patient survival (56). This 
highlights the importance of spatial distribution as when CD8 T cells are 
restricted from the tumour centre they are not associated with better outcomes 
(56, 57), even when they are located at the tumour margin or within the stroma. 
Poor infiltration of CD8 cells was associated with an immunosuppressive 
microenvironment comprising of regulatory lymphocytes, M2-like polarised 
macrophages, PD-L1 positive tumour cells and cancer associated fibroblasts (57). 
The same has been observed in breast cancer patients, where a significant 
proportion of cases with dense NK and lymphocytic infiltrates contained areas 
with large distances between immune cells and tumour cells, suggesting a low 
chance of direct contact and therefore interaction with those cytotoxic effector 
immune cells (58). A study focusing on macrophage heterogeneity in gastric 
cancer using mIF and gene expression analysis showed that the abundance of 
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specific macrophage subpopulations and their proximity to tumour cells were 
key for predicting outcome, suggesting that direct contact and/or paracrine 
mediators are important for their function (59).  
Tissue immune profiling is becoming an important tool for identifying predictive 
markers for response to immunotherapy as well as other treatments. In breast 
cancer, specific lymphocyte immune cell infiltration (CD3 T cells, CD8 cytotoxic 
T cells, CD20 B cells) has predicted better response to neo-adjuvant 
chemotherapy and trastuzumab (60-62). In chronic myeloid leukaemia, 
combining the proportion of CD4 helper T cells and PD-1+TIM3− CD8 T cells in 
the bone marrow with clinical parameters improved the prediction of remission 
after tyrosine kinase inhibitor therapy (63).  In melanoma patients, 
characterising the in situ tumour profile using seven immune markers could 
successfully predict the generation of tumour infiltrating lymphocytes (TILs) for 
autologous adoptive T cell therapy (64). In another study, tumours with myeloid 
dominated tumour immune composition were associated with CD8 T cell 
exhaustion and poor response to neo-adjuvant GVAX vaccination in PDAC 
patients (65).   
It is obvious that the exact composition as well as spatial organisation of the 
immune tissue microenvironment is critical to building and maintaining an 
effective antitumor immune response (35, 39). Therefore characterising the 
exact immune cell composition, functional orientation, tissue density and 
localisation within tumour regions is crucial for elucidating how the immune 
microenvironment affects cancer development and progression.  Furthermore, 
those features may be associated with patient prognosis and response to 
therapies (35, 38, 47). 
1.2.3 Prostate cancer immune microenvironment 
Relative to other cancer types described above, the characterisation of primary 
PCa tumour immune microenvironment has been challenging with conflicting 
results. A detailed summary of the studies on human PCa immune 
microenvironment is presented in Table 1. The reason for their inconsistent 
results lays partly on the study of limited immune cell types (macrophages or 
limited lymphocytic subpopulations), different specimens used (tissue 
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microarrays or whole sections), variable methodologies for protein detection 
(IHC or immunofluorescence), visual quantification assessment (inter and intra 
observer variability), small patient cohorts and measurement of disparate 
outcomes. In addition, very few studies have integrated tumour molecular 
subtyping in relation to immune cell infiltration (25, 66).  
The presence of inflammatory cells in the prostate is well documented (67). PCa 
is generally considered to have a relatively immunologically ‘cold’ 
microenvironment compared to other solid tumour types. However spatial 
distribution and functional orientation are emerging as more important features 
that the mere quantification of immune cells. Interestingly, a recent study using 
deep learning computational analysis on haematoxylin and eosin (H&E) slides 
from TCGA patients, showed that even though PCa was not among the highest 
immune infiltrated cancers it had distinctive structural patterns reflecting the 
nature of immune responses (68).   
The macrophage presence in primary PCa has been investigated in several 
studies with inconsistent results regarding patient survival outcomes (69-73). 
Part of the literature has shown a negative impact of macrophage density to 
patient survival (69, 72). High macrophage density was also predictive of a 
shorter relapse-free survival after ADT (72) and PCa specific death (69). On the 
contrary, high macrophage infiltration has been predictive of prolonged disease-
free survival (73) or has resulted in no difference in patient outcomes (70, 71). 
These studies have been limited by the absence of uniform patient treatment 
and small sample sizes, making it difficult to draw definitive conclusions on the 
significance of macrophages in prostate cancer.  One consistent finding is that 
macrophage infiltration is increased in PCa when compared to normal prostate 
(70, 72, 73), however its clinical significance in PCa progression and survival 
remains unclear. 
There is evidence that prostate cancer induces recruitment of lymphocytes into 
the prostate microenvironment but information regarding precise biological 
functions and their potential reciprocal interactions with tumour cells are very 
limited (67). T regulatory cells are increased in blood as well as tumour tissues 
of PCa patients and have confirmed in vitro immunosuppressive potential (74-
76). Interestingly, CD8 T regulatory cells are also present in PCa TME with cell 
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contact dependent suppressive function (77). Another functionally important 
observation showing negative immune regulatory activity was the expression of 
PD-1 on PCa infiltrating CD8 T lymphocytes (75, 78). These CD8 T cells were 
oligoclonal and antigen driven, suggesting a functional inhibition or exhaustion 
of CD8 T lymphocytes (78). The PD-1 ligand PD-L1 is however rarely expressed on 
prostate cancer tumour cells (79, 80), suggesting that prostate cancer cells do 
not impact on immune cells directly via PD-1/PD-L1 pathway.  
Lymphocytic infiltration of primary PCa is often increased and perturbed 
compared to normal prostate tissue (67) but its prognostic implication remains 
elusive. One of the largest cohort studies found that patients with either high or 
very low numbers of intratumoural CD3 T lymphocytes, but not B-lymphocytes, 
had a shorter relapse-free survival (66). Similarly, poor survival outcomes were 
observed in patients with tumours containing high CD4 (81) and intratumoural 
CD3 and CD8 T lymphocytic infiltration (82), while other studies had opposite 
findings (83, 84). Part of the literature has also shown that high FoxP3 T 
regulatory T cell infiltration was associated with shorter disease free survival 
(85) and increased risk of dying of PCa specific death (86). More recently, 
effector CCR4 expressing T regulatory cells were identified as the subpopulation 
associated with poor survival outcomes (87). The effect of TILs in PCa cancer 
development is complex and their prognostic value may depend on factors 
beyond density, such as specific immune subtype, spatial localisation and 
functional orientation. 
Tumour infiltrating immune cells have previously been identified as prognostic 
and predictive biomarkers in several cancers (38), however in PCa further 
research is necessary. The contradicting results highlight the need for studying 
well defined patient cohorts with similar disease stage, risk status and 
treatments in order to obtain meaningful results. Furthermore, investigation of 
different immune cell subsets, taking into consideration their spatial 
organisation and phenotype combined with high-throughput digital 
quantification will lead to a robust characterisation of PCa tumour immune 
microenvironment. Multiplex immunofluorescence (mIF) with tyramide signal 
amplification (TSA) is a suitable methodology for gaining a better understanding 
of immune-epithelial cell interactions. 





















81 CD68 Whole 
RP 
sections  
Visual  Patients with high 
MΦ had higher T 
stage and LN 
metastasis  
Patients with high  
MΦ had longer RFS  
Nonomura, 
2011 (72) 
71 CD68 PCa 
biopsies 
Visual  Patients with high 
MΦ had higher T 
stage and GS 
Patients with high  
MΦ had shorter RFS  
Gollapudi, 
2013 (70) 
537 CD68 TMA Visual  Patients with high 
MΦ had higher 
GS 









Visual  Patients with high 
M2-like MΦ had 
more frequently 
EPE 




592 CD163 TMA Digital  Patients with high 
MΦ had higher 
GS 
Patients with high 
MΦ had increased 




80 CD4  Whole 
RP 
sections  
Visual  None Patients with high 
CD4 T cells had 
shorter PCa-specific 
survival   
Fox, 2007 
(88) 




2,144 CD3 TMA Visual  Patients with high 
CD3 T cells had 
increased ERG 
expression 
Patients with very 





2,002 FoxP3 TMA Visual  Patients with high 
T regulatory cells 
had higher T 
stage  
Patients with high 
regulatory T cells 





TMA Visual  None Patients with high 
CD4 regulatory T 
cells had increased 






TMA Visual  None Patients with high 
CD3 and CD8 T cell 
had shorter RFS 
Woo, 2014 
(84) 
53 CD20 Whole 
RP 
sections  
Digital  None High risk PCa 
patients with high B 









Visual  Patients with high 
CCR4+Tregs had 
higher T stage 
and GS  
Patients with high 
CCR4+ regulatory T 
cells had shorter 
RFS and OS  
Table 1 Summary of studies characterising human primary prostate cancer immune 
microenvironment 
RP=Radical prostatectomy, MΦ= macrophages, RFS= relapse free survival, GS=Gleason score, 
EPE=extra-prostatic extension, PCa=prostate cancer, OS=overall survival 
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1.3 Multiplex immunofluorescence as a tool for immune 
cell characterisation 
The understanding of spatial cellular composition and heterogeneity of tissues in 
cancer provides vital insights about the biology and clinical progression of the 
disease. Thus, it is imperative to have effective and reliable tools to detect 
different immune cell subtypes within tumour samples. Flow cytometry 
successfully evaluates a large number of markers, however the lack of 
morphology information and inability to use on archival tissue pose significant 
limitations. The gold standard method for in situ protein detection is 
chromogenic immunohistochemistry (IHC) on formalin-fixed paraffin-embedded 
(FFPE) tissues with is followed by visual assessment of antibody reactivity using 
3,3′-Diaminobenzidine (DAB) or equivalent stains. This approach, although 
widespread and relatively cheap has its limitations.  
The information that can be obtained from traditional IHC is confined to a low 
number of markers per tissue section, usually limiting the classification of 
immune cells to up to two markers, e.g. CD4+ FOXP3+ regulatory cells. 
Furthermore, this information is obtained from consecutive tissue sections, 
making it difficult to relate cells to each other and more importantly using 
unnecessarily precious clinical tissue. This approach cannot resolve mixtures of 
chromogens if the target antigens spatially overlap to reliably study co-
localisation. Its assessment remains challenging, as it is time consuming, 
subjective, often poorly reproducible and dependent on the experience of the 
observer (89). This is done by using binary (positive versus negative), tiered (0, 
1+, 2+, and 3+) or semi quantitative (Histo-score) scoring systems, which are 
unable to discern subtle differences of protein expression and provide only rough 
estimates of immune cell counts (90). In order to dissect the biological processes 
that take place and deliver more accurate patient stratification and prognosis, 
tumours need to be characterised more comprehensively, combining cellular 
information with intact spatial context of the surrounding microenvironment.  
Multiplex immunofluorescence (mIF) has been a great asset in immune profiling 
of the tumour microenvironment because it overcomes the limitations of 
traditional chromogenic IHC (91). The benefits of multiplexing lie in collecting 
maximal information from a single tissue section - it allows the simultaneous 
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examination of 5 or more different biomarkers (92). Therefore, cell populations 
can be classified accurately and their spatial associations and frequency of 
marker co-expression can be determined (92). A key component for the success 
of this technology is pairing the multiplex fluorescence staining with 
multispectral imaging (MSI). Using a ‘spectral library’, MSI separates overlapping 
fluorophore spectra (including auto fluorescence) enabling accurate fluorophore 
quantitation for each marker on a FFPE samples. In addition, sophisticated 
software (i.e. InForm) have been developed for these type of image outputs and 
can be incorporated for an automated analysis workflow.   
We used the tyramide system amplification (TSA) methodology, in which the 
primary antibody binds to the antigen of interest, which is then bound to a 
horseradish peroxidase (HRP)-conjugated secondary antibody to the host species. 
With the addition of tyramide-fluorophore system, HRP activates the fluorophore 
and tyramide binds to tyrosine residues on or immediately around the epitope 
through covalent bonds (92). This allows for heat mediated removal (stripping) 
of primary and secondary antibodies whereas the fluorophore remains bound to 
the tissue allowing staining with more pairs of primary-secondary antibodies of 
the same species (Figure 1) (92). In this way, several antibodies of the same 
species can be used, simplifying the protocol requirements.  Furthermore, 
fluorescent signals are more amenable to quantitation because of their linear 
and additive nature and relatively well-defined emission spectra. This linear 
responsiveness allows for more objective and reproducible intensity quantitation 
(92). Finally, TSA methodology is ideal for detection of low abundance targets, 
like scarce immune subpopulations present.  
While this technique is providing many benefits compared to traditional IHC it is 
essential to follow extensive optimisation and be aware of possible pitfalls. 
Firstly, all antibodies used need to be validated with conventional chromogenic 
staining and confirm sensitivity and specificity of the staining. The fluorophores 
used need to be chosen carefully so that they have minimal bleed through. Each 
antibody needs to be paired with the optimal fluorophore based on the signal 
intensity and signal/noise ratio. As a general rule, low abundance targets are 
best paired with the brightest fluorophores. Finally, the optimal sequence in 
which the antibodies will be added has to be determined. Repetitive rounds of 
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heating can compromise the integrity of some antigens and weaken the 
fluorophore signal. Therefore, most sensitive targets and fluorophores impacted 
the least by microwaving should be added early on. Lastly, it is good practice to 
compare singleplex with multiplex staining in order to account for ‘antigen 
sheltering’, whereby existing tyramide-fluorophore deposits may preclude 
subsequent deposition of tyramide-fluorophores if their target is located in their 
vicinity (92).  
The mIF methodology has robustly been validated in mouse (93, 94) and in a 
larger extent in human FFPE tissues in previous studies (91, 95-97). It has 
gradually progressed from manual to automated staining to become less time 
consuming and avoid the risk of human error leading to staining variability (98, 
99). Additionally, previous work has confirmed its reliability showing a high 
correlation between mIF and other established methodologies, such as 
conventional chromogenic IHC (91, 97, 98, 100, 101) or flow cytometry (65, 93). 
More recent studies have expanded the capabilities of this method, increasing 
the number of markers up to 12 (65), using whole-slide tissue imaging and 
analysis (102) and combining fluorescent with chromogenic staining (102, 103).   
 
 
Figure 1 Multiplex immunofluorescence with tyramide signal amplification method 
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The multiplex immunofluoresnce using tyramide signal amplification methodology lies in the 
covalent bonds developing between tyramide and tissue that allow for heat induced removal of the 
non-covalently bound primary and secondary antibodies. Iterative rounds of staining allow for the 
visualisation of up to seven markers on the same tissue section. 
 
1.4 B7-H3 immune checkpoint molecule 
1.4.1 Immune function of B7-H3 
As a new member of the B7 superfamily, B7-H3 (CD276) was first identified in 
2001 (104). It is a type I transmembrane protein that contain an immunoglobulin 
(Ig) extracellular domain, a transmembrane domain and a short intracellular 
domain. Its expression can be induced on mature dendritic cells, T cells, B cells, 
macrophages, monocytes and natural killer cells (104, 105). Whilst B7-H3 protein 
expression is limited in normal tissues (106), it is overexpressed in different 
types of tumours, including PCa, pancreatic and breast cancer (107-109), making 
it a promising target for immunotherapies. Further research has confirmed that 
there are two main isoforms, 2Ig-B7-H3 and 4Ig-B7-H3, being the dominant forms 
in mouse and human respectively (105). Human 4Ig- B7-H3 structure is the result 
of an exon duplication that contains two immunoglobulin-like V and C domains, 
whereas 2Ig-B7-H3 contains a single V and C domain (110, 111).  
B7-H3 was initially reported to function promoting the TCR mediated CD4 and 
CD8 T cell proliferation and inducing IFN-ɣ production (104, 105). In a lymphoma 
mouse model, injection of B7-H3 expressing plasmid into the tumour, resulted in 
a complete regression of 50% of tumours which was dependent on cell mediated 
cytotoxic CD8 T and NK anti-tumour immune response (112). In an orthotopic 
colon cancer murine model, intratumoural injection with adenovirus expressing 
mouse B7-H3 resulted in a reduction of tumour size and metastatic foci. Treated 
mice had significantly higher IFN-γ producing tumour specific CD8 T cells (113). 
Another study showed that in a transgenic adenocarcinoma mouse prostate 
(TRAMP) model, ablation of B7-H3 lead to an increased tumour burden and 
regulatory T cell infiltration (114).  
Although initially reported to function as a co-stimulator of T cell response, 
mainly from in vivo studies, the current body of evidence strongly supports the 
role of B7-H3 as a co-inhibitor, contributing to immune cell evasion.  With 
Chapter 1 35 
 
regards to murine B7-H3, mice treated with a blocking anti- B7-H3 antibody 
showed decreased growth of PDAC (108), melanoma and lymphoma (115), which 
depended on the cytotoxicity of NK and CD8+ T cells (108, 115). A study using 
pancreatic and lung syngeneic mouse models showed improved anti-tumour 
immunity with anti-B7-H3 blockade that was orchestrated by CD8 cytotoxic T 
cells (116). In a recent study chimeric antigen receptor T cells (CART) targeting 
2Ig and 4Ig B7-H3 isoforms was developed. Targeting PDAC, ovarian and 
neuroblastoma in vitro reduced tumour proliferation via increase of the cytolytic 
activity and IFN-γ and IL-2 release (117). Validating this in in vivo orthotopic and 
metastatic xenograft models, as well as patient derived xenografts, confirmed 
that administration of CART B7-H3 controlled tumour growth (117).  
Accumulating evidence also indicates that human B7-H3 acts as a co-inhibitory 
factor of immune responses. A study investigating the consequences of B7-H3 
and T cell interaction using different experimental conditions showed that B7-H3 
negatively regulated naïve and activated T cells, reduced IL-2, Th1 and Th2 
cytokine production (118). Another study showed DCs isolated from non-small 
cell lung cancer (NSCLC) patients had upregulated B7-H3 and reduced T cell 
proliferation in mixed lymphocyte reactions compared to healthy controls (119). 
In neuroblastoma, B7-H3 expressed at the tumour cell membrane was shown to 
exert a protective role from NK cell mediated lysis by interacting with a still 
undefined inhibitory receptor expressed on NK cells. A bispecific anti-CD3 x anti-
B7-H3 antibody armed with activated T cells was synthesised recently (120) and 
showed increased cytotoxicity against human cancer cells in vitro and in vivo, at 
least partly due to increased IFN-ɣ, TNF-a and IL-2 secretion (120, 121). B7-H3 
was also used as a target of antibody-drug conjugate therapy that exhibited 
potent tumouricidal and anti-metastatic activity in human lung, cancer and 
breast human tumour xenografts targeting tumour and tumour vasculature (106). 
Another humanised anti-B7-H3 (MGA271) IgG1 monoclonal antibody showed 
potent antibody-dependent cellular cytotoxicity (ADCC) in vitro and in 
xenografts against a variety of B7-H3 expressing tumours (122). MGA271 is 
currently under evaluation in a phase I study for several B7-H3 expressing 
tumours, including PCa (123). 
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In summary, while initially B7-H3 immune function was controversial, current 
consensus supports its classification as a co-inhibitory molecule of T-cell 
activity. It is conceivable that the contradicting results may be due to 
interactions with both inhibitory and stimulatory receptors, therefore the co-
stimulatory or co-inhibitory effect could prevail depending on the experimental 
system used. There is the possibility that B7-H3 may interact with different 
affinities to several receptors and exert different functions. Also, differences 
between known as well as potentially unknown mouse and human isoforms or 
splice variants may affect its function and data derived from mouse studies may 
not be transferable to humans. So far, the only potential receptor of murine B7-
H3 identified was Triggering receptor expressed on myeloid cell-like transcript 2 
(TREML2) (124, 125). TREML2 is a modulator of innate and adaptive immune 
responses and its binding to B7-H3 lead to enhancement of CD8 T cell response 
(124, 125). However, later studies have disproved the engagement of human B7-
H3 to this receptor (118). The binding partner of B7-H3 on immune cells remains 
elusive.   
1.4.2 Non- immune function of B7-H3 
Apart from the immune regulatory function, B7-H3 has been shown to have a 
non-immunological role in cancer progression. For the first time in 2008, 
downregulation of B7-H3 with siRNA resulted in up to 50% decrease of cell 
adhesion to fibronectin and up to 70% in vitro decrease of migration and invasion 
in melanoma and breast cancer cells (126). Further in vitro studies showed that 
silencing of B7-H3 lead to reduction of cell adhesion to fibronectin, migration 
and invasion in PCa (127). This was further validated in vivo by reduction of 
tumour metastasis in nude mice harbouring PDAC xenografts (108). Of note, a 
few studies have also associated B7-H3 with increased tumour proliferation in 
vitro (128, 129) and tumour growth in mouse orthografts (130).  
Further studies identified regulation of matrix metalloproteases (MMPs) as one of 
the downstream pathways involved. In a melanoma study, stable knock out (KO) 
of B7-H3 decreased migration and invasion in vitro and metastasis in in vivo 
xenograft models (130). It also showed that B7-H3 KO reduced the expression of 
known key metastasis players, such as matrix metalloproteinases 2 (MMP2), 
phosphorylation of STAT3, secretion of IL-8 and increased the expression of 
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tissue inhibitors of metalloproteinase 1 & 2 (TIMP1&2) (130). A study using 
overexpression and silencing of B7-H3 in bladder cancer cell lines, showed B7-H3 
promoted cell migration and invasion by upregulating MMP2 and MMP9, at least 
partly via the PI3K/AKT/STAT3 signalling pathway (131). B7-H3 overexpression in 
osteosarcoma was associated with poor prognosis, inversely correlated with CD8 
T cell infiltration, promoted invasion in vitro and upregulated expression of 
MMP2 (132). B7-H3 also promoted migration and invasion in colorectal cancer in 
vitro and enhanced MMP9 expression by upregulation of Jak2/Stat3 pathway 
(133).  
In other tumour types, modulation of epithelial to mesenchymal transition (EMT) 
markers appears to be the dominant downstream pathway of B7-H3 mediated 
functions. In hepatocellular carcinoma, B7-H3 overexpression correlated with 
metastasis and poorer survival, and silencing of B7-H3 significantly decreased 
migration and invasion in vitro (134). This was accompanied by decreased 
expression of MMP2, MMP9 and epithelial to mesenchymal transition (EMT) 
markers that could be attributed at least partially to a decreased 
phosphorylation of STAT3 and Jak2 (134). B7-H3 overexpression in NSCLC 
patients correlated with LN and distant metastasis, transient silencing of B7-H3 
reduced in vitro cell proliferation, migration and invasion and expression of EMT 
markers (135). A study on colorectal cancer cells using overexpression and KO 
cell lines for B7-H3 showed that B7-H3 promoted in vitro and in vivo 
migration/invasion and EMT by activating the PI3K-AKT pathway and 
upregulating SMAD1 (136). 
A few other possible downstream targets of the invasive phenotype associated 
with B7-H3 have been under investigation. A study focused on soluble B7-H3 
(sB7-H3) and showed that pancreatic cancer cells released sB7-H3 according to 
their membranous bound levels. Exposure to sB7-H3 lead to an increase in 
migration and invasion through the TLR4/NF-κB pathway and its downstream 
targets, IL-8 and Vascular endothelial growth factor (VEGF) (137). A study on 
gastric cancer human cell lines reported the direct interaction with the 
chemokine receptor CXCR4 and potential contribution of phosphorylation of AKT, 
ERK and Jak2/STAT3 (138). 
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B7-H3 is also shown to play a role in resistance to cancer chemotherapy drugs. 
B7-H3 silencing enhanced gemcitabine cytotoxicity in vitro and in vivo PDAC by 
inducing apoptosis and downregulating anti-apoptotic protein survivin (139). B7-
H3 also induced sensitivity to paclitaxel in vitro and in vivo breast cancer, at 
least partially by regulating phosphorylation of the Jak2/Stat3 pathway and 
downstream targets Mcl-1 and survivin (140). In colon cancer cell lines, 
overexpression of B7-H3 inhibited drug-induced apoptosis and showed increased 
Jak2/STAT3 phosphorylation, upregulation of anti-apoptotic proteins bcl-2 and 
bcl-xl and down-regulation of pro-apoptotic protein Bax (128). Finally, in a 
recent study, B7-H3 increased chemoresistance of breast cancer cells by 
regulating stem cell enrichment through major vault protein mediated MEK 
activation (141). Summarising, the role of B7-H3 in cancer progression as well as 
in normal biologic functions extends far beyond its first reported 
immunoregulatory abilities.  
1.4.3 B7-H3 immune checkpoint in prostate cancer 
Assessment of B7-H3 expression in large cohort of 823 PCa patients treated with 
RP showed variable degree of B7-H3 expression in 93% of the tumours. High 
expression was present in 26% of cases and significantly associated with 
extracapsular extension, seminal vesicle invasion, cancer recurrence, and PCa 
related death (107). In a separate study of 338 men treated with RP, high B7-H3 
expression significantly correlated with adverse pathological features and cancer 
progression after surgery (142). B7-H3 expression was maintained in bone 
metastases, even after ADT treatment (143) and its high expression correlated 
with biochemical recurrence after salvage radiation therapy (SRT) in recurrent 
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Chapter 2 Materials and methods 
2.1 Reagents  
The details of all reagents used in the following experiments are listed in Table 
2. 
Reagent Cat number Supplier 
Xylene X/0250/17 Fisher Chemicals 
Ethanol absolute 20821.365 VWR Chemicals 
Methanol 20846.326 VWR Chemicals 
EDTA  (Ethylenediaminetetraacetic acid)  D10700153 Thermo Fisher Scientific 
Tri-sodium-citrate S/3320/60 Thermo Fisher Scientific 
Hematoxylin solution modified acc. to Gill III 105174 Merk 
Hydrogen Peroxide 30-32% (w/w) H/1800/15 Fisher Chemicals 
Parafilm ‘M’ PM-996 Bemis 
RPMI-1640 medium 1640 Sigma-Aldrich 
FBS (fetal bovine serum)  10270 Thermo Fisher Scientific 
L-glutamine 25030 Thermo Fisher Scientific 
Trypsin solution from porcine pancreas T4549 Sigma-Aldrich 
DMSO (dimethyl sulfoxide) D/4121/PB08 Fisher Scientific 
BSA (Bovine Serum Albumin)  A3059-506 Sigma 
MOPS SDS running buffer NP0001 Thermo Fisher Scientific 
Immobilon-FL PVDF Membrane IPFL00010 Merk 
Amersham ECL Western Blotting Detection 
Reagent 
RNP2106 GE Healthcare Life 
Sciences 
Pierce ECL Plus Western Blotting Substrate 32132 Thermo Fisher Scientific 
Halt™ Protease and Phosphatase Inhibitor 
Cocktail (100X) 
78440 Thermo Fisher Scientific 
PhosSTOPTM Phosphatase Inhibitor Cocktail  4906837001 Roche 
Bradford Assay 5000006 Biorad 
RNase Zap AM9780 Invitrogen 
2-mercaptoethanol M-3148 Sigma 
Opti-Mem 31985070 Thermo Fisher Scientific 
Lipofectamine RNAiMAX  13778-150 Thermo Fisher Scientific 
Matrigel 354234 Corning 
Transwell Boydon Chamber 3422 Corning 
Calcein AM 1430 Invitrogen 
 Table 2 Commonly used reagents 
 
 
2.2 Solutions and buffers 
The composition of buffers and solutions used in the following experiments are 
listed in Table 3. Tris Buffered Saline and Tween (TBST), Tris Buffered Saline 
(TBS) and Phosphate Buffered solution (PBS) buffers were provided by our core 
facility services at the Beatson Institute. 
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Solutions and buffers  Composition  
Tris Buffered Saline and Tween 
(TBST)  
25mM Tris-HCl pH7.4  
137mM NaCl  
5mM KCl  
0.1% Tween-20  
Tris Buffered Saline (TBS) 
 
25mM Tris-HCl pH 7.4 
137mM NaCl 
5mM KCl 
Phosphate Buffered solution (PBS)  170mM NaCl  
3.3mM KCl  
1.8mM Na2HPO4  
10.6mM KH2PO4  
pH7.4  
5% goat serum IHC blocking solution 5% goat serum (Dako) 
1% BSA  
0.1% Triton in TBS  
RIPA Cell Lysis Buffer (for protein 
extraction)  
Tris 1M pH7.6  
NaCl 4M  
Triton 10%  
Deoxycholaate 10%  
SDS 10%  
Sodium Orthovanadate 100mM  
Sodium Fluroride 0.5M 





 Table 3 Working solutions and buffers 
 
2.3 Human tissue  
 
2.3.1 Construction of intermediate/high risk discovery primary 
prostate cancer tissue microarray  
Formalin-fixed, paraffin-embedded (FFPE) histologic sections from intermediate 
and high-risk PCa patients who underwent RP and extended regional 
lymphadenectomy with curative intent (half with and half without evidence of 
nodal disease) were retrospectively identified between 4th June, 2008 and 23rd 
January, 2018 at the Queen Elizabeth University Hospital in NHS Greater Glasgow 
and Clyde. I reviewed all H&E stained histologic sections and when necessary 
slides were double checked by a specialist Uropathologist (Dr J. Salmond). The 
index prostate cancer lesion was marked for each case and three 1 mm thick 
tissue cores were punched out and transferred onto a tissue microarray (TMA) 
format. PCa commonly has multiple distinct foci, the index lesion was selected 
as the largest focus according to the pathology report (7). The work described 
here is carried out in accordance with approval from the West of Scotland 
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Research Ethnics Committee (REC) 4 granted to the NHSGGC Bio-repository and 
Pathology Tissue Resource II (REC reference: 16/WS/0207). 
This format was chosen because TMAs have an inherent capacity to process 
hundreds of tumour specimens at once (145). Two hundred and eighty two cores 
were distributed among three blocks, each containing 94 tumour samples. There 
were 10 control tissue cores on each block including tissue from tonsil, lymph 
node, kidney, liver, skin, breast cancer, lung cancer and normal prostate tissue 
from two different patient samples. From the resultant TMA paraffin blocks, 3 
µm serial histologic sections were prepared. The first set of sections was 
routinely stained with H&E and presence of cancer was confirmed. The cores 
were further analysed only when more than 60% of the core contained tumour 
glands.  
The patients’ selection for inclusion in the discovery TMA was based on their 
intermediate and high-risk status. Clinicopathological information were 
extracted from the pathology report including total number of excised lymph 
nodes at surgery, peak pre-operative PSA (ng/dl), age at diagnosis, pathological 
tumour stage (pT) according to the 7th edition of American Joint Committee on 
Cancer (AJCC), Gleason score and perineural invasion (PNI). Follow up 
information was retrieved from the medical records and included overall survival 
(OS), cancer-specific survival and relapse-free survival (RFS), defined as rise of 
PSA (≥0.2 ng/dl) in two consecutive measurements or presence of distant 
metastases. The first PSA value above or equal to 0.2 ng/mL was used to define 
the time of relapse. Patients without evidence of tumour relapse were censored 
at the last follow-up.  
2.3.2 Validation intermediate/high risk primary prostate cancer 
tissue microarray 
We established a collaboration with Professor George Thalmann (Department of 
Urology, University of Bern, Switzerland) and obtained an incidence primary 
prostate PCa TMA containing intermediate and high-risk tumours for validation of 
findings from the discovery TMA. This TMA included treatment naïve, newly 
diagnosed prostate cancer patients who underwent RP. Tissue cores of 0.6 µm 
were taken from the index prostate cancer lesion of each patient and were 
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distributed in one block. Four µm serial histologic sections were cut and sent to 
us alongside anonymised patient clinical information. The first set of sections 
was stained with H&E and cores were further analysed only when more than 60% 
was cancerous.  
2.3.3 Low risk primary prostate cancer tissue microarray 
We established a collaboration with Professor David Berman (Department of 
Pathology, Queen's University, Kingston, Ontario, Canada) and obtained a 
primary PCa TMA consisting of low risk tumours at the time of diagnosis. This 
included tissue cores from the index tumour lesion, surrounding PIN and benign 
tissue from RP specimens. Tissue cores of 0.6 µm were distributed in nine 
blocks. Three µm serial histologic sections were cut and sent to us alongside 
anonymised patient clinical information. Only the annotated index tumour cores 
were included in my analysis.  
2.3.4 Benign prostatic hyperplasia tissue microarray 
Transurethral resection of the prostate (TURP) specimens from 390 men with no 
evidence of prostate cancer were used to construct a benign prostatic 
hyperplasia (BPH) TMA previously by Dr Joanne Edwards (146). Three 0.6 µm 
cores were obtained from every patient and they were distributed in three 
slides. Already cut sections were available in our lab, with no clinical 
information attached to these patients.  
2.4 Chromogenic immunohistochemistry 
Chromogenic immunohistochemistry was performed manually after 1-2 hours 
oven incubation at 60oC the day before. Following antigen retrieval buffer and 
antibody concentration optimisation, the list of the primary antibodies used is 
presented in Table 4. These were incubated with appropriate secondary 
antibodies (EnVision System HRP labelled Polymer anti rabbit #K4003 or anti-
mouse #K4001) and the staining was visualised using 3,3′-Diaminobenzidine (DAB) 
Quanto (TA-125-QHDX).  
 









Anti-CD68 Citrate 1:400 76437 Cell Signalling 
Anti-CD163 Citrate 1:50 93498 Cell Signalling 
Anti-CD20 EDTA 1:400 60271-1 Proteintech 
Anti-CD8 EDTA 1:200 70306 Cell Signalling 
Anti-CD4 EDTA 1:100 ab133616 Abcam 
Anti-FoxP3 Citrate 1:100 98377 Cell Signalling 
Anti-PD-1 Citrate 1:200 86163 Cell Signalling 
Anti-AE1/3 (PanCK) EDTA 1:1 GA053 Dako 
Anti-ERG (EPR3864) EDTA 1:50 Ab92513 Abcam 
Anti-PTEN (138G6) Citrate 1:100 9559 Cell Signalling 
Anti-Ki67 (MIB1) EDTA 1:100 M7240 Dako 
Anti- Collagen I EDTA 1:100 ab138492 Abcam 
Anti- Collagen III Citrate 1:50 ab7778 Abcam 
Anti- Fibronectin 1 Citrate 1:100 ab2413 Abcam 
Anti- FAPa EDTA 1:200 ab207178 Abcam 
Anti-B7-H3 Citrate 1:100 14058 Cell Signalling 
Table 4 Antibodies used for chromogenic immunohistochemistry 
 
2.4.1 Chromogenic immunohistochemistry protocol 
Step 1 – Deparaffinisation and rehydration: Slides were incubated in the 
following order: Xylene three times for 10 min, 100% Ethanol two times for 10 
min, 95% Ethanol two times for 10 min, dH20 two times for 5 min. 
Step 2 - Antigen retrieval: Either 10 mM sodium citrate buffer (pH 6.0) or 1 mM 
EDTA buffer (pH 8.0) were made fresh on the day and pre-heated for 10 min in 
the microwave. Slides were added in the buffer in a pressure cooker for 3 min 
under pressure. The slides were then left to cool down at room temperature for 
30 min, followed by three 5 min washes in dH20.  
Step 3- Quenching of endogenous peroxidases: Slides were incubated with 
freshly made 3% H2O2 for 10 min. They were then washed in dH20 three times for 
5 min and in TBTS for 5 min. 
Step 4 - Blocking of non-specific binding: Tissue containing areas were circled 
with a hydrophobic barrier PAP pen (R37622, Invitrogen) and incubated in 5% 
goat serum for 1 hour in a humid chamber. 
Step 5 - Primary antibody incubation: The primary antibody was diluted in 5% 
goat serum in the appropriate concentration and left overnight at 4oC. This was 
followed by three 15 min washes in TBST the next day.  
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Step 6 - Secondary Antibody Incubation: Secondary anti-mouse or anti-rabbit 
antibody was added for an one hour incubation at room temperature, followed 
by three 15 min washes in TBST.  
Step 7 – Substrate visualisation: DAB chromogen was applied for 5 min according 
to manufacturer’s instructions.  
Step 8 – Counterstain and mounting: Slides were then washed in water, 
counterstained with haematoxylin and coverslipped using Dibutylphthalate 
Polystyrene Xylene (DPX) mountant (CellPath, UK). Stained slides were then 
scanned with Leica Aperio AT2 bright field microscope, x 20 magnification for 
digital image recording.  
2.4.2 Dual CD4-FoxP3 chromogenic immunohistochemistry 
protocol 
For selected validation experiments, histologic slides were manually stained for 
dual CD4-FoxP3 immunohistochemistry. The same steps as in section 2.4.1 were 
followed up to DAB substrate visualisation for FoxP3 (1/100 v/v) and slides were 
washed in dH2O for 1 min and TBST twice for 5 min. Horse serum (2.5%, v/v) was 
added for 1 hour and then slides were incubated with CD4 (1/100, v/v) for 1 
hour at room temperature. The slides were then washed in TBTS twice for 5 min 
and incubated with ImmPRESS-Alkaline phosphatase Polymer Anti-Rabbit IgG 
Reagent (MP-5401, 1:1) for 30 min. Slides were washed again in TBST twice for 5 
min and ImmPACT Vector Red Alkaline Phosphatase Substrate (SK-5105) was 
added according to manufacturer’s instructions for 15 min. For counterstaining, 
slides were manually washed in dH2O for 1 min, incubated in Mayer’s 
Haematoxylin for 2 min, washed in dH2O for 1min, incubated in Scotts Tap Water 
for 2 min and washed in in dH2O for 1 min. Lastly, sections were dried in the 
oven at 60oC for 30 min and mounted with EcoMount (M897L).  
2.4.3 HALO scoring 
Digital images were analysed using the HALO™ Image Analysis Platform (v2.1.1637.6) 
to objectively quantify the number of positively stained cells within an area. The 
software enables tissue classification (epithelium vs stroma vs background) based 
on the morphological characteristics and the quantification of positively stained 
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cells in each of the tissue compartments. The number of cells positive for each 
marker within a tissue compartment was then expressed as tissue cell density 
(cells/mm2).  
2.4.4 ERG, PTEN, Ki67 scoring 
ERG scoring was based on visual scoring systems validated in previous studies, 
using endothelial and immune cell staining as internal control (26-28). For each 
tumour core, only nuclear staining was assessed and defined as negative or 
positive when there was immunoreactivity in at least 30% of tumour tissue. It 
was given an intensity score of 0-4 but for the subsequent analysis any degree of 
intensity staining was considered positive as there has been previously verified 
that there is no significant difference between ERG intensity staining and ERG 
gene rearrangement detected by FISH (27). A patient’s tumour was defined as 
ERG positive if at least one core was defined as ERG positive and negative if all 
cores had no ERG staining.  
PTEN scoring was based on the intensity of cytoplasmic and nuclear staining 
described in previous studies (18, 28, 31) . In brief, if there was protein 
expression in >90% of malignant glands of a core that was considered PTEN 
intact. If the PTEN expression was absent in 100% of the glands that was 
regarded as homogeneous PTEN loss. If there was between 10% and 100% of PTEN 
immunoreactivity observed, the case was scored as having heterogeneous PTEN 
loss (focal loss). Benign prostate and stromal staining were used as internal 
positive controls and in their absence, the staining was considered ambiguous 
and the core was not given a PTEN score. Each patient was scored for the 
presence or absence of PTEN loss by summarising the scores of each individual 
TMA core. A patient’s tumour was designated as having intact PTEN if all cores 
showed intact PTEN expression and homogeneous loss of PTEN if all cores 
showed complete absence of PTEN expression. A tumour was defined as having 
heterogeneous PTEN loss if there was at least one core showing heterogeneous 
PTEN loss (intracore heterogeneity), or alternatively, if at least one core showed 
intact PTEN and another one showed heterogeneous and/or homogeneous PTEN 
loss (intercore heterogeneity). 
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Ki67 scoring was defined as low (≤10%), moderate (10-20%) and high (≥20%) 
according to the fraction of tumour cells showing nuclear immunoreactivity 
(147).  
2.4.5 Histoscoring 
Histoscore (H-score) was used to quantify B7-H3 expression on tumour cells. This 
is a well-established visual semi-quantitative assessment that uses intensity of 
staining (scored as: 0, no staining; 1, weak; 2, moderate; or 3, strong) multiplied 
by the percentage (%) of positive cells (148). The scoring range spans from 0 to 
300.  
2.5 In situ hybridisation for CXCL14 
In situ-hybridisation for the detection of CXCL14 mRNA (using probe 425298 from 
Advanced Cell Diagnostics) was performed by Mr Colin Nixon, the Beatson 
Histology Laboratory. RNAscope 2.5 LS (Brown) detection kit (Advanced Cell 
Diagnostics) was used on a Leica Bond Rx autostainer according to the 
manufacturer's instructions (146). Positive staining was measured by brown 
punctate dots present within the nucleus and/or cytoplasm. 
2.6 Second generation harmonic image acquisition and 
analysis for determination of collagen quantity and 
quality 
Five µm FFPE TMA sections from the discovery TMA were deparaffinised 
manually, imaged using Second generation harmonic (SGH) and analysed by Ewan 
McGhee as described  previously (149). In brief, collagen SGH images were 
collected using a LaVision Biotec Trimscope 1 system equipped with a Coherent 
Chameleon Ultra II femtosecond pulsed laser. A 500 x 500 x 30 μm z-stack was 
acquired at the centre of each TMA core and generated collagen stack images. 
Three slides from the discovery TMA were imaged.  
Image analysis was performed using Image J. The UMB GLCM plugin 
(http://arken.nmbu.no//~kkvaal/eamtexplorer/imagej_plugins.html) was used. 
This removed the background noise and selected only the collagen SHG signal. 
The output of the plugin for each image was saved as a text data file and then 
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the data files were processed using another ImageJ macro, generating outputs 
for both the mean and individual values for each image. These were then 
imported into GraphPad Prism for plotting.  
2.7 Multiplex immunofluorescence 
2.7.1 Optimisation steps for multiplex immunofluoresnce panel 
development 
My aim was to develop a panel of antibodies paired with fluorophores in order to 
detect different immune cell populations on the same tissue slide. Initially, 
several optimisation steps for the multiplex immunofluoresnce (mIF) panel 
development were performed manually in our facility. Sections from tonsil 
blocks were cut at 3 µm thickness and used for optimisation because of its 
immune cell abundance and well characterised immune cell spatial distribution. 
Antibodies were tested for each marker using chromogenic IHC in order to 
validate their sensitivity and specificity and also to determine their optimal 
concentration (Table 4). The antibodies were tested in different dilutions using 
the concentration for IHC recommended by the company as a reference and 
trialling concentrations above and below that. A negative control was used for 
each antibody and DAB chromogen staining was assessed visually with a light 
microscope. Not all commercially available antibodies claiming to work in human 
FFPE tissue showed a strong and/or specific staining. Such examples were CD4 
(4SM95, 14-9766-82, Invitrogen), CD4 (CL03995, AMAb90754, sigma), CD68 
(ab125212), Pan-Keratin (4545, Cell signalling).  
For transition to immunofluorescence (IF) staining, some alterations were 
implemented to the chromogenic IHC protocol. There were changes in the 
reagents used, as primary antibodies were diluted in Signal stain antibody 
diluent (#8112) and Signal stain Boost IHC reagents (rabbit #8114, mouse #8125, 
Cell signalling) were used as secondary antibodies. After secondary antibody 
incubation, TSA conjugated fluorophores were added according to 
manufacturer’s instructions and visualised under the confocal microscope for 
singleplex immunofluorescence (sIF) staining. For multiple marker staining, a 
microwaving step was performed after the addition of fluorophores (for primary 
and secondary antibody removal) and tissue was subsequently stained with the 
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next primary antibody (Figure 2). Slides were mounted with ProLong® Gold 
Antifade Reagent (#9071, Cell Signalling) for sIF and ProLong® Gold Antifade 
Reagent with DAPI (#8961, Cell Signalling) for multiplex staining. 
 
 
Figure 2 Multiplex immunofluorescence staining workflow 
TSA: Tyramide signal amplification 
 
Prior to conducting a multiplex experiment, the antibody concentration for each 
primary antibody was determined in the singleplex setting. After tonsil and 
prostate cancer whole tissue sections were stained with each marker, the slides 
were imaged in Zeiss 880 Airyscan Confocal Microscope. The optimal 
concentration was determined based on the assessment of highest signal 
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intensity in combination signal to noise ratio (Figure 3A). ZEN.2 software was 
used for these calculations. Once the optimal dilution for each antibody in the 
singleplex setting was determined, different antibody-fluorophore pairs were 
tested and the optimal combination was determined as before (Figure 3B). The 
aim of this was to balance signal intensities, generally pairing low abundance 
targets with the brightest fluorophores. Lastly, multiple rounds of heating can 
compromise the antigen integrity. For this reason, the order in which the ab-
fluorophore pairs will be added requires optimising. Each tissue section was 
stained only once and subjected to microwave heating the same amount of times 
irrespective of the labelling order (Figure 3C).  
These data were used in a five marker multiplexing proof of principle 
experiment that confirmed the feasibility of this method (Figure 3D). The panel 
showed specific staining but there was fluorescence intensity variation between 
staining rounds and the tissue auto-fluorescence was pronounced in red blood 
cells, vessels, muscle and occasionally stromal areas. The manual staining of five 
antibodies was a five day protocol, susceptible to technical errors that were 
likely responsible for the batch variations. More importantly, there were 
limitations with image acquisition capabilities in our facility and I could not use 
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Figure 3 Manual multiplex immunofluorescence staining optimisation 
(A) Representative example for PD-1 antibody optimal titration (1:400). (B) Representative example 
for PD-1 antibody fluorophore pairing comparison (Cy5). (C) Representative example for PD-1 
antibody order optimisation. Positioning PD-1 in the second step was chosen. (A-C) Mean 
fluorescence intensity in blue bars and signal to noise ratio in red line. (D) Representative image of 
tonsil tissue stained manually with five antibodies using spectral unmixing with microscope airyscan 
zeiss 880. FoxP3 (1:200) paired with FITC in green, PD-1 (1:400) paired with Cy5 in cyan, CD68 




2.7.2 Automated multiplex immunofluorescence staining and 
image acquisition  
Due to the difficulties mentioned above, we developed a collaboration with Dr 
John Le Quesne (Department of Pathology, University of Leicester; now at 
University of Glasgow). Dr Le Quesne’s laboratory has already established 
protocols for simultaneous automated staining of multiple markers alongside the 
necessary imaging equipment (Vectra Polaris) and analysis software (InForm 
2.4.2). My data were shared with his team in order to assist in their panel 
optimisation, however some antibodies were incompatible with their automated 
staining and were substituted accordingly. Also, they used the PerkinElmer Opal 
kit (Perkin-Elmer, Waltham, MA), therefore my fluorophore combinations were 
translated into their system. A prostate cancer test TMA that was created for 
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optimisation. This comprised of four 1 mm cores from four cases (16 cores in 
total) from old TURP blocks. The same optimisation steps were followed. All 
stainings were performed in Ventana Discovery Ultra.  
Two mIF were developed, presented in Table 5. In detail, Panel 1 comprised of  
CD68 (macrophage marker, 1:200, #76437, Cell signalling) with Opal 520 (1:200), 
AE1/AE3 (epithelial marker, 1:250, #NCL-L-AE1/AE3, Leica) with Opal 650 
(1:200), CD20 (B cell marker, 1:1,  #760-2531, Ventana) with Opal 690 (1:150), 
CD163 (macrophage marker, 1:200, #NCL-L-CD163, Leica) with Opal 570 (1:550), 
discovery QD DAPI (#760-4196, Ventana). Panel 2 consisted of AE1/AE3 (1:250, 
#NCL-L-AE1/AE3, Leica) with Opal 620 (1:100), FoxP3 ( regulatory T cell marker, 
1:20, #ab20034, abcam) with Opal 690 (1:200), PD-1 (immune checkpoint, 1:1, 
clone NAT 105, #760-4895 Ventana) with Opal 650 (1:200), CD4 (helper T 
marker, 1:1, clone SP35, #790-4423, Ventana) with Opal 570 (1:150), CD8 (1:100, 
clone C8/144B, #70306, Cell signalling) with Opal 520 (1:100) and discovery QD 
DAPI. Slides were mounted with Prolong TM Diamond Antifade Mountant 
(#P36979, Invitrogen).  






























CD68 Macrophages  
CD163 Macrophages  
CD20 B-cells 





























CD4 CD4 helper T cells 
CD8 CD8 T cells 
PD-1 Immune checkpoint 
FoxP3 Regulatory T cells 
AE1/3 (PanCK) Tumour epithelium 
DAPI Nucleus 
Table 5 Multiplex immunofluorescence panels developed and used for staining 
PanCK= Pancytokeratin 
 
The stained slides were scanned with 3.0 Vectra microscope system 
(PerkinElmer, MA) in 10x magnification. A spectral library was generated using 
each fluorophore signal and an unstained section for auto-fluorescence. 
Fluorescence bleed-through between different fluorophores was addressed by 
spectral unmixing of the multiplex image data after image acquisition. This 
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spectral library was the cornerstone of our marker quantitation, as the 
fluorescence intensity of each target was extracted from the multispectral data 
based on their specific spectral properties. 
2.7.3 Multiplex immunofluorescence analysis 
The InForm 2.4.2. software package was used for our analysis because of its 
unique pattern recognition based image analysis. The spectral library created 
from singlex IF staining (including auto-fluorescence) was used in order to un-
mix the signal from each fluorophore in the multiplex image. By doing this, the 
fluorescent bleed-through was eliminated. The analysis comprised of three 
steps: tissue segmentation, cell segmentation and cell phenotyping (Figure 4). A 
selection of representative multispectral images was used for machine learning 
alongside a simulated ‘brightfield’ image that was produced from the software 
in order to facilitate tissue recognition with classic pathology views. This was an 
iterative process in which settings were refined with each round under my 
supervision until the output image met the desired criteria described in detail 
below. Only then were the settings saved within an algorithm which was used for 
automated batch analysis of the rest of the multispectral images.  
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Figure 4 Multiplex immunofluorescence analysis workflow 
(A) Representative multiplex immunofluorescence image, spectrally unmixed. (B) Tissue 
Segmentation with magenta as epithelium, blue as stroma and grey as background. (C) Cell 
segmentation, nuclei shown in green and cytoplasmic membranes in orange. (D) Cell phenotyping 
in which each cell is given a colour coded identity. All images are from the same core.  
 
Tissue segmentation was the first step which allowed for segmentation of the 
image in tissue compartments (epithelium vs stroma vs background) (Figure 4B). 
Thirteen representative multispectral images were used for training. Due to 
tissue heterogeneity, the accuracy of the segmentation was proportionate to the 
number of images used for training. However, the use of 14 images or more 
caused significant delays in each processing step and software crashes, therefore 
thirteen images were used as a compromise. PanCK staining was used as a 
‘mask’ for the epithelial compartment to facilitate tissue segmentation. 
Acceptable tissue segmentation was arbitrarily defined as 80% of the entire core 
image. The outcome of tissue segmentation (epithelium vs stroma vs 
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background) for each core image was assessed visually and cores that did not 
meet the criteria were excluded from the analysis.  
Cell segmentation was the second step which allowed for segmentation of the 
subcellular compartments (nucleus vs cytoplasm vs membrane), shown in Figure 
4C. Nuclear identification was reliably conducted using DAPI staining for nuclei. 
However, occasional nuclei closely situated (without any intervening cytoplasm) 
were recognised as one large nucleus. This was addressed by several iterative 
rounds of segmentation fine-tuning the ‘cell roundness’ and ‘distance to 
nucleus’ parameters. Acceptable cell segmentation was arbitrarily defined as 
90% of the entire core images with 10% poorly segmented area. It should be 
noted that more than 95% of cores had near perfect cell segmentation.  
Cell phenotyping was the third step in which each cell can be given a phenotype 
identity (Figure 4D). The software was trained manually to identify several 
immunophenotypes based on tissue architecture, cell morphology and 
fluorophore staining of the cell. For panel 1 (Figure 5A), the cell phenotyping 
was: M1-like macrophages (CD68+ CD163-), M2-like macrophages (CD68- CD163+ 
and CD68+ CD163+), B cells (CD20+), epithelial cells (AE1/AE3+) and other cells 
(negative for all markers). In panel 2 (Figure 5B) cells were defined as: CD4 
effector T cells (CD4+ FoxP3- PD-1-), CD4 regulatory T cells (CD4+ FoxP3+ PD-1-
), PD-1 expressing CD4 T cells (CD4+ FoxP3- PD-1 +), CD8 effector T cells (CD8+ 
FoxP3- PD-1+), CD8 regulatory T cells (CD8+ FoxP3+ PD-1-), PD-1 expressing CD8 
T cells (CD8+ FoxP3- PD1-), epithelial cells (AE1/AE3+) and other cells (negative 
for all markers). The ‘other cells’ comprised of fibroblasts, blood vessels, 
nerves, muscle etc. Acceptable cell phenotyping was arbitrarily defined as 90% 
of the entire core images with 10% poorly segmented area. All cores that did not 
meet this threshold were not included in the analysis. 
After training was complete, the analysis algorithm was run on all images and 
automated identification and counting of each cell phenotype in each tissue 
compartment was performed. This output was available for each core in an excel 
format. Any cores with tissue folding, more than 5% artefact staining (such as 
unspecific staining of prostate crystalloids) or less than 60% malignant 
epithelium were excluded from the analysis. 




Figure 5 Multiplex immunofluorescence cell phenotyping 
Cell phenotyping for the macrophage and B cell panel (A) and T cell lymphocyte panel (B). 
Spectrally unmixed images (left) with corresponding colour coded cell phenotypes (right).  
 
2.8 Gene expression analysis of formalin fixed paraffin 
embedded tissue using HTG EdgeSeq Precision 
Immuno-Oncology Panel 
The HTG EdgeSeq Immuno-Oncology Assay (HTG Molecular Diagnostics, Inc., 
Tucson, AZ) was performed in order to compare mRNA expression levels of 
multiple immune markers on FFPE prostate tissue biopsies. Forty-eight 
diagnostic biopsy cores from patients within the discovery TMA cohort were 
selected for gene expression analysis, including 24 without LN metastasis and 24 
with LN metastasis respectively. This assay contained probes to measure the 
expression of 1,410 RNAs. Annotated H&E slides alongside an unstained 5 µm 
blank serial section were sent to HTG EdgeSeq Company (Tuscon, Arizona). The 
samples were processed at HTG Molecular Diagnostics, Inc. (HTG), Tuscon, 
Chapter 2 57 
 
Arisona, USA. I performed the data analysis using the HTG reveal software. The 
processing steps that were undertaken are briefly described.  
2.8.1 Sample preparation 
The HTG EdgeSeq System chemistry workflow follows an automated procedure, 
thus avoiding common operating errors. The samples were randomly allocated on 
a 96-well plate and put on the HTG EdgeSeq processor. HTG EdgeSeq Lysis Buffer 
was added to lyse the sample making the RNA available. The lysed samples were 
transferred to another standard 96-well micro-titer plate. Then, functional DNA 
Nuclease Protection Probes (NPPs) were added in excess amounts and hybridised 
with target RNAs. S1 nuclease was subsequently added to digest excess non-
hybridised RNA and NPP probes. NNPs were flanked with universal wing 
sequences which hybridised to universal DNA wingmen, preventing S1 nuclease 
digestion. This produced a 1:1 ratio of NNP detection probes to RNA initially 
present in the sample. The processed samples were then transferred to a 96-well 
micro-titer plate with a v-bottom, the stop plate. The S1 digestion step was 
terminated by termination solution followed by heat denaturation which 
released the NPPs from the DNA-RNA duplexes. Each processed NNP from the 
stop plate was used as a template to set up a PCR reaction. 
2.8.2 Library preparation 
The library was prepared using HTG EdgeSeq PCR processing. Specifically 
designed primers (referred to as tags) complementary to the 5’- and 3’ end 
‘wing’ sequences of the NPPs were added, along with common adaptors for 
cluster generation on an illumine sequencing platform. Each tag contained a 
unique barcode used for sample identification and multiplexing. No Template 
Control reactions (H2O alone) were made for each master mix used during qPCR 
process as a test for no probe or qPCR reagent contamination. The library was 
subsequently prepared.  
2.8.3 Library quantification and Normalisation 
After the PCR amplification was finished, clean up was performed to remove 
unincorporated tags with HTG EdgeSeq AMPure cleanup of Illumina Sequencing 
Libraries. Following library preparation, all samples and controls were quantified 
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using HTG EdgeSeq KAPA Library Quantification for Illumina Sequencing in 
triplicate. The HTG EdgeSeq RUO library calculator was used for ensuring there 
was sufficient sample concentration for library pooling and determined the 
appropriate sample dilution for the library pool. All samples had sufficient levels 
of PCR product to be pooled for sequencing. It also determined the volume of 
denaturation reagents to be added to the library. In brief, 2M NaOH was added, 
samples were vortexed, spun down and incubated for 8’ at room temperature. 
Then, cold HT1 buffer was added, followed by 2M HCl and the sample was 
vortexed and spun down. The PhiX control adaptor-ligated library was spiked at 
a concentration of 12.5 pM to the pooled library. The concentration of the 
pooled library loaded on the NextSeq flow cell was 3 pM. The library was 
vortexed, spun down, denatured for 4 min at 98oC and immediately chilled on 
ice for 5 min. The denatured library was loaded into the well of NextSeq 
sequencing catridge.  
2.8.4 Sequencing 
The sequencing was performed on the Illumina NextSeq sequencer in accordance 
with HTG EdgeSeq Illumina NextSeq sequencing.  
2.8.5 Data analysis 
The sequencing data on mRNA expression of target genes were imported into 
HTG EdgeSeq parser software for alignment to previously defined target 
sequences. The HTG Reveal App (https://reveal.htgmolecular.com/) was used 
for quality check and data normalisation. Data from three samples that did not 
pass quality control (QC) metrics and were excluded from the analysis. 
2.9 In vitro experiments 
2.9.1 Cell Culture and Cell Storage 
Human prostate cancer cell lines were acquired from the American Type Culture 
Collection (ATCC) and they were routinely tested six monthly for mycoplasma 
using an in-house MycoAlert™ Mycoplasma Detection Kit (Lonza, Switzerland), 
according to the manufacturer’s instructions. All cell lines were grown in 
standard conditions containing 5% CO2 at 37°C in a tissue culture class I 
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incubator. PC3M, C4-2, LNCaP and DU145 cells were grown in RPMI-1640 
medium, 10% FBS and 1% L-Glutamine. All the reagents are listed in Table 2. 
Cells were passaged approximately every 3 to 4 days at 60-80% confluency 
depending on cell line growth rate. Medium was aspirated, cells were washed 
with PBS, and trypsin was added for 2-3 min incubation for cell detachment. 
Fresh medium was added to neutralise the trypsin and cells were counted using 
a CASY® counter (Innovatis) and seeded as required. Cell suspensions were 
transferred to new flasks/ plates. 
Cell lines were stored using cryo-freezing. Cells were trypsinised and 
resuspended in fresh media. They were subsequently centrifuged at 300 rpm and 
cell pellets were resuspended in 90% (v/v) FBS and 10% (v/v) dimethyl 
sulphoxide (DMSO). 1 ml aliquots were transferred to cryotubes (Nunc) on dry ice 
wrapped in cotton wool. They were frozen overnight at -80°C and placed in 
liquid nitrogen for permanent storage the next day. 
2.9.2 Protein extraction 
RIPA lysis buffer was used for protein extraction. RIPA lysis buffer was added 
according to plate volume and cell confluency, e.g. 100 µl in 80% confluency in a 
6 well plate. Cells were scraped off and placed on ice for 15 min. They were 
then centrifuged at 11,200 rpm for 15 min at 4°C. The supernatant was retained 
and samples were stored at -80°C.  
2.9.3 Western Blot  
Protein lysates were quantified by Bradford protein dye assay (protein assay dye 
reagent concentrate, Biorad) in a spectrophotometer. Western Blots were 
performed using 10 well pre-set gradient SDS-PAGE electrophoresis gels. Briefly, 
20 μg of cell lysate were re-suspended into 6.25 μl sample reducing agent buffer 
with 2.5 μl NuPAGE loading dye and dH20 (25 μl total volume). Samples were 
then loaded onto a 4-12% BIS-TRIS gel with MOPS running buffer and 
electrophoresed at 100 V for initially 15 min then increased to 130 V until the 
dye front reached the end of the gel. Proteins were then transferred to a PVDF 
membrane at 100 V for 1 hour in a transfer buffer of 10% methanol and 10% 10x 
blotting buffer in dH2O. Membranes were then blocked with 5% milk in TBST for 
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1 hour. They were then probed with anti-B7-H3 primary antibody (14058, Cell 
Signalling) at 1:1000 (v/v) dilution in 5% bovine serum albumin (BSA) in TBST 
with 0.1% sodium azide overnight. The next day the membranes were washed 
with TBST on a shaker 3 times for 15 min and then a secondary goat anti-rabbit 
IgG HRP-linked antibody (7074, Cell signalling) was added at 1:5000 (v/v) 
dilution in 5% milk in TBST. Membranes were incubated for an hour and then 
washed with TBST on a shaker 3 times for 15 min. ECL or ECL Plus were added to 
the membrane according to manufacturer’s instructions and chemiluminescence 
was imaged in Biorad ChemiDoc system. Anti-HSC 70 (sc-7298, Santa Cruz) was 
used as the loading control paired with secondary goat anti-mouse IgG HRP-
linked antibody (7076, Cell signalling). Image analysis was performed using 
ADOBE photoshop. 
2.9.4 RNA extraction and cDNA preparation  
Total RNA was extracted from cell lines grown using the RNeasy mini kit (Qiagen) 
according to manufacturer instructions when cells reached approximately 60% 
confluency. The additional recommended step to remove genomic DNA using 
RNase-free DNase 1 (Qiagen) was included. RNA was eluted in 20 μl of nuclease 
free water. The quality and quantity of the purified RNA was assessed using 
Nanodrop 2000/200c (Thermo Scientific). 
cDNA was reverse transcribed using 2-4 μg of the extracted RNA using the High 
Capacity cDNA Transcription Kit (Applied Biosystems) according to the 
manufacturer’s instructions. The final reaction volume was 20 μl, comprising of 
10 μl RNA, 2 μl 10x RT buffer, 0.8 μl 25 dNTP Mix, 2 μl 10x RT Random Primers, 1 
μl Multiscribe Reverse Transcriptase and 4.2 μl nuclease free water per reaction.  
This was placed in a thermocycler with the following successive thermal 
conditions: 25oC for 10 min, 37oC for 120 min, 85oC for 5 min, followed by 4oC 
until the samples were removed. Samples were subsequently stored at -80oC. 
2.9.5 Quantitative Polymerase chain reaction (qPCR)  
Roche universal probe library was used for all primer design (Table 6). qPCR was 
done using a 96 well plate with a 20 μl reaction volume per well comprising of 10 
μl 2x Taqman® universal PCR Master Mix (Applied Biosystems), 0.2 μl Universal 
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Library probe (Roche), 0.2 μl of forward and reverse primers respectively, 2 μl 
cDNA (routinely diluted 1/7) and 7.4 μl nuclease free H20.  Each sample was 
loaded in triplicate and the 96 well plate was sealed with microAmp optical 
adhesive film (Thermo Fisher Scientific) and spun prior to thermal cycling 
conditions to ensure the samples were at the bottom of the wells. The 
consecutive thermal cycling conditions were as follows: 50oC for 2 min, 95oC for 
10 min, 40 cycles of denaturation at 95oC for 15 min and 60oC for 1 min 
(ThermoFisher Scientific Quant studio 3 Real-Time PCR System). Casc3 was used 
as the housekeeping control for all genes examined.   
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) Probe 
CASC-3 accaccgcctcatctgtatc tgggcggggttatagtaggt 25 
B7-H3 tgcaaatggcacctacagc cctcagggacctggacct 18 
MMP2 ccccaaaacggacaaagag cttcagcacaaacaggttgc 43 
MMP3 gcagtttgctcagcctatcc tttctcctaacaaactgtttcacatc 58 
MMP9 gaaccaatctcaccgacagg gccacccgagtgtaaccata 6 
TIMP1 ctgttgttgctgtggctgat aacttggccctgatgacg 3 
TIMP2 gaagagcctgaaccacaggt cggggaggagatgtagcac 43 
TIMP3 cacccctcacctgtggaa tgacccaaaccagaaccaac 3 
CCL2 agtctctgccgcccttct gtgactggggcattgattg 40 
CCL26 ctgggtgcgaagctatgaat tcttgcctcttttggtagtgaa 32 
CLDN1   cctatgaccccagtcaatgc acagcaaagtagggcacctc 20 
CLDN7 cacctgctggctcacctc ccggcaagtcccaaagta 26 
CLDN11 cccggtgtggctaagtacag caacaagggcgcagagag 20 
CXCL1 cgaaaagatgctgaacagtga gcctctgcagctgtgtctc 35 
CXCL6 gtccttcgggctccttgt cagcacagcagagacaggac 68 
CXCL16 tgattgagtcttctttatggaaaca gaagccaggaatcacagtaagg 30 
CXCL8 agacagcagagcacacaagc Atggttccttccggtggt 72 
IL4R gtgctcattcatttaacagagctt actgaacaccccttgacagc 16 
IL11 ggacagggaagggttaaagg gctcagcacgaccaggac 37 
IL33 ccaccaaaaggccttcact aaggcaaagcactccacagt 27 
MMP1 gctaacctttgatgctataactacga tttgtgcgcatgtagaatctg 7 
MMP10 ctgacgttggtcacttcagc gcaaatctggtgtataattcacaatc 72 
Table 6 Primers and probe pairs used  
 
2.9.6 Transient silencing transfection using Lipofectamine 
RNAiMAX 
Cells were seeded the day before transfection in a 6 well plate, typically 
100,000 cells/well so that they were transfected at 60-80% the following day.  
On the day, Lipofectamine RNAiMAX was diluted in Opti-Mem medium (9 μl in 
150 μl) and siRNAs (Table 7) were also diluted in Optimem medium (9 μl in 150 
μl). The solutions were combined at a 1:1 ratio and left for 5 min at room 
temperature. 250 μl were added to each well and cells were incubated for 24-48 
hours.  
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siRNA name Cat Number Target sequence 
ON-TARGETplus Human 



















CD276 siRNA (S4 siRNA) 
J-007813-12-0005 ACCAAAGACACGAUGCAUA 
ON-TARGETplus Non-
targeting Control Pool  
(NT siRNA) 
D-001810-10 Not disclosed 
Table 7 List of siRNA sequences 
 
2.9.7 Generation of stable cell clones with reduced levels of B7-
H3 expression 
Stable knock out (KO) clones for B7-H3 were generated using CRISPR/Cas9 
plasmid specific to human B7-H3 sequence and homology directed repair (HDR) 
insertion plasmid (sc-402032) in PC3M and C4-2 cell lines. Amaxa Cell Line 
Nucleofector Kit V (VCA -1003, Lonza) was used for electroporating PC3M cells, 
and Amaxa Cell Line Nucleofector Kit R (VCA-1001, Lonza) was used for C4-2. 
Electroporation setting code T013 was used for PC3M cells and T009 for C4-2 
cells. Scrambled CRISPR plasmid and an in-house Infra-Red Fluorescent Protein 
plasmid with puromycin resistance was used as control. 10 cm plates were 
prepared with 4 ml full media.  Media was then changed every 5 days and 
puromycin was added to the media at 2 μg/mL for PC3M and 1.2 µg/ml for C4-2. 
After approximately 21 days for PC3M and 35 days for C4-2, clones were picked 
using selection disks soaked in trypsin. B7-H3 expression was checked with 
Western blotting and PCR. Four knock out (KO pool, KO4, KO10, KO13) B7-H3 
clones were picked for PC3M cells, and five knock out (KO pool, KO2, KO3, KO10, 
KO18) B7-H3 clones were picked for C4-2 cells. For both, one control pool was 
picked. For both cell lines, two KO clones and one control pool (referred to as 
PC3M cntr and C4-2 cntr) were used in subsequent experiments. 
2.9.8 In vitro Growth Assay  
LNCaP B7-H3 pool siRNA (si B7-H3) and NT siRNA (siNT) controls were seeded in 6 
well plates, 400,000 cells/well. PC3M si B7-H3 and si NT controls were seeded in 
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6 well plates, 200,000 cells/well. After 72 hours cells were counted in CASY® 
cell counter (Innovatis). All experiments were done in three biological and four 
technical replicates.  
2.9.9 In vitro apoptosis assay 
Cells were seeded in a 6 well plate and transfected with lipofectamine RNAiMAX 
as previously described. The plate was incubated for 72 hours at 37oC and 
stained with Annexin V and propidium iodide using the FITC Annexin V Apoptosis 
Detection Kit I (Cat: 556547, BD Biosciences) according to manufacturer’s 
instructions. In brief, floating (in the media) and attached (trypsinised) cells 
from each well were put in one eppendorf and were spun down at 1000 rpm for 
5 min. They were washed with cold PBS two times and spun down at 1000 rpm 
for 5 min.  The cell pellet was resuspended in 200 µl of 1x binding buffer and 
100 µl of the solution were transferred to a 5 ml FACS tube. 5 µl of Annexin V 
and 5 µl of propidium iodide were added and the solution was vortexed and 
incubated for 15 min in the dark at room temperature. An unstained sample was 
always used as a control. Another 300 µl of 1x binding buffer were added to each 
tube and proceeded to analysis by flow cytometry in the ATTUNE NxT flow 
cytometer (ThermoFisher Scientific). Three biological replicates with two 
technical replicates were used. 
In the flow cytometer, cells were firstly visualised in a data plot of SSC-A and 
FSC-A in order to exclude cell debris. Then, they were visualised in a FSC-H and 
FCS-A plot in order to exclude any duplicate cells. The unstained sample was 
used for setting up the negative gates. The data were saved in excel format and 
further analysis was performed in FlowJo 10.  
2.9.10 In vitro colony formation assay 
Cells were seeded in 6 well plates in low numbers so that they could form 
discernible separate colonies. 500 cells per well were seeded and 3 wells were 
seeded for each cell condition (PC3M cntr, KO pool, KO10). Cells were left to 
grow for 3 weeks (this time frame has previously been optimised in our lab). 
Afterwards, they were fixed in 100% methanol for 30 min at -20°C and stained 
with 0.25% crystal violet (V5265 Sigma) for 10’. Cells were then washed in dH20 
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until there was no more dye to come off and plate was left to dry overnight. The 
next day, the plate was imaged in LI-COR (LI-COR Biosciences) with 700 
wavelength, and Image Studio Lite Ver 5.2 was used for image analysis. 
2.9.11 In vitro transwell migration assay 
Cells were seeded in 6 well plates and when they reached 60%-80% confluency 
they were serum starved for 24 hours. Then cells were tryspinised and 
resuspended in full serum media to deactivate the trypsin. Cells were 
centrifuged at 1000 rpm for 5 min and re-suspended in serum free media. They 
were then counted using CASY® cell counter (Innovatis) and made up to a cell 
concentration of 1 x 105/ml of serum free medium (unless otherwise stated). 750 
μl of full serum media was added to the bottom of each well of a 24 well plate 
and a transwell Boydon Chamber was inserted into each well. 500 μl of the cell 
suspension was then added onto each chamber. This created a top to bottom 
cell migration flow resulting in migrating cells adhering to the lower surface of 
the boydon chamber membrane.  
Cells were routinely incubated at 37oC for 48 hours. First the medium was removed 
from the upper chamber and each chamber was fixed at -20oC in 100% methanol for 
30 min. Subsequently, methanol was removed and each chamber was placed in 
filtered haematoxylin for 30 min. Then, each chamber was washed in H2O scrubbing 
off the cells attached to the upper membrane. They were then placed inverted at 
room temperature to dry for 15-20 min.  Once dried, each membrane was detached 
using a scalpel and mounted onto a slide using DPX mountant. They were left to 
stabilise overnight and cells of each membrane were counted in a light microscope 
at x20 magnification.  
2.9.12 In vitro scratch wound healing assay  
Essen Bioscience 96 well ImageLock Microplates were seeded with 30,000 cells/ 
well and incubated for 24 hours in a culture incubator. Once the cells reached 
90-100% confluence, the WoundMakerTM was applied in order to create 
homogenous 700-800 µm wide scratch wounds. The cells were then washed with 
PBS to wash away any floaters and cell debris and then 100 μl of media was 
added. Cells were then placed in the IncuCyte within an incubator and two 
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hourly images were recorded for 72 hours. The output used for analysis was 
wound confluence/time, calculated using the IncuCyte software.  
2.9.13 In vitro invasion assay 
A Boydon Chamber was inserted into each well of a 24 well plate. 100 l of Matrigel 
was added in each chamber diluted 1:1 in ice cold PBS. The plate was incubated 
for 30 min at 37oC to allow matrigel to set. Suspensions of PC3M cells were 
prepared in RPMI supplemented with full serum at 5 x 105 cells/ml. Once the 
matrigel was set, the transwell chambers were inverted and 100 l of the cell 
suspension (5 x 104 cells) were placed onto the underside of the filter (which was 
now the uppermost). The inverted transwells were then covered carefully with 
the base of the 24 well plate such that the droplet of cell suspension was in 
contact with the base. The plate was incubated for 3 hours to allow cells to attach 
to the chamber. It was then turned again right-side-up and each transwell was 
washed in serum free RPMI three times and then left in it. On top of the matrigel, 
100 l full serum RPMI was added. The plate was incubated at 37oC for 4 days.   
Each transwell chamber was then placed in 1 ml of 1:1000 (v/v) Calcein AM in 
serum free RPMI in a 24 well plate. The plate was incubated for 1 hour at 37oC 
and imaged using an Olympus FV100 confocal microscope the same day. Stained 
cells were visualised using a 20x objective. Optical sections (Z-stack) were taken 
at 15 m intervals moving up from the underside of the filter into the matrigel, 
producing a series of images. To quantify these, Image J software was used. For 
analysis, only cells in the 15 m section or above were considered invasive and 
quantified according to their pixel intensity. The sum of these values was 
calculated and normalised to the value obtained from the corresponding 0 m 
section as a “loading” control. It is important that the same pixel threshold was 
used for all the samples each experiment. Three biological replicates with two 
technical replicates were used.  
 
2.9.14 RNA sequencing  
RNA sequencing (RNA-seq) with poly-A-tailed mRNA selection based RNA-seq 
library preparation was performed by our Molecular Technology Services.  RNA 
was extracted from PC3M cntr, KO pool and KO10 clone for B7-H3 using Qiagen 
kit as previously described, including the additional DNase step for genomic DNA. 
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For tapestation RNA quality control, 5 µl of 50 ng/µl per sample was required, 
and for library preparation 1 µg from each sample was used. Quality and 
quantity of the libraries were assessed on an Agilent 2100 Bioanalyser and Qubit 
(Thermo Fisher Scientific), respectively. The libraries were subsequently run on 
the Illumina Next Seq 500 using the High Output 75 cycles kit (2 × 36 cycles, 
paired-end reads, single index). Three biological replicates of each sample with 
three technical replicates were sequenced. Quality checks on the raw RNA-
Seq data files were conducted by Mr William Clark (Core Sequencing Services, 
Beatson Institute) using fastqc 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Analysis of the 
RNAseq data was carried out by Dr Ann Hedley (Informatician, Beatson Institute) 
using genes with an absolute fold change > 2 and an adjusted P value < 0.05 in 
Metacore.   
2.10 Statistical methods 
Statistical analyses were carried out with Graph Prism 8 and IBM SPSS statistics 
25. Comparisons between groups were conducted using Mann–Whitney U test 
(unpaired, nonparametric, two-tailed), t-test (unpaired, parametric, two-
tailed), ANOVA, Fisher’s and Chi-square test where appropriate. Spearman 
correlation and Cohen’s Kappa coefficient for agreement were preformed to 
examine correlations between numerical and categorical values respectively. 
Kaplan Meier curves were compared with log-rank test. Multivariate logistic 
regression models were used to identify novel predictive factors of lymph node 
metastasis. Covariates consisted of peak preoperative PSA value, stage, Gleason 
Score and percentage of positive biopsy cores (when available). Receiver 
operative curve (ROC) analysis was performed and area under the curve (AUC) 
was used to quantify the predictive accuracy. For the targeted gene expression 
panel, HTG reveal software was used for statistical analysis using the DESeq2 
test with an adjusted p value less than 0.05 and a log fold change value of 
greater than 1.5. 
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Chapter 3 Immune profiling of prostate cancer 
tumour microenvironment in the context of 
lymph node metastasis 
Prostate cancer is known for its biological and clinical heterogeneity, with a 
large discrepancy observed between incidence and mortality rates (7). 
Identifying patients with a prostate tumour that grows slowly and does not 
metastasise is critical for patient treatment decision, including whether 
extended pelvic lymph node dissection is indicated at the time of radical 
surgery. During tumour progression, lymph nodes are often the first organs 
affected by metastases. The presence of lymph node metastasis increases the 
15-year prostate cancer specific mortality risk from 0.8-1.5% for organ confined 
disease to 22-30% (150). All cancer staging systems, including the TNM staging 
system for prostate cancer, assess the presence or absence of lymph node 
involvement for the evaluation of patient prognosis (151). Therefore, metastasis 
to the lymph nodes has a big impact on patient outcomes.  
Tumour immune evasion is one of the hallmarks of cancer and tumour infiltrating 
immune cells are decisive factors of cancer progression (33, 38). The immune 
landscape of prostate cancer has been surprising difficult to characterise with 
multiple conflicting results regarding clinical outcomes (67), likely due to study 
limitations as well as inherent tumour heterogeneity. It is therefore essential to 
comprehensively characterise the baseline immune status of well-defined 
patient cohorts in order to gain a better understanding of disease progression. I 
hypothesised that local immune cell infiltration shapes the local host anti-
tumour response and influences the spread to regional lymph nodes. My 
objective was to provide additional novel biomarkers that could improve the 
current predictive nomograms of lymph node invasion. 
I applied multiplex immunofluoresnce to characterise the tumour immune 
microenvironment at the tissue level using specimens obtained from radical 
prostatectomy (RP) and extended pelvic lymphadenectomy. The discovery cohort 
included patients with pathologically confirmed regional lymph node metastases 
(LN+) and patients free from regional lymph node metastases (LN-). The 
identified immune signature of LN+ disease was validated in a comparable 
independent patient cohort. I further investigated for potential correlation 
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between key reported genetic alterations in PCa, such as ERG translocation and 
loss of PTEN expression, and the tumoural immune cell composition. Finally, I 
explored the potential for translating this immune signature in the clinic and its 
significance in low-risk prostate cancer patients. 
3.1 Validation of multiplex immunofluorescence assay 
Using chromogenic IHC and singleplex IF staining, serial sections of FFPE human 
tonsil tissue were stained. Tonsil was chosen because of its well-characterised 
tissue architecture and immune cell spatial distribution. Both techniques 
resulted in similar patterns of staining, as shown in Figure 6A-B. CD20 (B cell 
lymphocytes), CD68 (Macrophages-M1 like), CD163 (Macrophages-M2 like), CD4 
(helper T cells), CD8 (cytotoxic T cells), FoxP3 (regulatory T cells), PD-1 
(immune checkpoint) and AE1/3 (pan cytokeratin) had specific staining without 





Figure 6 Photographs of representative examples of validation from IHC and H&E (bottom 
panels), uniplex and multiplex IF (top panels) in tonsil tissue 
(A) Macrophage and B cell panel: CD20 (B cell lymphocytes), CD68 (Macrophages-M1 like), 
CD163 (Macrophages-M2 like), AE1/3 (cytokeratin positive epithelium). 10x magnification.   
(B) T cell lymphocytic panel: CD4 (helper T cells), CD8 (cytotoxic T cell), FoxP3 (regulatory T 
cells), PD-1 (immune checkpoint and AE1/3 (cytokeratin positive epithelium). 10x magnification.   
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3.1.1 Correlation between mIF and DAB chromogenic IHC 
Serial sections from the discovery TMA were stained with the mIF panels and 
chromogenic DAB IHC for individual markers. Immune cell densities for each core 
were quantified using inForm and HALO automated scoring respectively. I 
compared mIF and individual IHC staining using Spearman r value for correlation. 
Overall, there was significant positive correlation between mIF and IHC 
stainings. CD68 (r=0.67, p<0.0001), CD163 (r=0.46, p<0.0001), CD20 (r=0.31, 
p=0.02), CD4 (r=0.68, p<0.0001), CD8 (r=0.752, p<0.0001), FoxP3 (r=0.3, 
p=0.003), PD-1 (r=0.23, p=0.05) showed significant positive correlations. PD-1 
had the weakest, but significant, positive correlation, which was unsurprising 
due to the scarcity of this marker.  
3.1.2 Co-localisation of markers 
One of the main advantages of using mIF was the co-localisation of markers 
within individual cells (Figure 7), thus defining their specific cell phenotypes. We 
were able to identify M2-like macrophages (CD68+ CD163+), CD8 regulatory T 
cells (CD8+ FoxP3+), PD-1 positive CD8 T cells (CD8+ PD-1+), CD4 regulatory T 
cells (CD4+ FoxP3), PD-1 positive CD4 T cells (CD4+ PD-1+). Unexpectedly, we 
observed cells with double staining for CD4 and CD8 which has been observed 
before (91). The proportion of cells with double staining was minimal and they 
were not quantified further.  
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Figure 7 Representative examples of co-localisation of the cell markers 
Representative image of M2-like macrophages (CD68+ CD163+) in (A), CD8 regulatory T cells 
(CD8+ FoxP3+) in (B), PD-1 positive CD8 T cells (CD8+ PD-1+) in (C), CD4 regulatory T cells 
(CD4+ FoxP3) in (D), PD-1 positive CD4 T cells (CD4+ PD-1+) in (E) and double CD4+ CD8+ cells 
in (F). White arrows indicate the co-localisation of markers.  
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3.2 Immune profiling of the discovery TMA cohort 
3.2.1 Clinical characteristics of lymph node discovery TMA 
Of the ninety-four patients that were identified, 50 had pathologically confirmed 
regional nodal metastasis (LN+) and 44 had no evidence of lymph node 
metastasis (LN-). Patient clinicopathological characteristics are presented in 
Table 1. All studied patients had newly diagnosed prostate cancer and had not 
received pre-operative chemotherapy or ADT. LN+ patients were younger than 
LN- patients (62 years vs 67 years, p=0.0001). The two groups were otherwise 
comparable in all clinicopathological parameters, including number of excised 
lymph nodes, pre-operative PSA levels, pT stage, Gleason score and presence of 
perineural invasion (PNI). There were 65 patients with Gleason score 7, 15 
patients with 3+4 and 50 patients with 4+3. Due the small number of patients 
with Gleason score 3+4 (11 in LN+ and 4 in LN- groups), all patients with a sum of 
Gleason score 7 were grouped together in order to perform meaningful 
statistical analysis.  Follow-up data were available for 91 patients, ranging from 
33 to 70 months (median 41 months). Fifteen patients had disease relapse after 
surgery and four patients died during follow-up, two of them due to prostate 
cancer. These limited numbers prohibited any meaningful conclusions for overall 
or cancer specific survival, and relapse-free survival was used as surrogate for 
these events. 
 Overall Lymph node metastasis 


















15.5 (11.5- 17.7) 14.2 (11-17) 0.831 
Stage, N (%)    0.089 
    pT2 34 (36.17) 20 (45.45) 14 (28)  
    pT3-T4 60 (63.83) 24 (54.55) 36 (72)  
Gleason 
Score, N (%) 
   0.109 
7 65 (69.15) 34 (77.27) 31 (62)  
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>7 (8-9) 29 (30.85) 10 (22.73) 19 (38)  
PNI, N (%)    0.156 
Negative 15 (15.96) 10 (22.73) 5 (10)  
Positive 79 (84.04) 34 (77.27) 45 (90)  
     
 
Table 8 Clinical and histopathological characteristics of discovery TMA of patients with 
(LN+) and without lymph node metastasis (LN-) 
CI= Confidence interval, PSA: Prostate specific antigen, PNI: Perineural invasion. Mann-Whitney 




3.2.2 Immune profiling of intermediate and high risk prostate 
cancer patients 
Characterising the baseline immune status of intermediate and high-risk PCa is 
essential for understanding disease progression as well as planning targeted 
immunotherapies. I aimed to describe the frequencies as well as spatial 
localisation of macrophage and lymphocytic immune cell populations. The 
discovery TMA described previously was stained with mIF (1) Macrophage and B 
cell panel: CD68, CD163, CD20, PanCK and (2) T cell lymphocyte panel: CD4, 
CD8, FoxP3, PD-1, PanCK. The immune cell densities of different cell 
populations were quantified within the epithelial and stromal compartments 
separately using inForm 2.1 analysis software. The results are summarised in 
Table 9. Unsurprisingly, immune cell infiltration was more prominent within the 
stroma (232.9 cells/mm2) compared to epithelium (90.44 cells/mm2). 
Macrophages were the most prominent immune cell type irrespective of spatial 
compartment, 41.21 cells/mm2 within epithelium and 130.4 cells/mm2 within 
stroma. CD4 T cells were the second most frequent immune cell type within 
epithelium (35.42 cells/mm2) and within the stroma (90.29 cells/mm2). The most 
uncommon immune cell type overall were B cells. When encountered, they had 
formed tertiary germinal centres but that was present in very few cases (approx. 
10 out of 282 cores). 
Further characterisation of cellular subtypes showed that macrophages 
infiltrating the epithelium were polarised in M1 and M2 in comparable levels 
(19.02 cell/mm2 and 18.07 cells/mm2 respectively). Stromal macrophages had 
slightly more frequently M2-like phenotype (66.17 cells/mm2) compared to M1-
like (52.23 cells/mm2). CD4 effector T cells, CD4 regulatory T cells and PD-1 
positive T cells had median cell densities of 66.93 cells/mm2, 6.68 cells/mm2 
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and 6.48 cells/mm2 respectively within the stoma. Within the epithelium, CD4 T 
cell subtypes were present in lower densities, CD4 effector 21.6 cells/mm2, CD4 
regulatory 4.2 cells/mm2 and CD4 PD-1 positive cells 6.2 cells/mm2. Within the 
stroma, CD8 effector T cells had a median density of 29.85 cells/mm2, CD8 
regulatory T cells 0.51 cells/mm2 and CD8 PD-1 positive 5.64 cells/mm2. 
Intraepithelial cytotoxic CD8 T cells had a density of 6.33 cells/mm2, CD8 
regulatory T cells 2.85 cells/mm2 and CD8 PD-1 positive T cells 3.65 cells/mm2. 
It is noteworthy that CD8 regulatory cells were the scarcest immune subtype.  
 
N=94 total Immune cell densities  (cells/mm2) 
Epithelium 91 90.44 (82.84-113.8) 
Macrophages 83 41.21 (33.58-49.85) 
M1-like macrophages 83 19.02 (16-22.84) 
M2-like macrophages 83 18.07 (13.36-22.98) 
B cells 83 1.8 (1.41-3.66) 
CD4 T cells 66 35.42 (30.96-45.6) 
CD4 effector T cells 66 21.6 (15.5-23) 
CD4 regulatory T cells 66 4.2 (2.9-5.8) 
CD4 PD-1 positive T cells 57 6.2 (4.5-13.1) 
CD8 T cells 66 20.65 (14.6-24) 
CD8 effector T cells 66 10.33 (3.9-12.8) 
CD8 regulatory T cells 66 2.85 (1.3-4.1) 
CD8 PD-1 positive T cells 66 3.65 (0-6.9) 
Stroma 91 232.9 (202.9-269.8) 
Macrophages 83 130.4 (106.5-155.4) 
M1-like macrophages 83 52.23 (40.89-64.66) 
M2-like macrophages 83 66.17 (60.3-77.21) 
B cells 83 8.14 (5.46-12.3) 
CD4 T cells 66 90.29 (50.2-102.5) 
CD4 effector T cells 66 66.93 (34.31-82.77) 
CD4 regulatory T cells 66 6.68 (5.35-7.78) 
CD4 PD-1 positive T cells 66 6.48 (3.8-9.2) 
CD8 T cells 66 39.37 (32.16-52.7) 
CD8 effector T cells 66 29.85 (22.1-40.63) 
CD8 regulatory T cells 66 0.51 (0.32-1.5) 
CD8 PD-1 positive T cells 66 5.64 (3-8.55) 
Table 9 Immune cell densities of intermediate and high-risk patients included in the 
Discovery cohort 
Data are presented as median immune cell densities (cells/mm2) with 95% Confidence Intervals. 
N= number of cases with available data. 
 
An interesting observation was that stromal CD4 effector T cells were 
predominantly located at the tumour-stromal interface. This lead to a 
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collaboration with Dr Ian Powley (University of Leicester) who quantified the 
distance of CD4 effector T cells from epithelium using the phenoptr package in R 
software. Density plots were generated that showed the distance of CD4 effector 
T cells from the PanCK+ tumour cells (Figure 8). The median distance for all 
high-risk patients was 23.3 µm (20.6-27.3 95%CI), shown in Figure 8A. For LN+ 
and LN- patients the distance was similar, 25.85 µm (21.6-30 95%CI) and 20.65 
µm (18.8-26.2 95%CI, p=0.17) respectively (Figure 8B). 
 
Figure 8 Spatial distribution of CD4 effector T cells (CD4+ FoxP3- PD-1-) in  intermediate and 
high risk prostate cancer patients 
Density plot graphic representation of CD4 effector T cells (CD4+ FoxP3- PD-1-) according to their 
distance from the nearest PanCK+ cancer cells for all PCa patients (top) and in patients with (LN+) 
vs without (LN-) lymph node metastasis (bottom).  




3.2.3 Immune cell densities and ratios in discovery cohort 
patients with vs without lymph node metastasis 
The discovery TMA was designed and constructed to detect differences 
pertaining to lymph node spread in prostate cancer patients. Comparisons of the 
epithelial and stromal compartment immune cell densities between patients 
with (LN+) and without (LN-) lymph node metastasis are presented in Table 10. 
Intraepithelial M1-like macrophages were decreased in patients with lymph node 
metastasis (16.2 cells/mm2 vs 18.46 cells/mm2, p=0.046) and intraepithelial CD8 
cytotoxic T cells were also significantly decreased in the same patients (1.8 
cells/mm2 vs 12.6 cells/mm2, p=0.001). Stromal M1-like macrophages were 
decreased in LN+ patients, 45.03 cells/mm2 vs 64.04 cell/mm2, p=0.047. Stromal 
CD4 effector T cells were also decreased in the same patients, 32.5 cells/mm2 vs 
91.35 cells/mm2, p=0.0003. Lastly, CD8 effector T cells were decreased in LN+ 
patients, 22.7 cells/mm2 vs 40.63 cells/mm2 in LN- patients, p=0.008. There 
were no significant differences in M2-like macrophages, B-cells, CD4 and CD8 
regulatory T cells, CD4 and CD8 PD-1 positive T cells between patient groups.  
Biologically relevant immune cell density ratios were also calculated. The 
stromal ratio of M1/M2 macrophages was significantly lower in LN+ patients 
(0.56, 0.5-0.8 95%CI) compared to LN- patients (0.89, 0.6-1.1 95%CI, p=0.03). 
More intriguingly, the ratio of CD4 effector T cells to CD4 regulatory T cells 
within the stroma was also lower in LN+ patients (7.59, 1.7-16.2 95%CI) 
compared to LN- patients (18.76, 12.7-47 95%CI, p=0.0006). Lastly, the 
epithelium to stroma ratio of CD8 effector T cells was used as a surrogate for the 
CD8 cell infiltration within the tumours and was lower in LN+ patients (0.19, 











Lymph node metastasis 
Epithelium Negative =44 Positive =50 p value 
M1-like macrophages 83 20.64 (17.07-27.45) 16.38 (11.01-21.15) 0.046 
M2-like macrophages 83 18.46 (11.49-24.9) 16.2 (11.98-31.94) 0.895 
B cells  83 2.807 (1.41-8.29) 1.7 (0.84-4.2) 0.205 
CD4 effector T cells 66 23 (13.3-32.9) 18 (11.8-22) 0.093 
CD4 regulatory T cells 66 3.250 (1-6.2) 1.5 (0-4.2) 0.159 
CD4 PD-1 positive T 
cells 
57 8.015 (0-18.7) 6.2 (5.87-12.7) 0.19 
CD8 effector T cells 66 12.6 (6.5-21) 1.8 (0.68-5.7) 0.001 
CD8 regulatory T cell 66 3.8 (0.41-5.69) 2.2 (0.5-4.8) 0.772 
CD8 PD-1 positive T 
cells 
66 5.3 (0-9.4) 0 (0-6.82) 0.277 
Stroma    
M1-like macrophages 83 64.04 (39.11-89.31) 45.03 (39.7-55.3) 0.047 
M2-like macrophages 83 65.32 (53.91-76.92) 73.83 (54.69-83.85) 0.7 
B cells 83 8.9 (5.27-23.53) 7.05 (4.27-11.51) 0.193 
CD4 effector T cells 66 91.35 (55.41-154.1) 32.5 (14.1-70.61) 0.0003 
CD4 regulatory T cells 66 4.65 (1.6-7.94) 4.71 (3.6-5.4) 0.971 
CD4 PD-1 positive T 
cells 
66 7.74 (0-16.2) 8.73 (1.8-13.3) 0.597 
CD8 effector T cells 66 40.63 (28.1-95.46) 22.7 (11.5-31.38) 0.008 
CD8 regulatory T cells 66 0.56 (0.29-1.9) 0.51 (0.31-1.7) 0.9 
CD8 PD-1 positive T 
cells 
66 8.1 (2.9-16.3) 4.66 (0.7-7.9) 0.06 
Table 10 Summary of discovery cohort immune cell densities stratified according to lymph 
node status 
Comparison of intraepithelial and stromal immune cell densities in patients with vs without lymph 
node metastasis. Data presented as median immune cell densities with 95% Confidence interval 




3.2.4 Correlations between immune cell densities 
Further investigation of the relationships between different immune cells 
revealed a positive correlation between stromal CD4 effector cells and stromal 
CD8 effector cells (Spearman r= 0.648, p<0.0001), as well as intraepithelial CD8 
effector T cells (Spearman r= 0.256, p=0.003). Intraepithelial CD4 effector T 
cells positively correlated with intraepithelial CD8 effector T cells (Spearman r= 
0.4976, p<0.001) and M1-like macrophages (Spearman r= 0.373, p=0.004). 
Stromal CD4 effector cells also correlated with stromal M1-like macrophages 
(Spearman r= 0.346, p=0.008). Stromal CD8 effector T cells positively correlated 
with stromal M1-like (Spearman r= 0.4, p=0.001) and M2-like (Spearman r= 
0.278, p=0.003) macrophages. This was not surprising as there was a positive 
association between stromal M1-like and M2-like macrophages (Spearman r= 
0.413, p=0.0001).  
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The positive correlation between CD4 effector cells with CD8 effector cells and 
M1-like macrophages within the epithelium and stroma, in combination with the 
significantly increased immune cell density in the patients without lymph node 
metastasis suggest a possible interaction between those immune cell subtypes in 
order to orchestrate their anti-tumour response.  
3.2.5 Immune cell densities and clinicopathological 
characteristics      
The next step was to investigate the relationship between different immune cell 
densities and patients’ clinicopathological characteristics. Table 11-13 
summarise the associations of different immune cell populations within 
epithelium and stroma with patient clinical parameters. More intraepithelial M1-
like macrophages were associated with higher pT stage (14.45 vs 20.84, 
p=0.036), a finding somewhat counterintuitive (Table 11). Stromal CD4 effector 
T cells were increased in patients with lower pT stage (77.8 vs 36.46 cells/mm2, 
p=0.04) showing an association with early staged disease (Table 12). There were 
no statistically significant differences among immune cell counts with Gleason 
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 M1-like macrophages   M2-like macrophages  B cells 
Epithelium 
 N Median p 
value 
N Median p 
value 
N Median p 
value 
Stage   0.036   0.453   0.315 
   T2 28 14.45  28 19.6  28 2.9  
    T3-T4 55 20.84  55 16.36  55 1.7  
Gleason  
score 
  0.122   0.235   0.620 
=7 55 18.7  55 15.82  55 2.11  
>7(8-9) 28 20.17  28 24.59  28 1.75  
PNI    0.611   0.266   0.877 
Absent 11 17.82  11 28.66  11 2.9  
Present 72 19.13  72 17.21  72 1.75  
Stroma 
Stage   0.226   0.898   0.484 
    T2 28 44.3  28 65.28  28 8.81  
    T3-T4 55 55.3  55 69.2  55 7.94  
Gleason 
score 
  0.394   0.337   0.65 
=7 55 47.09  55 63.16  55 7.94  
>7(8-9) 28 59.99  28 77.62  28 8.977  
PNI    0.861   0.657   0.853 
Absent 11 52.15  11 94.86  11 4.92  
Present 72 52.3  72 65.87  72 8.35  
Table 11 Macrophage and B cell densities of discovery cohort stratified by 
clinicopathological parameters 
Data are presented as median immune cell densities (cells/mm2). N= number of cases with 
available data. Mann-Whitney test used for all statistical calculations. CI= Confidence interval, PNI= 
Perineural invasion 
 












Stage   0.11   0.654   0.318 
    T2 22 30.1  21 2.6  20 8.01  
    T3-T4 44 18.9  44 2  37 12.3  
Gleason  score   0.97   0.446   0.406 
=7 46 20.6  45 2.2  40 12.35  
>7(8-9) 20 20.9  20 2.1  17 8.57  
PNI    0.742   0.787   0.12 
Absent 10 10.55  9 2.2  10 4.3  
Present 56 20.95  56 2.1  47 11.6  
Stroma 
Stage   0.045   0.328   0.665 
    T2 28 77.8  22 4.13  22 6.69  
    T3-T4 57 36.46  44 4.84  44 8.8  
Gleason  score   0.393   0.549   0.582 
=7 46 63.78  36 4.64  46 7.99  
>7(8-9) 20 73.69  20 4.68  20 8.79  
PNI    0.411   0.66   0.752 
Absent 10 78.61  10 2.94  10 10.17  
Present 56 63.78  56 4.68  56 8.48  
Table 12 CD4 T cell densities of discovery cohort stratified by clinicopathological 
parameters 
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Data are presented as median immune cell densities (cells/mm2). Mann-Whitney test used for all 
statistical calculations. N= number of cases with available data. CI= Confidence interval, PNI= 
Perineural invasion 
 
 CD8 effector T cells CD8 regulatory T ells CD8 PD1+ T cells 
Epithelium 









Stage   0.2   0.76   0.5 
    T2 22 10.6  22 3.2  22 1.9  
    T3-T4 44 5.29  44 2.7  44 3.8  
Gleason  score   0.09   0.92   0.24 
=7 46 7.57  46 2.45  46 2.7  
>7(8-9) 20 1.95  20 3.25  20 5.85  
PNI    0.713   0.358   0.324 
Absent 10 2.35  10 1.1  10 8.56  
Present 56 6.63  56 3.25  56 1.95  
Stroma 
Stage   0.641   0.997   0.541 
    T2 22 27.75  22 5.98  22 1.9  
    T3-T4 44 30.64  44 5.34  44 3.8  
Gleason  score   0.714   0.595   0.2 
=7 46 31.59  46 0.53  46 5.16  
>7(8-9) 20 27.7  20 0.48  20 8.89  
PNI    0.07   0.388   0.504 
Absent 10 44.99  10 0.37  10 9.6  
Present 56 28.18  56 0.59  56 5.16  
Table 13 CD8 T cell densities of discovery cohort stratified by clinicopathological 
parameters 
Data are presented as median immune cell densities (cells/mm2). N= number of cases with 




In summary, comparison of different infiltrating immune cells with 
clinicopathological parameters revealed that tumours of higher pT stage (pT3-4) 
were associated with less stromal CD4 effector T cells and more intraepithelial 
M1-like macrophages.  
 
3.3 Immune profiling of Validation cohort 
3.3.1 Clinical characteristics of Validation cohort (Validation TMA) 
A validation TMA of intermediate and high-risk patients was used to test whether 
our results were maintained in a larger, independent patient cohort from 
another institution. The validation cohort included 285 patients with primary 
PCa who underwent RP and regional lymph node dissection. Two hundred and 
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fifty-one patients had one 0.6 µm core and 34 patients had two 0.6 µm cores 
from the index lesions. The median age at diagnosis was 64.05 years (63.27-
65.09 95% CI). The median follow-up time was 12.87 years (12.07-13.43 95%CI), 
during which 246 men developed biochemical recurrence, 145 men died (among 
whom, 70 men died from PCa). Table 14 presents the clinical characteristics of 
patients included in the validation cohort. A significant proportion of the cases 
were not informative due to complete lack of tissue samples, absence of cancer 
tissue and interpretable staining; however there was no significant difference 
between overall cohort and the informative cases. 
 All patients (285) Available for analysis 
(184) 
p value 
Age at diagnosis, 
median (95% CI) 
64.05 (63.27-65.09) 63.93 (63.06-65.32) 0.557 
Peak pre-op PSA, 
median (95% CI) 
13.55 (12-15.6) 12 (10.2-15.3) 0.883 
Gleason score, N (%)   0.98 
≤6 216 (76%) 138 (75%)  
7 22 (8%) 16 (9%) 
≥8 45 (16%) 29 (16%) 
missing 2 (0%) 1 (0%) 
pT stage, N ( %)   0.695 
2 150 (53%) 90 (49%)  
3 128 (45%) 90 (49%) 
4 7 (2%) 4 (2%) 
missing 0 (0%) 0 (0%) 
pN status, N (%)   0.677 
0 204 (72%) 128 (70%)  
1 81 (28%) 56 (30%) 
missing 0 (0%) 0 (0%) 
M status, N (%)   0.692 
0 282 (99%) 183 (100%)  
1 2 (1%) 1 (0%) 
missing 1 (0%) 0 (0%) 
Table 14 Clinicopathological characteristics of the validation cohort 
Of 285 patients with intermediate and high-risk disease, 184 were informative due to lack of 
interpretable tissue samples. Mann-Whitney and Chi-square test were used for statistical 
comparisons. CI= Confidence interval 
 
3.3.2 Immune profiling of validation cohort patients in the context 
of lymph node metastasis  
A summary of all the immune cell densities stratified by nodal status is 
presented in Table 15. Data from the T lymphocyte panel were available for 181 
patients, 59 with and 122 without lymph node metastasis. CD4 effector T cells 
were significantly decreased in patients with lymph node metastasis (51.8 
cells/mm2 vs 100.5 cells/mm2, p<0.0001), validating our previous observation. 
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There was no significant difference between the ratios of CD4 effector/ CD4 
regulatory T cells within the stroma (18.18 vs 12.66, p= 0.211), likely due to the 
lack of CD4 regulatory T cell immune cells.  There was a non-significant trend 
for increased intraepithelial CD8 effector T cells (28.7 cells/mm2 vs 19 
cells/mm2, p=0.063), but there was no different in the CD8 effector T cell 
density within the stoma which was previously observed.   Lastly, from 184 
informative cases (56 with and 128 without lymph node metastasis), there were 
no significant differences between the M1 macrophage densities within the 
epithelium or stroma, which does not replicate the earlier results from our 
discovery TMA.  It is noteworthy that no CD4 PD-1 positive T cells were 
detected, however this is a rather rare immune population and it is conceivable 
that due to under sampling there were not any cells present. In addition, CD8 
PD-1 positive T cells were detected therefore we are confident there were no 
technical problems with PD-1 staining.   




Epithelium Negative =128 Positive = 56 p 
M1-like macrophages  184 48.75 (38.3-58) 61.15 (51.5-76.2) 0.06 
M2-like macrophages  184 28 (22.7-32.8) 26 (21.1-38.9) 0.607 
B cells  184 0 (0-0) 0 (0-5) 0.65 
CD4 effector T cell  181 22.2 (16-30.4) 25.25 (11-32) 0.966 
CD4 regulatory T cells 181 0 (0-0) 0 (0-2) 0.935 
CD4 PD-1 positive T cells 181 0 (0-0) 0 (0-0) >0.99 
CD8 effector T cells 181 28.7 (22.5-41.8) 19 (7.5-26.55) 0.063 
CD8 regulatory T cells 181 0 (0-0) 0 (0-1.2) 0.986 
CD8 PD-1 positive T cells 181 0 (0-0) 0 (0-0) 0.92 
Stroma    
M1-like macrophages  184 104 (89.2-135) 122.2 (84-145) 0.801 
M2-like macrophages  184 86.6 (75-106) 68(56.85-106) 0.293 
B cells  184 3.9 (0-7.2) 2.5 (0-9.7) 0.18 
CD4 effector T cells 181 100.5 (78.5-113) 51.8 (39.9-70.4) <0.001 
CD4 regulatory T cells 181 2.7 (1.8-4.1) 1.7 (0-3.1) 0.317 
CD4 PD-1 positive T cells 181 0 (0-0) 0 (0-0) >0.999 
CD8 cytotoxic T cells 181 23 (18.2-27.3) 28.2 (20.2-37) 0.32 
CD8 regulatory T cells 181 0 (0-1.05) 0 (0-1.4) 0.5 
CD8 PD-1 positive T cells 181 0 (0-0.1) 0 (0-0) 0.633 
Table 15 Summary of validation cohort immune cell densities stratified according to lymph 
node status 
Comparison of intraepithelial and stromal immune cell densities in patients with and without lymph 
node metastasis. Data are presented as median immune cell densities (cells/mm2) with 95% 





Summarising, the key finding from mIF staining of the validation TMA was that 
stromal CD4 effector T cells were significantly reduced in the stroma of localised 
Chapter 3 82 
 
prostate cancer tumours with regional lymph node metastasis. Furthermore, 
there was a trend for reduced CD8 effector T cells in the same patient group. 
3.4 Prognostic value of tumour stromal CD4 effector T 
cells for lymph node metastasis 
A crucial question was whether different immune cell infiltrates could be used 
as predictive biomarkers of lymph node invasion. Since stromal CD4 effector T 
cells were identified as the immune cell population reproducibly associated with 
the status of nodal involvement, I tested if high stromal CD4 effector T cell 
infiltrates could predict the presence of pelvic nodal disease. Firstly, univariate 
regression was performed in the discovery (OR=0.157, 0.05-0.49 95%CI, p=0.01) 
and validation cohort (OR=0.26, 0.13-0.51 95%CI, p<0.001). Then, multivariate 
regression analyses was performed on data from the discovery cohort, including 
standard of care clinicopathological factors (namely pT stage, Gleason score 
from RP, peak pre-operative PSA level and percentage of positive cores).  
Stromal CD4 effector T cell density remained an independent predictor of lymph 
node spread (OR=0.38, p=0.004; Table 16). Similarly, from the validation cohort, 
high stromal CD4 effector T cell density was confirmed to be a significant 
independent predictor of lymph node metastasis (OR=0.26, p<0.001; Table 16).  
Multivariate regression analysis 
Discovery cohort  
 
OR 95% CI p value 
pT stage  2.96 0.72-12.12 0.131 
Gleason score 1.05 0.24-4.57 0.944 
Peak pre-op PSA 0.99 0.94-1.03 0.719 
Percentage of positive cores 1.01 0.99-1.03 0.175 
High stromal CD4 effector T cells  0.15 0.04-0.53 0.004 
Validation cohort 
 
OR 95% CI p value 
pT stage  2.49 1.17-5.27 0.017 
Gleason score 3.74 1.48-9.44 0.005 
Peak pre-op PSA 1.04 1.02-1.05 0.0004 
High stromal CD4 effector T cells  0.26 0.12-0.54 0.0004 
Table 16 Multivariate regression analysis of stromal CD4 effector T cells with standard of 
care clinicopathological factors commonly used for the prediction of nodal metastasis 
In the discovery cohort high density of stromal CD4 effector T cells (upper tertile) was an 
independent predictor of lymph node metastasis. In the validation cohort high density of stromal 
CD4 effector T cells (upper two tertiles) was an independent predictor of lymph node metastasis. 
OR= odds  ratio, CI= confidence interval. 
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I then examined the receiver operator characteristic (ROC) curve in both patient 
cohorts to assess the benefit of adding stromal CD4 effector T cell density in a 
prediction model. In the discovery cohort (Figure 9A), the area under the curve 
(AUC) of a model with standard of care clinicopathological factors was 0.635 
(0.49-0.78 95%CI, p=0.07), which was improved significantly to 0.768 (0.65-0.89 
95%CI, p<0.0001) with the addition of stromal CD4 effector T cell density.  
Similarly, in the validation cohort (Figure 9B), the AUC increased from AUC=0.77 
(0.7-0.84 95%CI, p<0.0001) to AUC=0.804 (0.73-0.87 95%CI, p<0.0001) when 
stromal CD4 effector T cell density is incorporated into the model. Even though 
the improvement observed in the validation cohort is not as impressive, this 
represents a significant confirmation of an association between decreased 
stromal effector CD4 T cell infiltration and nodal invasion. 
 
Figure 9 Clinical impact of stromal CD4 effector T cells in lymph node metastasis 
Receiver Operator Curve (ROC) curves of the addition of stromal CD4 effector T cells to standard 
of care clinicopathological factors for predicting lymph node metastasis in the discovery (A) and 





3.5 Prognostic value of stromal CD4 effector T cells in 
survival 
During tumour progression, lymph node spread has a negative impact on patient 
survival (2, 150). Increased immune cell densities of stromal CD4 effector T cells 
(values were dichotomised into the upper tertile compared to the bottom two 
tertiles) were associated with improved relapse-free survival in the discovery 
cohort (log-rank test, p=0.029), as shown in Figure 10A . Increased stromal CD4 
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effector T cells (values were dichotomised into the upper two tertiles compared 
to bottom tertile) were also associated with improved relapse-free survival in 
the discovery cohort (log rank test, p=0.045), as shown in Figure 10B.  
 
 
Figure 10 Clinical impact of stromal CD4 effector T cells in survival 
Kaplan-Meier curves of prostate cancer patients in the discovery cohort (A) and validation cohort 
(B). Log rank test used for statistical comparison. 
 
 
Furthermore, this finding was in agreement with the negative impact that lymph 
node metastasis bears in patient survival (150, 151), which was confirmed in 
both discovery (log-rank, p=0.021) and validation cohorts (log-rank, p<0.001), 
presented in Appendix Figure 1.  
 
 
3.6 Prostate cancer common genetic alterations are not 
associated with immune cell infiltration 
The tumour immune microenvironment plays an important role in the 
pathogenesis and progression of tumours and may be associated with somatic 
genomic alterations (22, 25). From the immune profiling results, patients with 
lymph node metastasis had decreased infiltration of effector CD8 T cells that are 
known to contribute to local cancer confinement and reduction of cell 
proliferation (42). Also, the same patients reproducibly showed significantly 
decreased infiltration of CD4 effector T cells. I therefore investigated whether 
the observed differences in tumour immune landscape were associated with 
common prostate cancer molecular alterations. 
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Previous studies have shown that TMPRSS2/ETS fusion gene fusions may be 
caused, at least in part, by increased local inflammation and oxidative stress 
(24). In addition, the generation of fusion genes can result in the formation of 
new amino acid sequences, potentially generating fusion proteins that can 
function as neoantigens (152). Furthermore, PCa tumours with ERG 
overexpression have been reported to be significantly associated with increased 
lymphocytic infiltration (25, 66). Therefore, I hypothesised that patients with 
decreased CD8 and CD4 T cells infiltration and lymph node metastasis may be 
associated with ERG negative tumours. Also, PTEN inactivation can influence 
immune cell infiltration and immunosuppression (22) and has been largely 
associated with metastasis and poor clinical outcome (17, 28). Therefore, 
patients with PTEN loss may be more frequently associated with nodal 
metastasis and PTEN status could potentially improve the CD4 effector T cell 
predictive ability. Lastly, I hypothesised that high tumour cell proliferation, 
measured by Ki67 proliferation index, will be present in patients with lymph 
node metastasis that lack anti-tumour lymphocytes.  
ERG overexpression was used as a surrogate for TMPRSS2/ERG translocation (25, 
153). Only nuclear positivity was assessed and endothelial cells and/or 
lymphocytes were used as positive controls (Figure 11A). Lack of PTEN 
expression was used as a surrogate for PTEN loss (18, 31). Nuclear and 
cytoplasmic positivity were assessed (Figure 11B). Background benign glands, 
fibromuscular stroma and nerves were used as a positive control. Ki67 scoring 
was used as proliferation index based on nuclear immunoreactivity (Figure 11C). 
Thirty percent of the total cores were double scored by a specialist 
uropathologist (Dr Jonathan Salmond) for ERG, PTEN and Ki-67 staining, blinded 
to patient characteristics. There was almost perfect agreement in scoring for 
ERG (κ=0.89) and substantial agreement in scoring for PTEN (κ=0.74) and Ki67 
(κ=0.74).  
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Figure 11 Representative images of ERG, PTEN and Ki67 staining 
(A) Tissue cores with negative (left) and positive (right) ERG immunostaining. (B) Tissue cores with 
homogeneous PTEN loss (left), heterogeneous PTEN loss (middle) and intact PTEN (right). (C) 
Tissue cores with low (left), moderate (middle) and high (right) Ki67 nuclear immunoreactivity. 
(Scale bar = 100 m)   
 
3.6.1 Molecular characteristics in primary tumours of patients 
with vs without lymph node metastasis 
Out of 94 patients in our TMA, 92, 91 and 89 had at least two out of three 
evaluable cores for ERG, PTEN and Ki67 staining by IHC respectively (Table 17). 
Of the tumours with assessable staining, 43/92 (47%) had positive ERG 
immunostaining which is in keeping with the incidence of TMPRSS2/ERG 
translocation previously reported (154, 155). There was no difference in ERG 
status according to the presence of nodal metastasis (p= 0.836). PTEN staining 
was detected in 52/91 (57%) patients. PTEN loss was significantly associated with 
nodal metastasis (p=0.0001), as previously described in the literature (17, 18).  
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Lymph node metastasis 
Absent=44 Present=50 p value 
TMPRSS2/ERG fusion (ERG 
overexpression), N (%) 
92       
Positive 43 (47) 19 (21) 24 (26) 0.836  
Negative 49 (53) 23 (25) 26 (28)   
PTEN status, N (%) 91      0.0001 
Intact 52 (57) 33 (36) 19 (21)   
Loss 39 (43) 9 (10) 30 (33)   
Ki67 score, N (%)  89     0.573 
Low (≤ 10%) 43 (49) 19 (21) 24 (27)  
Moderate (>10%, ≤ 20%) 19 (21) 11 (12) 8 (9)   
High (>20%) 27 (30) 12 (14) 15 (17)  
Table 17 Molecular features of discovery cohort according to their lymph node status 




3.6.2 ERG, PTEN and Ki67 are not associated with immune cell 
infiltration 
There were no significant differences stratifying immune cell infiltrates by ERG 
status (Table 18). Similar results were obtained when immune cell densities 
were stratified according to PTEN status (Table 19) and Ki67 scoring (Table 
20Table 18). Overall, these results support the notion that immune cell 
infiltration is not associated with the presence of ETS translocation, PTEN loss 
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 ERG status 
Epithelium  
Immune densities, 
median (95% CI) 
All  
N=92 
Positive = 43 Negative = 49 
p 
value 
M1-like macrophages 80 16.75 (11.01-22.89) 20.84 (14.45-25.67) 0.273 
M2-like  macrophages 81 14.66 (11.95-22.4) 19.85 (11.49-33.32) 0.437 
B cells 81 1.66 (0.9-3.45) 2.6 (1-7.92) 0.571 
CD4 effector T cells 66 21 (16-27.3) 16.2 (10.1-30.5) 0.572 
CD4 regulatory T cells 63 3.5 (1-6.2) 1.18 (0-3.2) 0.092 
CD4 PD-1 positive T cells 55 5.3 (8.16-16.4) 9.83 (1.3-16.9) 0.65 
CD8 cytotoxic T cells 64 8.8 (4.2-14.5) 4.2 (0.85-6.8) 0.094 
CD8 regulatory T cells 64 3.9 (1.3-5.6) 0.88 (0-3.2) 0.067 
CD8 PD-1 positive T cells 64 3.5 (0-9.48) 0 (0-8.7) 0.72 
Stroma    
M1 macrophages 80 48.85 (39.11-75.67) 52.15 (35.58-89.31) 0.954 
M2 macrophages 81 65.28 (53.55-79.07) 66.48 (53.9-81.99) 0.745 
B cells 81 8.49 (4.44-15.22) 6.74 (3.96-11.51) 0.491 
CD4 effector T cells 66 40.81 (28.3-82.77) 75.83 (27.47-91.35) 0.769 
CD4 regulatory T cells 63 4.71 (1.7-7.94) 4.58 (1.7-6.12) 0.603 
CD4 PD-1 positive T cells 55 8.73 (1.7-17.7) 7.33 (0.84-11.2) 0.365 
CD8 cytotoxic T cells 64 29.8 (21.7-50.6) 28.1 (14-39) 0.479 
CD8 regulatory T cells 64 0.66 (0.34-1.9) 0.4 (0.28-1) 0.319 
CD8 PD-1 positive T cells 64 4.66 (0.87-8.5) 6.23 (3-18.6) 0.182 
Table 18 Immune cell densities of discovery cohort stratified by ERG status 
Immune cell densities of prostate cancer patients presented as median with 95% CI. N= number of 




 PTEN status 
Epithelium    
Immune densities, 
median (95% CI) 
All 
N=91 
Intact = 52 Lost = 39 
p 
value 
M1-like macrophages 80 19.74 (16.8-25.4) 17.63 (10.45-22.89) 0.152 
M2-like  macrophages 81 18.07 (11.95-24.9) 15.02 (11.4-27.35) 0.702 
B cells 81 2.11 (0.9-6.5) 1.7 (1-5) 0.703 
CD4 effector T cells 64 21.7 (14.7-30.5) 20 (10.9-27.3) 0.653 
CD4 regulatory T cells 64 1.5 (0.41-3.3) 3.65 (0.9-6.6) 0.208 
CD4 PD-1 positive T cells 55 10.4 (6.59-1.7) 13.15 (0.8-18.8) 0.667 
CD8 cytotoxic T cells 64 6.1 (4.2-12.6) 5.7 (0.68-13) 0.424 
CD8 regulatory T cells 64 3.8 (0.88-4.3) 1.9 (0-8.4) 0.668 
CD8 PD-1 positive T cells 64 5.3 (0-8.7) 1.9 (0-10.4) 0.555 
Stroma     
M1-like macrophages 80 54.62 (40.04-81.78) 48.73 (36.49-76.35) 0.522 
M2-like macrophages 81 66.17 (60.67-77.04) 62.97 (42.14-88.56) 0.704 
B cells 81 8.75 (3.9-14.22) 7.35 (4.44-13.07) 0.687 
CD4 effector T cells 64 64.72 (32.5-91.35) 47.92 (27.47-82.77) 0.756 
CD4 regulatory T cells 64 5.14 (3.35-7.47) 3.8 (1.6-6.85) 0.331 
CD4 PD-1 positive T cells 55 8.88 (1.3-16.3) 6.06 (0-12.6) 0.452 
CD8 cytotoxic T cells 64 24.94 (14-40.19) 29.9 (21.7-46.18) 0.829 
CD8 regulatory T cells 64 0.51 (0.32-1.5) 0.62 (0.26-1.8) 0.871 
CD8 PD-1 positive T cells 64 8.1 (3.01-16.3) 4.66 (0.87-7.9) 0.177 
 
Table 19 Immune cell densities of discovery cohort stratified by PTEN status 
Immune cell densities of prostate cancer patients presented as median with 95% CI. N= number of 
cases with available data. Mann Whitney test used for statistical comparisons. CI=confidence 
interval.  





 Ki67 score 
Epithelium  
Immune densities, 
median (95% CI) 
All 
N=89 







18.57 (10.65-26.1) 18.5 (13-22.89) 0.837 
M2-like macrophages 80 20.38 (15.4-28.6) 11.49 (9.68-40.2) 14.66 (10.95-31.94) 0.509 
B cells 80 2.8 (1.09-8.33) 1.8 (0.43-8.29) 1.45 (1-5) 0.568 
CD4 effector T cells 62 17.5 (9.5-32.9) 20 (8.26-32.4) 21.35 (13-31) 0.653 
CD4 regulatory T cells 61 1.8 (0-5.2) 3 (0-8.84) 3.4 (1-4.63) 0.875 
CD4 PD-1 positive T 
cells 
53 11.8 (0-18.7) 10.08 (0-19.7) 6.25 (0-13.6) 0.812 
CD8 cytotoxic T cells 62 3.9 (0-7.15) 8.8 (5.2-25.5) 10.5 (0.88-20.3) 0.557 
CD8 regulatory T cells 62 3.2 (0-9.36) 1.3 (0-4.1) 4 (1.9-7.6) 0.425 
CD8 PD-1 positive T 
cells 
62 0 (0-15.6) 5.5 (0-17.6) 1.95 (0-6.9) 0.817 
Stroma     
M1-like macrophages 79 48.85 (36.2-78.8) 81.78 (43.94-96.7) 48.42 (35.6-75.67) 0.586 
M2-like macrophages 80 62.21 (50-81.99) 65.28 (42.95-88.7) 72.87 (58.12-92.37) 0.708 
B cells 80 7.36 (4.7-13.07) 7.85 (2.67-19.85) 8.81 (3.64-23.53) 0.775 
CD4 effector T cells 62 75.83 (21-91.35) 79.77 (11.1-105) 54.4 (21.7-92.7) 0.741 
CD4 regulatory T cells 61 2.1 (1.1-7.55) 5.4 (3.6-13.5) 5.05 (3.8-8.09) 0.467 
CD4 PD-1 positive T 
cells 
53 8.25 (0.3-16.5) 9.65 (1.3-16.3) 5.52 (0-20.3) 0.86 
CD8 cytotoxic T cells 62 32.08 (21.1-
57.45) 
40.19 (22.1-51.6) 23.65 (8.86-62.13) 0.571 
CD8 regulatory T cells 62 0.34 (0.27-1.5) 0.82 (0.5-1.9) 1.6 (0.23-3.59) 0.27 
CD8 PD-1 positive T 
cells 
62 5.54 (2.8-14) 4.66 (0-20.8) 8.2 (1.4-11.8) 0.875 
Table 20 Immune cell densities of discovery cohort stratified by Ki67 score 
Immune cell densities of prostate cancer patients presented as median with 95% CI. N= number of 






3.6.3 Combining PTEN and stromal CD4 effector T cells in 
predicting lymph node metastasis does not improve 
prognostic value 
PTEN status was the only molecular feature that was associated with and 
predictive of lymph node spread with univariate regression. Intact PTEN had a 
negative predictive value, with OR= 0.173 (0.07- 0.44 95% CI, p=0.0002) in the 
discovery cohort and OR=0.44 (0.23- 0.83 95%CI, p=0.01) in the validation 
cohort. PTEN status remained a significant prognostic factor in the multivariate 
setting, including all currently used parameters for predicting nodal metastasis, 
as shown in Table 21.  
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Multivariate regression analysis 
Discovery cohort  
OR 95% CI p value 
pT stage  1.61 0.52-4.97 0.406 
Gleason score 1.7 0.54-5.28 0.357 
Peak pre-op PSA 1.01 0.96-1.04 0.955 
Percentage of positive cores 1.01 0.99-1.02 0.415 
Intact PTEN  0.22 0.08-0.61 0.004 
Validation cohort 
 
OR 95% CI p value 
pT stage  2.6 1.23-5.49 0.012 
Gleason score 4.23 1.69-10.592 0.002 
Peak pre-op PSA 1.03 1.02-1.05 0.005 
Intact PTEN  0.45 0.21-0.93 0.032 
Table 21 Multivariate regression analysis of PTEN status with standard of care 
clinicopathological factors commonly used for the prediction of nodal metastasis 
In the discovery cohort (top) and the validation cohort (bottom) PTEN status was an independent 




However, ROC curve analysis showed that the addition of PTEN status in the 
currently used parameters was inferior to the addition of stromal CD4 effector 
cells. In the discovery cohort addition of PTEN resulted in an AUC=0.67 (0.537-
0.813 95%CI, p=0.022) whereas CD4 stromal effector T cells had AUC=0.75 (0.62-
0.87 95%CI, p=0.001). In the validation cohort addition of PTEN resulted in 
AUC=0.76 (0.69-0.84 95%CI, p<0.0001) and CD4 stromal effector T cells had 
AUC=0.79 (0.71-0.86 95%CI, p<0.001). Combination of PTEN status with CD4 
effector immune cell density did not carry a significant benefit. In the discovery 
cohort it resulted in an AUC=0.77 (0.65-0.89 95%CI, p<0.001) and in the 
validation AUC=0.79 (0.71-0.87 95%CI, p<0.0001), as shown in Figure 12. 
 
 




Figure 12 Clinical impact of PTEN and stromal CD4 effector T cells in lymph node 
metastasis 
Receiver Operator Curve (ROC) curves of the addition of stromal PTEN and CD4 effector T cells  
to standard of care clinicopathological factors for predicting lymph node metastasis in the discovery 
(A) and validation (B) cohorts.  
 
3.7 Optimisation of dual CD4-FoxP3 
Immunohistochemistry 
The data collected so far suggest an important role of stromal CD4 effector T 
cells (CD4+ FoxP3- PD-1-). A quantitative mIF platform was used for reasons 
described previously, however this methodology is not currently available at the 
clinical setting or every research laboratory. For this reason, I explored the 
potential of a method more easily implemented clinically, such as dual 
chromogenic IHC for CD4 and FoxP3. CD4 effector T cells were defined as 
CD4+FoxP3-PD1- with multiplex IF and the CD4+PD1+ cells were the least 
common within the stoma (0.07% in discovery and 0% in validation cohorts), so 
PD-1 staining was omitted.  
Dual CD4-FoxP3 chromogenic IHC was successfully optimised, with CD4 stained 
with alkaline red and FoxP3 with DAB brown (Figure 13A). The discovery TMA 
was stained and analysed with HALO using a tissue classifier (epithelium vs 
stroma) based on the morphological characteristics, and the percentage of 
positively stained cells within the each area (cells/mm2) was quantified. There 
was a positive correlation between CD4 effector T cells detected by mIF and IHC 
within the stroma (Spearman’s r=0.37, p=0.002), thus confirming the validity of 
the dual staining approach (Figure 9B). 
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Figure 13 Optimisation of dual CD4- FoxP3 immunohistochemistry 
(A) Representative image of dual CD4-FoxP3 staining. CD4 cells are shown in red (alkaline red) 
and FoxP3 in brown (DAB), scale bar 10µm. (B) Stromal CD4 effector T cells are presented as 
median immune cell densities (cells/mm2) derived from dual CD4-FoxP3 immunohistochemistry 
(IHC) staining and multiplex immunofluoresence (mIF) in the radical prostatectomy (RP) tissue 
(n=62). Spearman’s correlation was used for statistical comparison.  
 
3.8 Exploration of stromal CD4 effector T cells in low risk 
prostate cancer patients  
Another question was whether stromal CD4 effector T cells had an impact on 
clinical outcomes in low risk prostate cancer. To explore this, we established a 
collaboration with Professor David Berman’s lab in Queen's University in 
Kingston, Ontario, Canada. He provided a primary prostate cancer TMA of 
patients with low risk disease at diagnosis. I stained this TMA with dual CD4-
FoxP3 IHC in order to assess the relationship of CD4 effector T cell density with 
relapse free survival in this patient cohort. 
3.8.1 Low risk prostate cancer cohort 
The low-risk patient cohort included 272 patients with three to five cores per 
patient. The median age of diagnosis 61 years (60-62 95%CI). The median peak 
pre-operative PSA level was 5.8 ng/ml (4.4-7.8 95%CI). Two hundred fourteen 
patients (78.7%) had pT2 stage disease and 58 (21.3%) had pT3 stage tumours. 
One hundred and thirty two patients had Gleason score 6 (48.5%) and 7 (48.5%) 
and eight patients had Gleason score >7 (3%). The median follow up was 4.92 
years (4.7-5.1 95%CI) and 54 patients had biochemical relapse. Thirty-four 
patients were lost in follow-up. 
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3.8.2 Stromal CD4 effector T cells are not associated with survival 
in low risk prostate cancer patients 
The low-risk prostate cancer cohort TMA was stained with dual CD4-FoxP3 IHC 
and scored with HALO as previously described. The overall stromal immune cell 
density was compared to data from the discovery cohort of high-risk disease. 
Interestingly, PCa patients diagnosed with more advanced (higher risk) disease 
had significantly higher overall stromal CD4 effector T cell density of 92.08 
cells/mm2 (62.7-117.1 95%CI) compared to low risk tumours, 8.53 cells/mm2 
(6.96 - 10.88 95%CI, p<0.0001), shown in Figure 14A. Within the low-risk disease 
cohort, there was no significant difference in relapse-free survival in patients 
with high (above median) stromal CD4 effector T cell density (p=0.34), shown in 
Figure 14B. 
 
Figure 14 Stromal CD4 effector T cells in low risk prostate cancer 
(A) Stromal CD4 effector T cell density is presented as median cells/mm2 with 95% confidence 
interval in patients with low-risk (n=260) and high-risk (n=89) prostate cancer. (B) Kaplan-Meier 
curves of low-risk prostate cancer patients according to CD4 effector T cell infiltration. Log rank test 
used for statistical comparison. 
 
 
3.9 Translation of stromal CD4 effector T cells detection 
in the clinical setting 
3.9.1 Staining of prostate cancer diagnostic biopsies  
The data collected so far support the use of stromal CD4 effector T cells in 
intermediate and high-risk disease in order to improve the current algorithms of 
nodal spread prediction. This would be applicable at the diagnostic biopsy stage 
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in order to spare patients from the unnecessary side effects of lymph node 
dissection.  
For this reason, 31 diagnostic biopsies for the patients included in the discovery 
cohort were obtained from Glasgow Biorepository (16 LN+, 15 LN-). These were 
stained with dual CD4-FoxP3 IHC and analysed in HALO. Only tissue regions 
containing more than 70% cancer were analysed and CD4 effector (CD4+FoxP3-) 
T cells were quantified within stroma (Figure 15A-C). There was a positive 
correlation (r=0.51, p=0.02) between stromal CD4 effector T cells detected with 
IHC in diagnostic biopsies and detected with mIF in discovery TMA from index 
lesions from the same patient (Figure 15D). However, when the stromal CD4 
effector immune cells detected in diagnostic biopsies were stratified according 
to nodal spread there was no significant difference (Figure 15E).  
Apart from the small number of cases examined, which limits the conclusion that 
can be drawn, the nature of prostate biopsy tissue could explain this 
discrepancy. In biopsy material, the stromal CD4 effector T cells are in close 
proximity to cancerous prostate glands, as well as benign glands and PIN. The 
tumour stromal area examined is therefore more heterogeneous compared to 
the prostate cancer stroma derived from the index lesion that was used for the 
discovery TMA. This raises interesting questions regarding the scoring system 
that should be applied in biopsy tissue. For example, a more stringent threshold 
cut-off above 70%, e.g. 90%, would be more appropriate. Also, using MRI/US 
guidance for specific sampling of the index lesion and scoring only those cores 
could be another possible approach. 




Figure 15 Staining of prostate cancer diagnostic biopsies with dual CD4-FoxP3 
immunohistochemistry 
Prostate cancer biopsy tissue stained with dual CD4-FoxP3 (A), classified in epithelium (magenta) 
and stroma (blue) (B), and scored using HALO (C), yellow indicating positively stained cells. (D) 
Stromal CD4 effector T cells are presented as median immune cell densities (cells/mm2) derived 
from dual CD4-FoxP3 staining of diagnostic biopsies and multiplex immunofluoresence (mIF) in the 
radical prostatectomy (RP) tissue, n=19. Spearman’s correlation was used for the immune 
infiltration in the same patient. (F) Stromal CD4 effector T cells are presented as median immune 
cell densities (cells/mm2) derived from dual CD4-FoxP3 staining on diagnostic biopsies from 
patients with (LN+, n=16) vs without (LN-, n=15) lymph node metastasis. Error bars indicate 95% 
confidence interval. Mann-Whitney test used for statistical comparison. 
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3.10 Concluding summary 
I aimed to dissect the clinical significance of the immune landscape in localised 
PCa patients. I explored the relationship of specific tumour infiltrating immune 
cells with malignant prostate epithelium to determine if this correlates with the 
ability of a tumour to metastasise to regional lymph nodes.  For this reason, we 
successfully developed and applied a novel mIF methodology combining up to six 
antibodies on a single slide (Figure 6-7). Low CD4 effector T cell (CD4+ FoxP3-
PD-1-) density was significantly associated patients with lymph node metastasis 
(Table 9). Using multivariate analysis, we established a predictive model based 
on stromal CD4 T cell expression for predicting nodal spread and validated the 
model in a larger independent cohort of patients (Table 16). I additionally 
correlated subsets of tumour infiltrating immune cells with commonly present 
molecular alterations and found no associations with ERG overexpression or 
PTEN deletion (Table 18-20). The detection of stromal CD4 effector T cells by 
mIF was comparable to a simpler and easily transferable to the clinic dual 
CD4/FoxP3 IHC assay (Figure 13). However, its implementation on prostate 
biopsies requires further investigation (Figure 15). Lastly, we measured CD4 
effector T cell (CD4+FoxP3-) density in a cohort of low risk prostate cancer 
patients and showed no impact on relapse-free survival (Figure 14).   
It is challenging to replicate the complexity of human immune system with in 
vitro or in vivo experiments. Therefore, we used patient derived tissue in order 
to comprehensively characterise the immune tumour microenvironment. The 
exploration of the in situ immune cell composition of baseline, treatment-naïve, 
higher risk PCa patient samples offers critical insights into the complex and 
heterogeneous immune landscape associated with the growth and progression of 
this tumour, such as the reproducibly higher presence of CD4 effector T cells in 
patients without nodal metastasis. I generated a discovery TMA (Table 8) in 
order to examine a large number of patients at the same time, however this 
always carries the disadvantage of under sampling heterogeneous tumour 
immune infiltrates. I mitigated this issue by using three large cores (1 mm) from 
each tumour. Other limitations of this cohort are its retrospective nature of and 
the lack of long-term patient follow-up.  
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Flow cytometry is the most commonly used method for investigating 
lymphocytes and cytokines in cancer but the requirement to examine cell 
suspensions, the spatial context and the respective biologic relationships are 
inevitably lost. With mIF, spatial relationships are preserved, enabling the 
assessment of infiltrating cells in the context of the adjacent tumour and 
differentiating between stromal and intratumoural localisation. We used a TSA 
automated staining platform combined with slide scanning, multispectral 
imaging and a pattern recognition–based image analysis is order to extract 
maximum proteomic and morphometric information from our FFPE tissue 
samples.  
Despite the overall validity of the data produced by mIF and multispectral 
imaging, some limitations should be mentioned. In terms of the immune cells 
subpopulations examined, CD68 is a recognised pan-macrophage marker, 
however low CD68 expression can be found on other monocytes, therefore our 
analysis likely contains a small proportion of non-macrophage cells. On the other 
hand, there is a risk that not all macrophages express CD68 or CD163 and we 
therefore might have missed small macrophage populations. It should also be 
noted that M1/M2-like is an oversimplified way of describing macrophage 
polarisation and I used those markers to describe macrophage phenotypic 
heterogeneity, not to define polarisation states. Lastly, due to limitations 
associated with the number of markers that can be used at the same time, we 
only investigated lymphocytic and macrophage populations. Using additional 
markers for T cell activation/exhaustion and other immune components, such as 
dendritic and natural killer cells will elucidate the PCa immune 
microenvironment further. 
In patients with intermediate and high-risk localised prostate cancer, 
macrophages were the most abundant infiltrating immune cells, followed by CD4 
T cells within stroma and epithelium (Table 9). CD4 regulatory T cells were 
proportionately distributed between stroma and epithelium, whereas CD8 T 
regulatory cells were scarce within epithelium. B cells were the least abundant 
immune cells. A previous study has shown that tertiary lymphoid follicles are 
commonly encountered in non-malignant areas surrounding the prostate cancer 
tissue (75). In my study I only looked into index lesions, therefore I cannot 
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exclude the role of B cells outside of the cancer mass lesions via non-cell 
contact mechanisms.   
My initial hypothesis was that patients with lymph node metastasis would be 
associated with an immunosuppressive microenvironment, comprising M2-like 
macrophages (40), T regulatory cells (77), and PD-1 positive cells (78). Even 
though we cannot confidently exclude a non-cell contract effect of these cells 
(75), there were no differences in their abundance within index tumour lesions 
between LN+ and LN- patients (Table 10). Interestingly, there were significant 
differences between immune cell subtypes that are traditionally considered anti-
tumorigenic (38). M1-like macrophages, and CD8 effector T cells were decreased 
in stromal and epithelial areas of LN+ patients (Table 10). In addition, stromal 
CD4 effector T cells that were consistently located at the interface between 
epithelium and stroma (Figure 8) were decreased in LN+ patients. Furthermore, 
the ratios stromal CD4 effector/CD4 regulatory T cells and epithelial/stromal 
CD8 effector T cells were lower in LN+ positive patients. These immune cells 
positively correlated with each other, consistent with potential functional 
interactions to determine host-tumour response. More importantly, stromal CD4 
effector T cells, and to a lesser degree CD8 effector T cells, were reproducibly 
decreased in LN+ patients in an independent patient cohort (Table 10 and 15).  
It is currently unknown if the lower number of tumoural effector T lymphocytes 
in LN+ patients is a primary or a secondary event. Although we are unable to 
describe a cell specific mechanism to explain this observation, these data 
provide evidence for a potentially clinically relevant role of CD4 effector T cells. 
A recent study of a humanised prostate cancer animal model is in agreement 
with my findings (156). Mice with human peripheral blood lymphocytes and DCs 
were unable to control PC3M tumour growth upon CD4 T cell depletion, whereas 
CD8 T cell depletion had no effect (156). In another large gene expression study 
of different tumour types, elevated Th1 and TH17 CD4 helper T cell expression 
was associated with an anti-tumourigenic phenotype (157). It is possible that 
CD4 effector T cells have a key role in prostate cancer tumour progression.  
One possibility is that tumour in situ or regional nodal interactions between CD4 
and CD8 cytotoxic T and other immune cell subsets is essential for mediating 
anti-tumour response and preventing lymph node metastasis by CD8 mediated 
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tumour cell killing at the primary tumour site (42, 158). While CD8 T cells are 
the key effector population that mediate tumour cell killing, they can be 
affected by the tumour immune environment to develop into regulatory and/or 
exhausted T cells in the absence of CD4 effector T cell help (42, 159). There is 
also some evidence that CD4 T cells can play an active role in tumour defence by 
themselves (160, 161). Even though cytotoxic potential of CD4 T cells is still 
controversial and not studied in the tumour context, there are seminal studies 
that confirm the cytotoxic capabilities of these cells in humans with chronic 
infections (160) and advanced age (161).  
Better stratification of PCa patients is an urgent unmet need that would facilitate 
earlier intervention of aggressive, fast growing disease and avoidance of 
overtreatment for slow growing, latent disease. There has been significant 
progress in gene expression approaches to prostate cancer prognostication (162). 
However, there has been little advancement in protein-based approaches, even 
though dysregulated protein levels are more directly linked with a perturbed 
phenotype. My data suggest that the addition of stromal CD4 effector T cells 
immune cell density of intermediate and high-risk patients can improve the 
current algorithms of nodal spread prediction (Figure 9). Even though the 
quantitative mIF platform that we used is not currently used in the clinical setting, 
there was good concordance with dual FoxP3 and CD4 IHC (Figure 13). The main 
issue we discovered is interpreting this stromal immune signature on the prostate 
biopsy, due to close proximity between normal and malignant glands. This could 
potentially be addressed by radiology-guided sampling of the index lesion only. 
Prior to suggesting its use in the everyday clinical practice, external validation in 
larger prospective cohorts is necessary.  
Distinct genomic alterations can shape the PCa immune microenvironment (22, 
23). For example, immune cell composition of prostate cancer genetically 
engineered (GEMM) animal models  was driven by the loss of the tumour 
suppressive gene PTEN, alone or in combination with other immunosuppresses at 
least partly due to different chemokine secretion (22). Therefore, I examined 
the association of common PCa genetic alterations with infiltrating immune 
cells. I stained the discovery cohort with ERG and PTEN IHC as surrogates for 
TMPRSS2/ERG fusion and PTEN loss respectively (Figure 11), and reassuringly 
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found the incidence of those alterations in agreement with the literature, 
reinforcing the generalisability of this patient cohort (Table 17). My hypothesis 
was that primary prostate tumours with absence of ERG gene translocation, 
presence of PTEN inactivation and high Ki67 would be associated with nodal 
metastasis. However, contrary to previous studies (25, 66) there was no 
association between immune cell densities and those features (Table 18-20). It is 
noteworthy that these previous studies included mixed patient cohorts with 
varying treatments (25, 66). Our study included only high-risk European PCa 
patients with localised disease, which may inherently have a rather 
homogeneous genetic background. 
Prostate cancer is rather heterogeneous, comprising of a continuum of lower-
risk, higher-risk and mCRPC patients (7). Our data do not contain androgen 
deprived or metastatic samples and are thus not applicable to mCRPC prostate 
cancer, which may have a very different immune microenvironment. I aimed to 
explore the presence of stromal CD4 effector T cells (CD4+FoxP3-) in a lower risk 
PCa cohort in a pilot experiment. Interestingly, lower-risk patients has 
significantly less infiltration of CD4 effector T cells compared to the discovery 
higher risk cohort (Figure 14A). It is possible that higher risk patients may have 
baseline levels of increased inflammation, contributing to oxidative stress 
mediated tumourigenesis and accelerated progression (24). Furthermore, there 
was no association with relapse free survival (Figure 14B), contrary to our 
findings in higher risk patients (Figure 10). This suggests a potentially different 
role of CD4 effector T cells in different stages of PCa progression and further 
work is needed in order to gain a better understanding.  
The data collected so far do not address the function of infiltrating CD4 effector 
T cells or the impact they may have on the prostate tissue as this will require a 
more thorough phenotypic analysis of the lymphocytes. This could be ideally 
elucidated with single cell gene expression profiling of purified human 
infiltrating CD4 T cells that could reveal biologically relevant CD4 T cells 
subpopulations. While a basic understanding of the composition and phenotype 
of tumour immune microenvironment can only be derived from human tumours, 
there is a need to directly investigate mechanisms and interactions. For this, 
either humanised PCa or GEMM animal models could be used for studying the 
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impact of specific CD4 T cell subset (or other immune cells of the innate and 
adaptive immune system), to determine the contribution of such cells to PCa 
progression. Even though these studies were not feasible during the limited time 
of my PhD, they could be followed up in the future.  
Summarising, our data associate stromal CD4 effector T cell infiltration with 
lymph node metastasis in PCa for the first time. Their specific localisation at the 
peritumoural border suggests that CD4 effector T cells within the direct vicinity 
of cancer cells could perform important biological functions, either by 
facilitating anti-tumour function of other cytotoxic cells or by directly lysing 
tumour cells themselves. While this is a reasonable hypothesis based on 
correlative observations, insights that are more mechanistic are necessary. 
Previous studies have highlighted the importance of functional orientation of 
different CD4 T cell immune cell subsets, with Th1 orientated CD4 T effector T 
cells collaborating with CD8 cytotoxic T cells and resulting in a better patient 
prognosis in colorectal cancer (163). Furthermore, the expression of specific 
chemokines and adhesion molecules were found to be critical for high densities 
of oligoclonal CD8 T cell subsets in colorectal cancer (164) and melanoma (165). 
Based on our results and those previous studies we next performed a targeted 
gene expression assay of immuno-oncology markers in order to explain the 
differences observed in immune cell infiltration between LN+ and LN- PCa 
patients.  
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Chapter 4 Phenotyping of prostate cancer using 
a targeted gene expression panel 
In Chapter 3 of this thesis, I presented evidence that, in intermediate to high-
risk PCa patients with regional lymph node metastasis, there was decreased 
infiltration of the tumour-stroma interface by CD4 effector T cells. 
Intraepithelial CD8 effector T cells were also decreased and there was positive 
correlation between CD4 effector, CD8 effector and M1-like macrophages within 
tumour epithelium and stroma. These findings suggested a possible interaction 
between tumour and those immune cell subtypes in LN- patients in order to 
orchestrate an anti-tumour response which was absent in LN+ patients. The 
development of an effective anti-tumour immune response depends on the 
coordinated interactions of immunocompetent cells (e.g. CD8 cytotoxic and Th1 
polarised CD4 helper T cells), whose spatial distributions are at least partly 
regulated by chemokines and adhesion molecules (38, 166).  
I hypothesised that LN+ patients would have decreased tumour and stromal 
secreted cytokines (CXCL9 and CXCL10) and adhesion molecules (ICAM, VCAM) 
which contribute to recruitment of effector T cells (39, 166). I also expected a 
decreased Th-1 polarisation of CD4 effector T cells resulting in decreased 
cytotoxicity (granzymes, perforin) and tumour cell killing (39, 157) in LN+ cases. 
In order to confirm this hypothesis and explain the differences in immune cell 
infiltration we performed a targeted gene expression profiling of the tumours 
with a panel of immuno-oncology markers comparing PCa patients with and 
without lymph node metastasis.   
Forty-eight diagnostic biopsy cores from patients within the discovery TMA 
cohort were selected for gene expression analysis, including 24 without LN 
metastasis and 24 with LN metastasis respectively. The patients had a median 
time interval of 113 days (81-151 range) between diagnosis and surgery. Each 
sample was macro-dissected to obtain tumour rich tissue with >70% tumour and 
<10% tumour necrosis. This methodology was selected because it was ideal for 
minimal tissue input (down to 6 mm2 area) which is crucial for limited PCa biopsy 
material, and has also been proven to reproducibly detect low expressing genes 
which is essential for the occasionally sparse immune cell infiltrates in PCa FFPE 
tissue (167, 168).  
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The targets of HTG Immuno-Oncology Panel are shown in Appendix Table 1 and 
include immune related genes as well as genes related to common cancer 
signalling pathways. These include genes involved in apoptosis, cell cycle and 
adhesion, DNA repair, immunosuppressive pathways as well as cytokines and 
cytokine receptors, immunophenotyping and MHC and associated receptors. One 
probe was designed for each gene. A total of 1,410 probes were used, including 
12 housekeeper control genes (DDX5, ATP5F1, EEF1G, NCL, OAZ1, PPIA, RPL38, 
RPL6, RPS7, SLC25A3, SOD1, YWHAZ), 4 positive process controls and 4 negative 
process controls. In addition, negative probes had sequences of non-human 
genes (Arabidopsis), while positive probes had sequences of targets that were 
mixed with all the probe mix (so these probes will hybridize with their targets 
during the hybridisation step).  
Forty-eight samples were sent for sequencing. One of them was omitted from 
the analysis due to tissue damage, leaving forty-seven samples processed and 
successfully sequenced according to company’s standards. 
4.1 Post-sequencing quality control 
Post-sequencing quality control metrics (QC0, QC1 and QC2) were performed 
using the HTG reveal software in order to detect three different sample failures 
(Figure 16). QC0 detected degraded RNA or poor quality RNA samples by 
assessing the percentage of overall reads being allocated to the positive process 
control for each sample; ≥ 40% was considered as a failure. QC1 detected 
samples with insufficient read depth; read depth ≤ 1.5 million / sample was 
considered a failure. QC2 detected samples with minimal expression variability, 
which was determined by the relative standard deviation (RSD) of reads 
allocated to each probe within a sample; RSD ≤ 0.1 was considered a failure. 
Five samples failed QC2 metric and were not included in further analysis. Failure 
of QC2 is commonly attributed to failure of the S1 digestion step of the sample 
processing according to the company’s protocols.  
  




Figure 16 Post sequencing quality controls 
Forty-seven samples were processed and underwent post-sequencing quality control metrics 
(QC0, QC1 and QC2) using the HTG reveal software. (A) QC0 plot represented the RNA quality by 
assessing the percentage of overall reads being allocated to the positive control for each sample. 
(B) QC1 plot represented the read depth. (C) QC2 plot represented the expression variability of 
each sample, which was determined by the relative standard deviation (RSD) of reads allocated to 
each probe within a sample. Five samples highlighted in red failed QC2 metric and were not 
included in further analysis. 
 
 
Chapter 4 105 
 
 
4.2 Extracellular matrix components genes are 
upregulated in prostate cancer patients with nodal 
metastasis  
We used the HTG EdgeSeq Immuno-Oncology panel to compare gene expression 
between primary prostate tumours from patients with and without pathologically 
confirmed pelvic lymph node metastasis (LN+ and LN- respectively). This was 
calculated using DESeq2 test with an adjusted p value less than 0.05 and a log 
fold change value of greater than 1.5. Nineteen genes were differentially 
expressed, 15 were upregulated and four were downregulated in LN+ cases, 
presented in Table 22. 
My initial hypothesis was that patients with lymph node metastasis will have 
reduced expression of chemotactic and adhesion factors, resulting in the 
decreased infiltration of CD4 effector T cells that was observed. However, even 
though an extensive list of adhesion molecules, cytokines and cytokine receptors 
was included in our panel, there were no differences between patient groups. 
An interesting finding though was that the highest upregulated genes in LN+ 
cases were extracellular matrix (ECM) core proteins, namely collagen type I and 
III and fibronectin 1 (FN1), as well as the cancer associated fibroblast (CAF) 
proteins, fibroblast activation protein alpha (FAPa) and Chemokine ligand 14 
(CXCL14) (Table 22).  
ECM remodelling is one of the cancer hallmarks and abnormal, typically dense or 
fibrotic ECM affects cancer progression and metastasis, generating a tumour 
promoting tumour microenvironment (169-172). Tumour associated fibrosis is a 
well-established regulator of tumour progression but may also be a critical 
regulator of immune surveillance (173-176). Following on this growing body of 
evidence, I firstly aimed to address whether tumoural ECM components were 
increased at the protein level prostate cancer patients with nodal disease.  
 
 
Chapter 4 106 
 
 Gene Full gene name Fold Change 




CXCL14 C-X-C Motif Chemokine Ligand 14 2.56 2.50E-05 
ISG15 Interferon-stimulated gene 15 2.14 4.20E-04 
IFI6 Interferon Alpha Inducible Protein 6  1.85 0.0251 
FAPa Fibroblast Activation Protein Alpha 1.83 2.50E-05 
LYZ Lysozyme 1.8 0.0156 
COL1A1 Collagen Type I Alpha 1 Chain 1.73 0.0156 
FCGR3A_3B Fc Fragment Of IgG Receptor IIIa 1.7 4.20E-04 
FN1 Fibronectin 1 1.68 0.0392 
OAS3 2'-5'-Oligoadenylate Synthetase 3 1.62 0.0029 
COL3A1 Collagen Type III Alpha 1 Chain 1.6 0.0251 
LAPTM5 Lysosomal Protein Transmembrane 5 1.58 0.0156 
HLA-DRA Major Histocompatibility Complex, Class II, DR 
Alpha 
1.54 0.0405 
FCGR2A_2C Fc Fragment Of IgG Receptor IIa 1.53 0.0023 
IGFBP3 Insulin growth factor binding pr 3 1.52 0.0425 
TYROBP TYRO Protein Tyrosine Kinase Binding Protein 1.51 0.0092 
Downregulated  
PAGE3 Prostate-Associated Gene 3 Protein -1.69 0.0452 
CD244 CD244 Molecule -1.68 0.0481 
RND2 Rho Family GTPase 2 -1.65 0.0251 
TCL1B Activation Induced Cytidine Deaminase -1.55 0.0478 
Table 22 Differentially expressed genes in patients with vs without lymph node metastasis 
(LN+ vs LN-).   
HTG RNA sequencing results showed 15 upregulated and 4 downregulated genes in patients with 
LN metastasis. Extracellular matrix genes (collagen type I & II and fibronectin 1) are highlighted in 
grey. DESeq2 test with fold change >1.5, adjusted p value < 0.05 used for statistical analysis 
 
 
4.3 Extracellular matrix components are increased and 
disorganised in prostate cancer patients with lymph 
node metastasis  
The gene expression analysis which showed increased ECM components was 
performed on the diagnostic biopsies of a fraction of patients (47 patients) 
included in the discovery TMA (94 patients). I then investigated the abundance 
of ECM components using the discovery TMA to study more cases with good tissue 
availability. More importantly, investigating the TMA cores would be more 
informative compared to diagnostic prostatic biopsy materials because needle 
biopsies tend to comprise of intermixed benign and malignant components in 
close proximity with associated stroma. Even though the presence of benign 
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glands can never be completely avoided, it was significantly reduced in the TMA 
due to sampling from the index lesion.  
I used IHC for the detection of ECM components identified in the gene expression 
assay, specifically collagen I (Figure 17A), collagen III (Figure 17D) and FN 1 
(Figure17E). Even though FN1 and collagen III are primarily ECM components, 
they were also expressed in the tumour as well as in stromal cells, 
morphologically compatible with fibroblasts. Collagen I was restricted to stroma 
and in order to avoid confounding from the relative epithelial/stromal ratio in 
each core I quantified the presence of collagen I within the stromal 
compartment only, shown in Figure 17A-C. HALO image analysis was used to set 
up a tissue classifier (epithelium vs stroma) based on the morphological 
characteristics and to quantify the percentage of positively stained cells within 
the each area. Lastly, the same TMA was also investigated using multiphoton 
imaging and second harmonic generation (SHG) (performed and analysed by 
Ewan McGhee, Beatson Institute).  
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Figure 17 Extracellular matrix components staining 
(A-C) Analysis for collagen I staining: (A) Representative image of collagen I staining. (B) Tissue 
classifier using HALO image analysis, epithelium annotated in magenta, stroma in blue. (C) 
Positive staining quantification shown in yellow, orange and red according to the staining intensity 
(low, medium and high respectively). All images are taken from the same core. (D) Representative 
images of collagen III and (E) fibronectin 1 staining. Scale bar=200µm. 
 
 
The collagen score analysis derived from the mean decay distance of the SHG 
signal showed that collagen I was significantly associated with the presence of 
lymph node spread, 17.72 (11.52-34 IQR) in LN+ vs 13.43 (9.14-21.46 IQR) in LN-, 
p=0.0003 (Figure 18A). The percentage of collagen I positive staining within the 
stroma did not show any statistically significant differences within the two 
groups, 32.92 (29.89-21.8 95%CI) in LN+ vs 29.87 (21.8-37.49 95%CI) in LN-, 
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p=0.189 (Figure 18B). Tumours often display a fibrotic stroma with increased 
collagen deposition and altered organisation, such as increased collagen density 
and collagen fibre elongation (172, 177). While SHG collagen I density score in 
LN+ patients increased, the overall collagen abundance did not differ, eluding to 
a stroma with increased cross-linking and elongated fibres. This is reinforced by 
the fact that both analyses were performed on the same slide. The percentage 
of collagen III positive staining within epithelial and stromal compartments was 
significantly increased in LN+ 22.28 (15.93-23.79 95%CI) vs 16.11 (12.65-17.37 
95%CI), p=0.0056 (Figure 18C). Lastly, the percentage of FN1 positive staining 
was significantly increased in LN+ patients, 26.36 (20.32-36.94 95%CI) vs 17.93 
(10.83-24.23 95%CI), p=0.0096 (Figure 18D). 
These results suggested that the generation of fibrillar collagen I, collagen III 
and FN1 are associated with PCa lymph node spread and as a direct 
consequence, disease progression. Our data revealed reduced migration of 
effector T cells to the tumour stromal compartment in LN+ patients. The 
relatively reduced infiltration by immune subpopulations in the progressing 
tumours can be mediated by lack of migratory cues, including chemokines and 
TCR stimulation (173). The gene expression analysis of primary PCa tumours 
investigated potential mediators for recruiting immune cells extensively but no 
difference was detected between LN+ and LN- patients. However, core ECM 
molecules were increased at both mRNA and protein levels in LN+ patients, thus 
supporting the importance of enhanced ECM deposition and remodelling in 
shaping the TME including immune infiltrates. The reduced immune cell 
infiltration of LN+ tumours is more likely associated with dense ECM, which can 
function as a physical barrier (175, 176, 178). 
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Figure 18 Enhanced collagen I, collagen III and fibronectin 1 in patients with lymph node 
metastasis 
(A) Mean decay distance (collagen score) of the second harmonic generation (SHG) signal emitted 
by fibrillar collagen I. Mean decay distance is represented by boxplots showing the second and 
third quartile of the data with the whiskers indicating the maximum and minimum data points for 
LN- (n=89) and LN+(n=113) cores. Outliers are shown by individual data points. (B) Percentage 
(%) of stroma positive for collagen I staining is presented as median with 95% CI in LN- (n=41) and 
LN+ (n=46) patients. (C) Percentage (%) of collagen III staining is presented as median with 95% 
CI in LN- (n=44) and LN+ (n=47) patients. (D) Percentage (%) of fibronectin1 staining is presented 
as median with 95% CI in LN- (n=34) and LN+ (n=45) patients. Two-tailed Mann-Whitney test was 
used for all statistical comparisons presented in this figure.   
 
 
4.4 Exploratory investigation of cancer associated 
fibroblast markers (CXCL14 and FAPa) in prostate 
cancer patients with nodal metastasis  
The targeted gene expression analysis identified two more upregulated genes in 
patients with lymph node metastasis that were of interest, namely Chemokine 
ligand 14 (CXCL14) and Fibroblast Activation Protein alpha (FAP). Cancer 
associated fibroblasts (CAFs) are the fibroblasts found in the stroma of human 
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cancers (169). CAFs are activated compared to their quiescent counterparts 
(SMA+, FAP+) and have significant heterogeneity in marker expression leading 
to different CAF phenotypes (169). They also differ from normal fibroblasts in 
their increased collagen and ECM protein production and secretion of cytokines 
(CXCL14) (169, 179-181). Depletion of FAP+ CAFs in a PDAC mouse model 
decreased tumour growth and fibrosis and increased T-effector cell infiltration 
in a CXCL12/CXCR4 dependent manner (182). CXCL14, a pleiotropic cytokine, is 
expressed by CAFs and promotes epithelial to mesenchymal transition (EMT) and 
metastasis (183). I therefore explored whether LN+ patients who had decreased 
effector T cell infiltration were associated with increased FAPa+ CAFs and 
CXCL14 expression.  
CXCL14 IHC had been previously attempted in our Histology laboratory but no 
CXCL14 antibody tested showed specific staining (personal communication with 
Mr Colin Nixon, Beatson Institute). Therefore, I assessed RNA expression of 
CXCL14 using in situ hybridisation (ISH) on the discovery TMA. FAP expression 
was assessed by IHC on another section from the discovery TMA. CXCL14 
expression was mainly localised in the stroma, from cells morphologically 
consistent with fibroblasts (Figure 19A, arrows). In addition, scattered cells 
morphologically consistent with benign basal epithelial cells were also positive 
(Figure 19B, arrows). CXLC14 expression was quantified using an ISH probe 
copies counting module in HALO image analysis. FAP expression was confined to 
stroma areas only (Figure 19C) and was quantified as percentage area positive 
within stroma using HALO image analysis as previously described.  
Despite an apparent trend for higher probe copies in node positive cases, the 
observed average CXCL14 probe copies (per μm²) were not significantly different 
between lymph node positive (61.33x105, 24.4x105-129x105 95%CI) and lymph 
node negative patients (34.75x105, 22.05 x105- 55.6 x105 95%CI, p=0.3853), 
Figure 19D. However, when the tumours were dichotomised into high and low 
expressers of CXCL14 (above 400 probe copies x 105/µm2), there were 11 high 
expressers, 1 LN- and 10 LN+ (p<0.0001, Fisher’s exact test). FAP expression 
was also not statistically different between lymph node positive (0.08, 0.04-0.12 
95%CI) and lymph node negative group (0.04, 0.02- 0.04 95%CI, p=0.06), 
presented in Figure 19E.  
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Figure 19 CXCL14 and FAPa expression in prostate cancer patients with nodal metastasis 
(A-B) Representative images of CXCL14 ISH (Scale bar = 100 m). (C) Representative image of 
FAPa staining (Scale bar = 100 m). (D) Average CXCL14 probe copies per µm2 presented as 
median with 95% CI in LN- (n=42) and LN+ (n=48) patients. (D) (E) Percentage (%) of stroma 
positive for FAPa staining is presented as median with 95% CI in LN- (n=44) and LN+ (n=50) 






4.5 Concluding summary 
Targeted transcriptomic analysis was performed to study potential genes that 
may mechanistically mediate the TME with the observation of reduced immune 
subpopulation infiltrates in patients with regional lymph node metastasis (LN+). 
Although this methodology carries obvious disadvantages, such as a limited 
probe panel and the use of a single probe per gene missing possible splice 
variants, the analysis was technically successful (Figure 16) and revealed ECM 
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changes (rather than chemokine or adhesion molecule imbalance) as important 
factors in developing nodal disease (Table 22). Increased ECM deposition and 
reorganisation was confirmed in LN+ patients using IHC and multi photon 
microscopy (Figure 18). I examined different tissue types (prostate biopsy cores 
and TMA from index lesion) with different methodologies (gene expression, IHC, 
SGH). Overall, my data point to a more disorganised and fibrotic stroma in LN+ 
patients. 
CAFs are increasingly recognised as a diverse population with variable marker 
expression, such as SMA and FAP (169). Our gene expression analysis showed 
upregulation of FAP gene in tumours associated with LN+ disease, which was 
however not confirmed at the protein level by IHC (Figure 19E). The 
inconsistency in these results could be attributed to the heterogeneity of CAF 
FAP expression in different tissue areas that are detected using different 
methodologies. It is therefore difficult to draw definite a conclusion from these 
data. CXCL14 was the highest upregulated gene in LN+ patients (Table 22), and 
LN + patients were the highest expressers of CXCL14 (p<0.0001, Fisher’s exact 
test). Interestingly, it was expressed by both stromal (Figure 19A) and 
morphologically benign epithelial cells (Figure 19B), highlighting the importance 
of spatial context and cellular origin in gene expression. I attempted scoring of 
CXCL14 expression in epithelial and stromal compartment separately but due to 
staining at the interface between epithelium and stroma (basal cells) 
quantification of CXCL14 in the appropriate tissue compartment was not 
satisfactory. Even though the tumours with highest expression of CXCL14 were 
LN+, it was impossible to be certain whether this was due to stromal or benign 
epithelial expression and was not investigated further. 
All epithelial tumours, including PCa, are a complex of malignant epithelial cells 
organised within a specialised microenvironment, referred to as tumour stroma 
or TME. TME includes CAFs, endothelial cells, immune cells and ECM (169). The 
ECM is an organised structure of extracellular proteins, such as collagens, 
glycoproteins (i.e. fibronectin 1) and proteoglycans (169, 177). The ECM serves 
as structural scaffold that provides tissue support but also provides 
biomechanical and biochemical signals that are major regulators of cell 
proliferation, survival, migration and invasion (172, 173). In the cancer context, 
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it is well established that tumour stroma becomes enriched with ECM proteins 
such as collagen type I and fibronectin (169, 171-173, 177). Besides these 
quantitative changes, qualitative modifications also take place, such as 
increased collagen cross-linking and orientation leading to ECM stiffening (170, 
172, 173, 177). These structural ECM alterations have direct impact on tumour 
cell function and progression.  
A plethora of studies demonstrate that deregulation of ECM is more than just a 
secondary outcome but instead plays a causative role in cancer pathogenesis and 
progression. Increased stromal collagen in mouse mammary tissue significantly 
increased tumour formation, invasiveness and metastasis (171). Furthermore, in 
a breast cancer mouse model, collagen crosslinking induction caused ECM 
stiffening, promoted focal adhesion kinases, enhanced PI3 kinase activity and 
promoted invasion (170). Collagen crosslinking is almost exclusively mediated by 
the lysyl oxydase (LOX) enzyme, which post-translationally modifies collagens 
and elastin in the ECM (149). Knockdown of LOX expression or suppression of its 
function by a blocking antibody reduced in vivo tumour invasion and metastasis 
of PDAC (149). However, it is noteworthy that abrogating stromal fibroblasts 
from PDAC tumours which reduced ECM stiffening actually promoted tumour 
progression (184). These data suggest that interaction between ECM and cancer 
cells is complex and biological outcome may be dependent on specific stromal 
cell components, different cancer type and heterogeneity of genetic 
background.  
Apart from the intrinsic tumour cell properties, one of the cancer hallmarks is 
avoidance of immune destruction (33) and ECM can modulate critical immune 
functions, such as immune cell exclusion from tumour cells (174-176). ECM 
density and orientation have previously been shown to dictate T cell migration in 
ex vivo human lung and ovarian cancer tissue, with poor T cell infiltration and 
contact with tumour cells in dense ECM areas (174, 176). Furthermore, high 
collagen density functioned as a physical barrier of T cell infiltration in PDAC 
and was able to completely abolish chemokine-guided movement (175). These 
studies suggest that when chemokine responsive migrating T cells come in 
contact with tumour ECM, the actual recruitment of the immune cells are 
influenced by the structural properties of local ECM.  
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Tumour destruction by the immune system is a key physiological mechanism that 
suppresses local tumour progression and prevents tumour spread. This relies on 
the ability of cytotoxic immune cells to encounter the malignant cells. For 
example, CD8 cytotoxic T cells need to recognise foreign antigens displayed on 
transformed cells and thereafter induce their destruction through T-cell-
mediated cell death (39, 42). Our data suggested that decreased immune cell 
infiltration of CD8 and CD4 effector T cells in particular could be associated with 
enhanced and abnormal ECM deposition in prostate cancer patients with lymph 
node metastasis, indicating that limiting T cell infiltration is a potential immune 
evasion mechanism. My current working model is that, in LN+ PCa patients, 
dense ECM prevents CD4 and CD8 T cells interacting with antigen presenting 
cells and tumour cells, contributing to the failure of an effective anti-tumour 
response. 
Altogether, my data propose that the PCa-associated ECM has an overall 
negative influence on resident T cells, limiting their migration within the 
stroma. However, additional work needs to be done in order to advance our 
understanding of the mechanistic aspect of this event. The first experimental 
steps would be staining the PCa discovery TMA with Picrosirius red (PSR) special 
stain and LOX IHC. The former can be analysed under orthogonal and polarising 
light (170) in order to strengthen the finding of increased ECM density in LN+ 
patients. The latter could indicate a potential mechanism for this event. 
Developing a mIF panel that incorporates CD4, CD8, collagen I, collagen III and 
fibronectin as key markers would also be valuable in dissecting the associations 
between those different TME components.  
My data showed that epithelial prostate cancer cells as well as stromal cells 
morphologically compatible with CAFs are expressing collagen III and FN 1. Both 
tumour cells and stromal cells have been shown to contribute to the tumour ECM 
production (185). The relative contribution to abnormal ECM development of 
epithelial and stromal cells needs to be determined. Furthermore, it is essential 
to decipher at which time points of tumourigenesis and progression that ECM 
stiffening occurs, whether at tumour initiation or later when disease 
disseminates. Analysis of ECM components in normal prostate and low-risk 
prostate cancer samples would help answer these questions.  
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Apart from the valuable information derived from human samples, further in 
vitro and in vivo work could advance our molecular understanding of ECM 
contribution in prostate cancer initiation and progression. Firstly, tumour 
derived or peripheral blood monocytes from PCa patients could be cultured in 
high and low density matrices in order to assess the effect on migration and 
proliferation of CD4 as well CD8 T cells according to different chemokine stimuli. 
Importantly, single cell transcriptomic analysis of those differently cultured T 
cells could elucidate the downstream transcriptional regulators of differing ECM 
stiffness. Finally, it is essential to determine whether dense ECM and decreased 
T cell infiltration is a correlative phenotype or a causative factor driving this 
event. To answer this, GEMM studies can be performed, crossing a mouse 
prostate cancer model with collagen I/III null mice in order to see the effect on 
immune cell infiltration and lymph node spread. Finally, this could be combined 
with specific immune cell depletion (such as CD4 or CD8 T cell depletion) in 
order to pin down the exact immune cell population driving this event.  
Lastly, our data are in agreement with the general characterisation of PCa as an 
‘immune cold’ tumour, but make an important further distinction of an immune-
exclusion phenotype (35). This carries important clinical implications as the 
efficacy of immunotherapies in PCa have so far been unsuccessful (186, 187), 
reinforcing the perception that PCa is a poorly immunogenic tumour. Careful 
selection of PCa patients for immunotherapy in combination with stroma-
modifying treatments targeting factors, such as LOX inhibitors (149), could 
potentially improve therapeutic outcomes.  ECM density could be one of the 




Chapter 5 117 
 
 
Chapter 5 B7-H3 and prostate cancer 
Despite significant advances in other cancer types, immunotherapy with immune 
checkpoint inhibitors against CTL4, PD-L1 and PD-1 have so far been 
disappointing in PCa (188). There is therefore an urgent need for discovery of 
novel immune checkpoints that may be at play in PCa. B7-H3 is a newly 
discovered member of the B7 family of checkpoint molecules, with aberrant 
expression observed in multiple solid malignancies, including prostate cancer 
(107, 142). Previous studies have shown that prostate cancer patients with high 
B7-H3 expression were more likely to have adverse pathologic features, such as 
extraprostatic extension and seminal vesicle invasion (107, 142). Furthermore, 
B7-H3 intensity was associated with cancer relapse after radical prostatectomy 
as well as poor survival outcomes (107, 142). I aimed to validate externally those 
results in the discovery high-risk cohort of prostate cancer patients, with a 
special focus on the association of B7-H3 with regional lymph node status that 
has not been thoroughly explored before.   
B7-H3 has also been shown to promote tumour invasion and metastatic spread in 
different tumours (130, 131), including a single study in prostate cancer, in 
which human PC3 prostate cancer cells were transiently silenced for B7-H3 
expression. PC3 cells with suppressed B7-H3 expression showed 50% reduction in 
migration (p<0.001) and invasion (p=0.0005) in vitro while cellular adhesion to 
fibronectin was impaired by 30% (p=0.003) (127). I built on these observations 
and investigated the impact of silencing B7-H3 expression in a panel of human 
prostate cancer cell lines (namely PC3M, LNCaP, C4-2, DU145). Cell growth, 
apoptosis, migration and invasion were analysed by cell counting, flow 
cytometry, scratch wound and transwell assays. B7-H3 silencing had no effect on 
cell growth and apoptosis but showed a significant decrease in migration and 
invasion. Following that, I also generated stable knock out clones of C4-2 and 
PC3M cells and successfully replicated data from transient silencing of B7-H3 
expression. Finally, I aimed to investigate the transcriptional changes following 
manipulation of B7-H3 expression in order to explore its potential downstream 
targets.   
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5.1 B7-H3 is overexpressed in prostate cancer and 
associated with worse clinicopathological features 
5.1.1 B7-H3 staining of human tissue 
B7-H3 staining was performed manually and histoscoring was applied according 
to previous studies (107). The intensity score given was absent [0] for no 
staining, weak [1] for cytoplasmic staining, moderate [2] for incomplete 
membranous and cytoplasmic staining and strong [3] for complete, intense 
membranous staining. Prostatic cancer glands had strong B7-H3 membranous 
staining (Figure 20A) whilst benign prostatic glands showed mostly weak to 
moderate cytoplasmic staining (Figure 20B). Occasional inflammatory cells were 
also positive, particularly in germinal centres of lymph node tissue (Figure 20C), 
morphologically compatible with lymphocytes and dendritic cells. In primary 
prostate tissue, no inflammatory or endothelial cell staining was observed. All 
cases were evaluated by myself (CN) without knowledge of patient information. 
In addition, more than 10% of the total B7-H3 cases were reviewed by a second 
urologic pathologist (Jonathan Salmond, NHS Greater Glasgow and Clyde), 
yielding high interobserver agreement (Figure 20D, r=0.85, p<0.001, Spearman’s 
correlation). Therefore, the B7-H3 expression histoscoring was considered 
reproducible and easy to implement. The Benign Prostatic Hyperplasia (BPH) 
TMA as well as the discovery TMA of intermediate and high-risk prostate cancer 
patients were stained manually for B7-H3 (Figure 20E). Prostate cancer had 
significantly increased B7-H3 immunoreactivity, Histoscore median value of 
183.3 (163.3-197.7 95%CI) compared to BPH with median Histoscore of 70 (63.33-
76.67 95%CI), p<0.0001. 
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Figure 20 B7-H3 staining of human prostatic tissue and pelvic lymph nodes 
(A) Representative image of strong B7-H3 staining in prostate cancer. Histoscore=300. (B) 
Representative image of weak B7-H3 staining in benign prostatic hyperplasia. Histoscore=100. (C) 
Representative image of strong B7-H3 staining observed in germinal centres of lymph node tissue. 
(D) B7-H3 Histoscore values (n=55) provided by two independent pathologists (Chara Ntala & 
Jonathan Salmond) compared by Spearman’s correlation. (E) B7-H3 Histoscore values presented 
as median with 95% CI in benign prostate hyperplasia (BPH, n=259) and prostate cancer patients 
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5.1.2 High B7-H3 expression is associated with worse 
clinicopathological features in intermediate and high risk 
prostate cancer patients 
Among the 94 patients within the discovery cohort, each case was represented 
by at least two tumour cores with informative B7-H3 staining. Tumours with high 
expression of B7-H3 were significantly more likely to have lymph node 
metastasis (p=0.0006, Figure 21A), however there was no difference between 
the number of involved lymph nodes (p>0.99, Figure 21B). Interestingly, B7-H3 
expression was collectively retained in the regional lymph node metastatic foci 
compared to the primary tumour (p=0.49, Figure 21C-D). There was a lot of 
variation between cases, with some patients having comparable levels, some 
reduced and others increased expression of B7-H3 in the metastatic deposit 
compared to primary cancer (Figure 21C). 
 
Figure 21 High B7-H3 expression is associated with lymph node metastasis 
(A) B7-H3 Histoscore presented as median with 95% CI in patients without (LN-, n=44) and with 
(LN+, n=50) lymph node metastasis. Mann Whitney test used for statistical comparison. (B) B7-H3 
Histoscore presented as median with 95% CI in LN- (n=44), patients with 2 or less positive nodes 
(n=36) and patients with more than 2 positive nodes (n=14). Kruskal-Wallis test used for statistical 
comparison. (C) B7-H3 Histoscore presented as median value in primary prostate cancer tissue 
and the metastatic deposit of the same patients (n=35). Wilcoxon matched-pairs signed rank test 
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used for statistical comparison. (D) Representative image of strong B7-H3 staining in metastatic 
deposit. H-score=280. Scale bar=100µm. 
 
Furthermore, tumours with increased B7-H3 score were significantly associated 
with high pT stage (p<0.0001, Figure 22A) and the presence of perineural 
invasion (p=0.044, Figure 22B), but not Gleason score (Figure 22C). Given the 
short duration of post-treatment follow up, it is not surprising that there was no 
association between B7-H3 expression and the development of biochemical 
recurrence (Figure 22D).  
 
Figure 22 High B7-H3 expression is associated with worse clinicopathological features 
(A) B7-H3 Histoscore presented as median with 95% CI in patients with pT2 (n=27) and pT3-4 
(n=59) stage. (B) B7-H3 Histoscore presented as median with 95% CI in PNI- (n=15) and PNI+ 
(n=76). (C) B7-H3 Histoscore presented as median with 95% CI in patients with Gleason score=7 
(n=65) and Gleason score=8-9 (n=27). (C) (A-C) Mann Whitney test used for statistical 
comparisons. (G) Kaplan Meier curves of PCa patients in the discovery cohort. High B7-H3 defined 
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5.1.3 B7-H3 expression inversely correlates with immune cell 
infiltration 
I further explored the correlation between B7-H3 staining and immune cell 
infiltration. B7-H3 expression had a weak inverse correlation with epithelial CD8 
effector T cells (Spearman’s r=-0.26, p=0.03). Additionally there was a similar 
trend for stromal CD4 effector T cells (Spearman’s r=-0.21, p=0.08) and stromal 
CD8 effector T cells (Spearman’s r=-0.22, p=0.06). It should be noted that the 
stainings were not conducted in serial sections; therefore, even weak 
correlations were considered a strong indicator of potential association between 
these markers.  
5.2 Transient silencing of B7-H3 expression in prostate 
cancer cell lines 
Transient silencing of B7-H3 expression was performed on LNCaP, C4-2, PC3M 
and DU145 human prostate cancer cells using a pooled siRNA targeting B7-H3 
(siB7-H3 pool). It was evident in all cell lines that mRNA (Figure 23A) expression 
of B7-H3 was markedly decreased 48 h after siRNA transfection compared to 
non-targeting control (siNT) based on quantitative polymerase chain reaction 
(qPCR). A similar decrease was found in protein expression 48 h after siB7-H3 
pool transfection based on western blotting (Figure 23B). It was interesting that 
the baseline expression levels of B7-H3 varied between different cell lines, with 
LNCaP and C4-2 showing higher protein expression than PC3M and DU145 (Figure 
23B). 
Furthermore, I tested the efficiency of the singleton siRNA sequences (S1-S4) 
against B7-H3 within the siRNA pool in LNCaP and PC3M cells in an attempt to 
address any potential off-target effects with the use of pooled siRNA. All 
singleton siRNAs successfully decreased mRNA (Figure 23C) as well as protein 
(Figure 23D) levels of B7-H3. I used siB7-H3 pool and occasionally siB7H3 S1 and 
siB7H3 S4 for subsequent assays as their presence resulted in the largest 
decrease in B7-H3 expression. 
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Figure 23 Transient silencing of B7-H3 in prostate cancer cell lines 
(A) Quantitative polymerase chain reaction (qPCR) of B7-H3 mRNA expression in non-targeting 
control (siNT) and B7-H3 pool siRNA (siB7-H3 pool) transfected LNCaP, C4-2, PC3M and DU145 
cells. Normalised to Casc 3 expression (house keeping gene). (B) Western blotting of whole cell 
lysates prepared from PC3M, LNCaP, C4-2 and DU145 human prostate cancer cell lines which 
had been transiently transfected with siNT or siB7-H3 pool using anti- B7-H3 antibody. HSC70 
served as a loading control. (C) qPCR of B7-H3 mRNA expression in siNT, siB7-H3 pool, siB7-H3 
S1 and siB7-H3 S4 (singleton siRNAs) transfected LNCaP and PC3M cells. (D) Western blotting of 
whole cell lysates prepared from LNCaP and PC3M cell lines which had been transiently 
transfected with siNT, siB7-H3 pool, siB7-H3 S1 and siB7-H3 S4 (singleton siRNAs) using anti- B7-
H3 antibody. HSC70 served as a loading control.  (A&C) Bars indicate mean values and error bars 




5.2.1 Transient loss of B7-H3 expression does not affect prostate 
cancer cell growth or apoptosis in vitro   
To investigate the role of B7-H3 in PCa cell growth, I measured cell proliferation 
by cell counting. There was no significant difference in cellular proliferation 
between control siNT and siB7-H3 pool in LNCaP (Figure 24A) and PC3M (Figure 
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24B) cells. Also, silencing of B7-H3 did not increase apoptosis in LNCaP (Figure 
24C) or PC3M cells (Figure 24D), as measured by annexin V staining. 
 
Figure 24 Transient loss of B7-H3 expression does not affect prostate cancer cell growth or 
apoptosis in vitro   
(A) LNCaP and (B) PC3M cells were treated with control non-targeting siRNA (siNT) or pool siRNA 
directed against B7-H3 (siB7-H3 pool). The presented graphs show changes in cell proliferation by 
cell counting. (C) LNCaP and (D) PC3M cells were treated with siNT or siB7-H3 pool and stained 
with annexin V and analysed by flow cytometry. The presented graphs show percentage of 
apoptotic cells stained with annexin V. (A-D) n=3 (biological replicates), data in bar charts indicate 




5.2.2 Transient loss of B7-H3 expression reduces prostate cancer 
cell migration in vitro 
I conducted transwell migration assays to determine whether B7-H3 affects cell 
migration. Transient siRNA mediated silencing of B7-H3 expression significantly 
impaired migration in LNCaP (Figure 25A-B), C4-2 (Figure 25C-D) and PC3M 
(Figure 25E-F) cells, particularly pronounced in LNCaP and C4-2 cells, with >50% 
decreased migration.  
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Figure 25 Transient loss of B7-H3 expression reduces prostate cancer cell migration in a 
transwell Boydon chamber assay 
LNCaP (A-B), C4-2 (C-D) and PC3M (E-F) cells were silenced with control NT siRNA (siNT), pool 
siRNA (siB7-H3 pool) and/or two singleton siRNAs (S1, S4) directed against B7-H3 then subjected 
to transwell migration assay after 48 h incubation (n = 2 biological replicates for PC3M singleton 
B7-H3 siRNA’s; n=3 for all other cell lines/conditions). A,C and D are representative images of 
migrated cells under light microscope (20x). In B,D,F graphs bar charts indicate the mean± SD. t-
test (unpaired, 2 tailed) and 2-way ANOVA were used for statistical analysis, * = p <0.05. 
 
 
Next, I sought to validate the observed effects of B7-H3 mediated  cell migration 
using an additional in vitro methodology, namely a scratch wound healing assay. 
LNCaP and C4-2 wells could not be used in this assay due to their cell to cell 
adhesiveness that prevented the generation of a clean scratch wound and 
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resulted in detachment from the plastic in irregular shapes. Besides PC3M cells, 
DU145 cells were found to be suitable. B7-H3 silencing reduced PC3M (Figure 
26A-B) and DU145 (Figure 26C-D) cell wound healing capacity, measured by 
Incucyte analysis. The maximum difference between siB7-H3 treated and control 
siNT was 12.47% (± 2.36 SD p<0.0001) at 39 hours for PC3M and 13% (± 1.47 SD, 
p<0.0001) at 40 hours for DU145 cells. These data combined with the previous 
data from transwell experiments suggested that B7-H3 could play an important 
role in cell migration.  
 
Figure 26 Transient loss of B7-H3 expression reduces prostate cancer cell migration shown 
by  scratch wound assay 
PC3M (A-B) and DU145 (C-D) cells were silenced with control NT siRNA (siNT) or pool siRNA 
directed against B7-H3 then subjected to scratch-wound assay using incucyte (n = 3 biological 
replicates). A and C are representative images taken by incucyte, migrating cells are shown as 
orange mask and scratch wound is shown as yellow mask. In B and D individual data indicate 
mean± SD wound confluence, 2-way ANOVA was used for statistical analysis. 
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5.2.3 Transient loss of B7-H3 expression reduces PC3M cell 
invasion in vitro 
In order to assess the potential influence of B7-H3 on prostate cancer cell 
invasion, I conducted inverted transwell invasion assays. PC3M cells were used as 
suitable human prostate cancer cells capable of invading matrigel in an in vitro 
assay. Silencing of B7-H3 led to decreased invasion of PC3M cells compared to 
control (Figure 27). This was more pronounced using S4 singleton siRNA (21% 




Figure 27 Transient loss of B7-H3 expression reduces PC3M prostate cancer cell invasion 
shown by inverted transwell Boydon chamber assay 
PC3M cells were silenced with control NT siRNA or pool siRNA and/or two singleton siRNAs (S1, 
S4) directed against B7-H3 then subjected to transwell invasion assay (n = 3 biological replicates). 





In summary, in vitro assays with transient B7-H3 silencing showed no effect in 
prostate cancer cell lines proliferation and apoptosis, but a decrease in cell 
migration and invasion. Cell proliferation can be a confounding factor of migration 
assays, therefore I was confident that it had not contributed to the changes in 
migration observed.   
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5.3 Generation of stable knock out (KO) B7-H3 clones of 
PC3M and C4-2 cell lines 
To validate the in vitro phenotype observed following transient silencing of B7-
H3 expression, I generated stable knock out (KO) clones from PC3M and C4-2 
parental prostate cancer cells. PC3M cells represent poorly differentiated 
prostate adenocarcinoma cells generated from a bone metastases from a patient 
with prostate cancer. C4-2 cells are derived from subcutaneous xenograft of 
LNCaP cells (isolated from a patient with lymph node metastasis) and are more 
aggressive and metastatic than LNCaP cells. These two human prostate cancer 
cell lines were selected due to their inherent capacity to migrate/invade as well 
as their potential for use in in vivo studies in the future.  
B7-H3 was stably knocked out (KO) in PC3M cells using CRISPR Cas9 gene editing, 
generating four stable KO cell lines, namely, KO clone 10 (KO10), KO clone 4 
(KO4) and KO clone 13 (KO13) and KO pool of different clones. As shown by 
Western blot, KO clones expressed very low levels of B7-H3 compared to 
parental and control transfection cells (Figure 28A). PC3M KO pool and KO10 
clones were used in subsequent experiments. B7-H3 mRNA expression was also 
tested by qPCR in PC3M KO pool and KO10, confirming a significant reduction 
(Figure 28B).  
Similarly, B7-H3 was stably knocked out (KO) in C4-2 cells, generating five stable 
KO cell lines, namely KO pool, KO clone 2 (KO2), KO clone 3 (KO3), KO clone 4 
(KO4), KO clone 10 (KO10) and KO clone 18 (KO18) (Figure 28C). Transfection 
control, KO pool and KO2 were selected for subsequent experiments. B7-H3 
mRNA expression was also tested by qPCR and confirmed a significant decrease 
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Figure 28 Generation of stable B7-H3 knock out (KO) clones of PC3M and C4-2 cells 
(A) Western blotting of whole cell lysates prepared from PC3M prostate cancer cells which had 
been stably B7-H3 knocked out (KO pool, KO10, KO4) using CRISPR/Cas9. A control pool was 
used as control (PC3M control). HSC70 served as a loading control. (B) qPCR of B7-H3 mRNA 
expression in stable KO clones of PC3M compared to parental and control PC3M. Normalised to 
Casc 3 expression (house keeping gene). (C) Western blotting of whole cell lysates prepared from 
C4-2 prostate cancer cell lines which had been stably B7-H3 knocked out (KO pool, KO2, KO3, 
KO4, KO10, KO18) using CRISPR/Cas9.  A control pool was used as control (C4-2 control). 
HSC70 served as a loading control. (D) qPCR of B7-H3 mRNA expression in stable KO clones of 
C4-2 cells compared to parental and control C4-2. Normalised to Casc 3 expression (house 






5.4 Stable knock out (KO) of B7-H3 does not affect 
survival and proliferation of PC3M cells 
I applied the colony formation assay to investigate differences in survival and 
proliferation in stable B7-H3 KO clones derived from human prostate cancer 
cells. This assay required very sparse seeding and C4-2 cells were unable to grow 
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in such low concentrations. The number of colonies developed from PC3M 
control cells was comparable to that of its KO pool and KO 10 derivatives (Figure 
29). This suggests that suppressed B7-H3 expression did not alter the 
proliferation and survival of PC3M cells in vitro. 
 
Figure 29 Stable knock out (KO) of B7-H3 does not affect survival and proliferation of PC3M 
cells 
(A) Representative images of PC3M control (top), PC3M KO pool (bottom left) and PC3M KO10 
(bottom right) stained with crystal violet and imaged in LI-COR with 700 wavelength. (B) Graph 
indicates colony numbers of each groups as mean± SD. 2-way ANOVA was used for statistical 






5.5 Stable knock out (KO) of B7-H3 reduces prostate 
cancer cell migration and invasion in vitro 
To investigate whether B7-H3 affects prostate cancer cell migration, I performed 
transwell migration and scratch wound healing assay with the stable KO clones 
for B7-H3 expression. Both PC3M (Figure 30A) and C4-2 (Figure 30B) KO clones 
have significantly reduced migration (up to 50%). PC3M KO clones also showed 
significant decrease in wound healing capacity (Figure 30C). The maximum 
difference between KO pool and control was 16.2% (± 3.86 SD, p<0.0001) and 
34.91% (± 3.37 SD, p<0.0001) for KO10 at 36 hours. In a transwell invasion assay, 
PC3M KO pool and KO 10 cell clones showed a significant decrease in invasive 
capacity when compared to the PC3M control cells (Figure 30D). These data 
reinforced the potential role of B7-H3 in regulating migration and invasion of 
prostate cancer cells.   






Figure 30 Stable knock out (KO) of B7-H3 reduces prostate cancer cell migration and 
invasion in vitro 
(A) PC3M (control, KO pool and KO10 clones) and (B) C4-2 (control, KO pool and KO 2 clones) 
were subjected to transwell migration assay after 48 h incubation. Number of migrated cells are 
shown in A and B panels. (C) PC3M control, KO pool and KO 10 for B7-H3 were subjected to 
scratch-wound assay using incucyte. (D) PC3M control, KO pool and KO 10 for B7-H3 were 
subjected to transwell invasion assay. (A-D) Graph bar charts indicate the mean ± SD. 2-way 






5.6 RNA sequencing and metacore pathway analysis 
reveals extracellular space cytokines are decreased 
in B7-H3 deficiency 
Having established a decrease in migration and invasion associated with B7-H3 
knock out, we performed RNA sequencing comparing PC3M pool KO and KO 10 
with control PC3M cells (n=3 biological replicates) in order to gain a better 
understanding of the biological effect of B7-H3 loss. Principal component 
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analysis (PCA) showed good clustering between biological replicates and distance 
between PC3M control and KO clones (Figure 31A), confirming good 
reproducibility within each sample, and that loss of B7-H3 expression has an 
effect. KO pool and KO 10 did not cluster near each other, likely because KO10 is 
a single KO clone for B7-H3 whereas KO pool comprises of many different KO 
clones and has a larger heterogeneity. All genes that were differentially 
expressed in KO clones compared to control were defined to be significant if 
they have a fold change greater than 2 and an adjusted p value of <0.05. 
Analysis was performed by Dr Ann Hedley, Bioinformatician, Beatson Institute. 
368 genes were significantly changed in the same direction in both KO cells, 180 
upregulated and 188 downregulated (Figure 31B). All significantly downregulated 
genes were used in Metacore analysis in order to identify involved pathways. The 
ten top pathways are shown in Figure 31C and included cytokines and their 
receptors (CCL2, CXCL1, CXCL6, CXCL8, CXCL16, IL13RA2, IL11, IL33, IL4RA,), 
complement (C3, C3a, C3b, C3c, C3dg, iC3b) and ECM remodelling (MMP1, 
MMP10, Collagen III) genes. These cytokines and MMPs are secreted molecules 
known to be involved in chemotaxis and matrix remodelling respectively, and 
have been implicated in migration, invasion and metastasis of different tumour 
types.  
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Figure 31 Metacore pathway analysis  
(A) Principal component analysis (PCA) plot showing PC3M control (red), PC3M KO pool (green) 
and KO clone 10 (blue). (B) Venn diagram showing significantly changed genes in the same 
direction. Fold change >2, adj p value <0.05. (C) Top 10 significantly downregulated pathways in 
PC3M KO pool and KO10 compared to PC3M control using metacore pathway software analysis. 
 
 
5.6.1 Differentially expressed genes from RNA sequencing 
validate in PC3M cells 
The next step to confirm that the downregulated genes that were of most 
interest (i.e. cytokines and metalloproteinases) identified by the RNA 
sequencing could be validated with qPCR in PC3M cells (different biological 
replicates). CCL2, CXCL1, CXCL6, CXCL8, CXCL16, IL11, IL33, IL4R, MMP1 and 
MMP10 were significantly downregulated in PC3M KO pool and KO 10 for B7-H3 
compared to PC3M control (Figure 32A-J). Interestingly, CXCL8 is the only one 
that so far been implicated in the metastatic potential of B7-H3 in melanoma 
(130)  and pancreatic cancer (137).  
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Figure 32 Differentially expressed genes from RNA sequencing validate in PC3M cells 
(A-J) qPCR of mRNA expression of cytokine and metalloproteinase genes identified from RNA 
sequencing (performed in PC3M) in stable KO clones of PC3M compared to control PC3M. 
Normalised to Casc 3 expression (house keeping gene). Bars indicate mean values and error bars 
SD, n = 2 (biological replicates). 2-way ANOVA was used for statistical analysis, * = <0.05, ** = 





I next investigated whether any of the above target genes were also 
downregulated in C4-2 KO clones for B7-H3. However, none of these genes were 
significantly decreased in C4-2 B7-H3 KO clones when compared to C4-2 controls 
(Figure 33A-H). CXCL1, IL11 and IL4R genes were not expressed at all. 
Overall, the downregulated genes identified from RNA sequencing were robust 
for PC3M cells but do not show similar results in C4-2 cells, suggesting that there 
may be cell type differences in B7-H3 function. 
 
 





Figure 33 Differentially expressed genes from RNA sequencing do not validate in C4-2 cells 
(A-J) qPCR of mRNA expression of cytokine and metalloproteinase genes identified from RNA 
sequencing (performed in PC3M) in stable KO clones of C4-2 compared to control C4-2. 
Normalised to Casc 3 expression (house keeping gene). Bars indicate mean values and error bars 
SD, n = 2 (biological replicates). 2-way ANOVA was used for statistical analysis, * = <0.05, ** = 
<0.01, *** = <0.001, **** = <0.0001, ns= not significant). 
 
 
5.7 Concluding summary 
In summary, data presented in this chapter are consistent with the notion that 
B7-H3 may be involved in prostate cancer progression including metastasis. 
Firstly, B7-H3 chromogenic staining and histo-scoring is easy to implement and a 
reproducible methodology for B7-H3 protein quantification in FFPE tissue (Figure 
20). A correlation between increased B7-H3 expression and poor prognosis has 
been previously established (107, 142), however a strong association with 
metastatic spread to the lymph nodes is shown for the first time in this thesis 
(Figure 21).  
Furthermore, there were significant in vitro phenotypic changes related to B7-
H3 loss across a panel of human prostate cancer cell lines (namely PC3M, C4-2, 
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LNCaP and DU145) (Figure 23, 28). Both transient and stable suppression of B7-
H3 expression resulted in impaired cellular migration and invasion in vitro, in 
the absence of changes in proliferation or apoptosis (Figure 24-27, 29-33). These 
results are in agreement with the existing studies on non-immunoregulatory role 
of B7-H3 (127, 130, 189) in different cancer types. Our data confidently show 
that B7-H3 contributes to an invasive phenotype of different human prostate cell 
lines and raises interesting questions regarding the biological mechanisms 
involved and potential of B7-H3 therapeutic targeting.  
We performed RNA sequencing on PC3M B7-H3 KO and control clones in order to 
elucidate its downstream pathways, particularly in the context of its effects on 
migration and invasion (Figure 31). The top downregulated pathways identified 
in Metacore involved extracellular space chemotactic cytokines (CCL2, CXCL1, 
CXCL6, CXCL16, IL11, IL33, IL4R) and their receptors as well as 
metalloproteinases (MMP1, MMP10). Each of these targets deserves further 
investigation in the future, with CCL2 being one of the most promising 
candidates. CCL2, a known direct transcriptional target of NF-kB, is a potent 
enhancer of PCa cell migration and acting at least in part, via activation of the 
PI3 kinase/AKT pathway (190-192). 
Due to the finite time that was left during my PhD I did not investigate the 
above genes further. However, future experiments would include confirming 
that changes in the expression of candidate cytokine at the protein level 
following manipulation of B7-H3 expression in PC3M cells, perhaps using a 
targeted cytokine assay or secretome analysis since the majority of the top 
downregulated targets are extracellular molecules. Following that, a 
recombinant antibody for CCL2 (or other cytokines of interest) could be studied 
in in vitro migration/invasion assays to test whether the phenotypic changes 
could be rescued in KO B7-H3 clones. Furthermore, the molecular cascade 
between B7-H3 loss and altered cytokine expression can be explored. For 
example, as NF-kB is a major regulator of cytokine transcription (193), it would 
be interesting to test if NF-kB function is suppressed in B7-H3 KO clones. 
Evaluation of the role of B7-H3 in prostate cancer metastasis will require the use 
of in vivo metastasis models, for instance orthotopic xenograft model to assay 
for nodal disease using PC3M and/or C4-2 KO cell clones.  
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Chapter 6 Discussion and future directions 
6.1 Identification and validation of novel TME signature 
to identify patients with nodal metastasis 
Driven by the clinical unmet need for better PCa patient stratification I 
investigated the tumour immune microenvironment of a well-characterised 
intermediate and high-risk PCa patient cohort in order to identify novel prognostic 
biomarkers for lymph node metastasis. We developed and applied mIF panels for 
T lymphocytes (CD4, CD8, FoxP3, PD-1), B lymphocytes (CD20) and macrophages 
(CD68, CD163) to comprehensively characterise infiltrating immune cell 
subpopulations with spatial context. The primary tumours in patients with lymph 
node metastasis were less infiltrated by anti-tumourigenic immune cells, namely 
effector CD4 (CD4+ FoxP3- PD-1-), effector CD8 (CD8+ FoxP3- PD-1-) and M1-like 
macrophages (CD68+ CD163-). Stromal CD4 effector T cell density was similarly 
lower in an independent patient cohort and could independently predict pelvic 
lymph node spread. Importantly, addition of CD4 T cell density to the currently 
used nomograms improved their accuracy, showing promise as a future prognostic 
biomarker.  
This highlighted the importance of spatial composition, as only the density of 
stromal CD4 effector T cells were reproducibly predictive of lymph node spread. 
In the literature, a distinction of immune cell density assessment between the 
central area of the tumour and the invasive margin has been used repeatedly for 
cancer prognosis (49, 52). Although conceptually this makes sense in cancers 
such as colon and breast, this is more difficult to implement in PCa due to the 
multifocality of the disease and confidently identifying the index lesions on 
diagnostic biopsies. I explored the possibility of translating CD4 effector stromal 
T cell density to the clinic using a simple co-staining protocol easily applied in 
the diagnostic biopsy setting. I stained a pilot cohort of diagnostic biopsies with 
dual CD4-FoxP3 and convincingly demonstrated technical feasibility. Given the 
small optimisation sample number, it was not surprising that I did not observe 
significant differences according to nodal status. This highlighted that further 
work is needed on how best to assess tumour infiltrating immune cells in biopsy 
tissue material in determining the appropriate cut-off criteria for scoring and 
the presence of index lesion with radiologic guidance.    
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A pending question was the biological underpinnings for the differences in 
immune cell infiltration between patients with and without nodal spread. Using 
a targeted gene expression analysis, we identified increased expression of ECM 
components in lymph node positive patients (collagen I, collagen III and 
fibronectin 1). Increased ECM abundance and perturbed organisation was 
identified in different tissues (TMA, diagnostic biopsies) using different 
methodologies (IHC, SGH), solidifying the presence of increased stromal fibrosis 
in lymph node positive patients. This finding suggested a fibrotic stroma could 
potentially function as a physical barrier and prevent anti-tumourigenic immune 
cell infiltration in these patients (immune exclusion).   
A secondary project during my studies was the role of B7-H3 immune checkpoint 
molecule in PCa. Examining human tissue samples, I showed an association of B7-
H3 expression and aggressive clinical features, including lymph node spread. In 
vitro experiments with acute and chronic loss of B7-H3 revealed an effect on 
migration and invasion without any changes in proliferation or apoptosis. RNA 
sequencing of B7-H3 KO clones revealed downregulation of known pro-migratory 
molecules, such as extracellular secreted cytokines and MMPs. 
The identification of prognostic markers of nodal metastasis will also facilitate 
development of radiation therapy in a precision medicine context. The decision 
to extend the radiation field to include the entire pelvis remains controversial and 
the practice ranges widely among oncologists. The incorporation of a prognostic 
signature as described here will support an evidence-based decision in the 
radiation field for treating patients with intermediate and high-risk prostate 
cancer. 
6.2 B7-H3 checkpoint molecule immune function insights 
The role of host immune system in cancer initiation and progression and how it 
can be exploited by immune therapies is currently a popular research topic (44).  
B7-H3 immune checkpoint molecule has a role in tumour progression that goes 
beyond its immune regulatory role (194), that was the focus of my experiments. 
However, some of my data provide useful insights into possible immune 
functions of B7-H3 in PCa. The primary tumour immune microenvironment is the 
location in which tumour cells interact with the host immune system for the first 
Chapter 6 139 
 
time. Immune infiltrates with the TME may have pro-tumourigenic or anti-
tumorigenic effects depending on the immune cell compositions. The phenotype 
of tumour immune evasion may at least be partly mediated by chemokines from 
tumour and stromal cells, and interactions with their cognate chemokine 
receptors in regulating the migration of certain immune populations into the 
TME as part of the host immune response to the tumour (195). 
RNA sequencing identified cytokines and cytokine receptors as the highest 
downregulated genes in KO clones for B7-H3 compared to control. In specific, 
CCL2, CXCL1 and CXCL8 are of particular interest due to their known role in 
promoting migration of pro-tumorigenic immune cells into the TME (196-198). 
Firstly, TAMs as well as MDSCs can be recruited to the TME via the CCL2-CCR2 
axis to promote tumour metastasis (197). Similarly, CXCL1 tumour secretion 
results in increased infiltration of CXCR+ MDSCs and CXCL1 ablation can increase 
T cell infiltration and sensitivity to immunotherapy (198). CXCL8 expressed by 
tumour cells also regulates MDSCs and tumour associated neutrophil migration 
into the TME to promote tumour progression and metastasis (196). CXCL8 also 
targets endothelial cells and promotes angiogenesis (199). Therefore, these 
identified downstream potential targets of B7-H3 signalling may suggest an 
additional role in immune suppression via promoting pro-tumorigenic immune 
cell infiltration and require further investigation.  
6.3 Future directions in tumour immune profiling 
There is increasing need for comprehensive characterisation of the TME retaining 
spatial context as well as gaining information from minority immune cell 
populations that are lost with bulk sample analyses. This has led to the 
development of novel imaging technologies, such as mIF which was applied in 
this thesis. An alternative methodology is the use of quantum dot nanocrystals 
instead of fluorescent dyes for detection of the site of antibody-antigen binding. 
Quantum dots have some advantages over traditional fluorescent dyes, such as 
high stability and narrow fluorescence excitation and  emission spectra resulting 
in less bleed through and theoretically larger capability of multiplexing (200). 
However, they also carry inherent limitations, such as inability to use antibodies 
from the same species hugely complicating the protocol.  
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Another novel approach for tumour immune profiling which is constantly gaining 
popularity is tissue mass cytometry by time-of-flight (CyTOF). It combines 
traditional immunohistochemical methods of antigen-antibody binding with mass 
cytometry by measuring the abundance of metal isotopes with defined atomic 
mass tagged to antibodies (201). This approach can detect the metal-labelled 
antibodies in their exact tissue location using lasers or ion beams for subsequent 
mass spectrometry detection with one simultaneous antibody incubation and 
single step data acquisition and high-dimensional imaging (201, 202). Currently it 
has been validated to reliably image up to 32 markers on FFPE human tissue 
sections (201) and has the potential to increase to 100 due to the near zero 
crosstalk between metal labels. It can clearly provide much more information 
compared to every other method retaining spatial context. The main 
disadvantages lay in the limited number of antibodies currently suitable for this 
process, their relative instability which can cause alteration of the binding 
properties, the cumbersome analysis workflow, long processing times, 
specialised equipment and high cost of the mass spectrometer and destruction of 
the tissue after use. These limiting factors currently hinder this technology from 
widespread use but will likely be addressed in the near future.  
It should be mentioned that all of these methods conducted on TMAs or 
representative tissue sections, suffer a key potential drawback, which is the risk 
of under-sampling. They examine only a fraction of the tumour tissue, missing 
information on tumour heterogeneity and rare events that may be present. 
However, in studies aiming to discover prognostic or predictive biomarkers, like 
the research presented here, the advantages of using mIF methodology on TMAs 
far out ways the drawbacks. The key benefit was that the patient tissue material 
used remained relatively intact and available for further examination in the 
clinic. Secondary considerations were the speed of biomarker analysis and 
decrease of cost and technical variability, as dozens of tissue samples were 
examined simultaneously. I aimed to address under sampling by using three large 
tissue cores (1mm) from each patient (routinely used size is 0.6 µm), but I 
recognise under sampling constituted an inevitable drawback of this screening 
high-throuput study.  
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6.4 Concluding summary 
My PhD research thesis identified stromal CD4 effector T cell density as a 
promising prognostic biomarker for regional lymph node metastasis and 
highlighted the areas that necessitate future work before its adoption in the clinic 
(Chapter 3). It also showed increased stromal density as a key feature of lymph 
node positive PCa TME, presenting immune exclusion as a target for future studies 
(Chapter 4). Finally, it revealed the association of B7-H3 with nodal spread and 
aggressive clinicopathological features, as well as an in vitro pro-migratory and 












Appendix Figure 1 Clinical impact of lymph node metastasis in survival 
Kaplan-Meier curves of prostate cancer patients in the discovery cohort (A) and validation cohort 


















AADAT aminoadipate aminotransferase 
ABCB1 ATP binding cassette subfamily B member 1 
ABCB11 ATP binding cassette subfamily B member 11 
ABCC2 ATP binding cassette subfamily C member 2 
ABCC6 ATP binding cassette subfamily C member 6 
ABCF1 ATP binding cassette subfamily F member 1 
ABCG2 ATP binding cassette subfamily G member 2 (Junior blood group) 
ABHD1 abhydrolase domain containing 1 
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase 
ABL2 ABL proto-oncogene 2, non-receptor tyrosine kinase 
ACKR3 atypical chemokine receptor 3 
ACP6 acid phosphatase 6, lysophosphatidic 
ACTG2 actin, gamma 2, smooth muscle, enteric 
ACTR3B ARP3 actin related protein 3 homolog B 
ADA adenosine deaminase 
ADAM17 ADAM metallopeptidase domain 17 
ADCY1 adenylate cyclase 1 
ADD2 adducin 2 
ADGRE5 adhesion G protein-coupled receptor E5 
ADORA2A adenosine A2a receptor 
ADORA2B adenosine A2b receptor 
ADRB2 adrenoceptor beta 2 
AGER advanced glycosylation end-product specific receptor 
AHR aryl hydrocarbon receptor 
AICDA activation induced cytidine deaminase 
AIF1 allograft inflammatory factor 1 
AKT1 AKT serine/threonine kinase 1 
AKT3 AKT serine/threonine kinase 3 
ALCAM activated leukocyte cell adhesion molecule 
ALOX15B arachidonate 15-lipoxygenase, type B 
ALOX5 arachidonate 5-lipoxygenase 
ANAPC1 anaphase promoting complex subunit 1 
ANKRD30A ankyrin repeat domain 30A 
ANLN Anillin, actin binding protein 
ANP32B acidic nuclear phosphoprotein 32 family member B 
ANPEP alanyl aminopeptidase, membrane 
ANXA1 annexin A1 
APAF1 apoptotic peptidase activating factor 1 
APC2 APC2, WNT signaling pathway regulator 
APOE apolipoprotein E 
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APP amyloid beta precursor protein 
ARG1 arginase 1 
ARG2 arginase 2 
ARHGAP11A Rho GTPase activating protein 11A 
ARHGAP11B Rho GTPase activating protein 11B 
ARHGDIB Rho GDP dissociation inhibitor beta 
ARHGEF26 Rho guanine nucleotide exchange factor 26 
ARMCX6 armadillo repeat containing, X-linked 6 
AS3MT arsenite methyltransferase 
ASCL1 achaete-scute family bHLH transcription factor 1 
ASF1A anti-silencing function 1A histone chaperone 
ASF1B ASF1 anti-silencing function 1 homolog B 
ASPM Asp (abnormal spindle) homolog, microcephaly associated 
ASRGL1 asparaginase like 1 
ATF1 activating transcription factor 1 
ATF2 activating transcription factor 2 
ATF3_activating activating transcription factor 3 (activating forms) 
ATF3_repressing activating transcription factor 3 (repressing forms) 
ATG12 autophagy related 12 
ATG16L1 autophagy related 16 like 1 
ATG5 autophagy related 5 
ATG7 autophagy related 7 
ATM ATM serine/threonine kinase 
ATOH1 atonal bHLH transcription factor 1 
ATP5F1 ATP synthase, H+ transporting, mitochondrial Fo complex subunit B1 
ATXN1 ataxin 1 
AUNIP aurora kinase A and ninein interacting protein 
AURKA Aurora kinase A 
AURKB Aurora kinase B 
AXIN1 axin 1 
AXIN2 axin 2 
AXL AXL receptor tyrosine kinase 
B3GAT1 beta-1,3-glucuronyltransferase 1 
BAGE B melanoma antigen 
BAGE_family B melanoma antigen (family probe) 
BAGE2_BAGE3 B melanoma antigen (members 2 and 3) 
BAGE4_BAGE5 B melanoma antigen (members 4 and 5) 
BATF basic leucine zipper ATF-like transcription factor 
BATF2 basic leucine zipper ATF-like transcription factor 2 
BAX BCL2 associated X, apoptosis regulator 
BCL10 B-cell CLL/lymphoma 10 
BCL2 BCL2, apoptosis regulator 
BCL2L1 BCL2 like 1 
BCL2L11 BCL2 like 11 
BCL6 B-cell CLL/lymphoma 6 
BEX1 brain expressed X-linked 1 
BEX2 brain expressed X-linked 2 
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BID BH3 interacting domain death agonist 
BIRC5 baculoviral IAP repeat containing 5 
BLK BLK proto-oncogene, Src family tyrosine kinase 
BLNK B-cell linker 
BMI1 BMI1 proto-oncogene, polycomb ring finger 
BMP6 bone morphogenetic protein 6 
BMP7 bone morphogenetic protein 7 
BNC1 basonuclin 1 
BORA bora, aurora kinase A activator 
BRCA1 BRCA1, DNA repair associated 
BRCA2 BRCA2, DNA repair associated 
BRIP1 BRCA1 interacting protein C-terminal helicase 1 
BRMS1L breast cancer metastasis-suppressor 1 like 
BST2 bone marrow stromal cell antigen 2 
BTK Bruton tyrosine kinase 
BTLA B and T lymphocyte associated 
BUB1 BUB1 mitotic checkpoint serine/threonine kinase 
BUB1B BUB1 mitotic checkpoint serine/threonine kinase B 
C11orf71 chromosome 11 open reading frame 71 
C17orf80 chromosome 17 open reading frame 80 
C19orf66 chromosome 19 open reading frame 66 
C1orf56 chromosome 1 open reading frame 56 
C1QA complement C1q A chain 
C1QB complement C1q B chain 
C20orf24 C20orf24 
C3 complement C3 
C3AR1 complement C3a receptor 1 
C4A_C4B complement C4A/C4B (Chido blood group) 
C5 complement C5 
CA4 carbonic anhydrase 4 
CALML3 calmodulin like 3 
CAMP cathelicidin antimicrobial peptide 
CARD11 caspase recruitment domain family member 11 
CASP1 caspase 1 
CASP10 caspase 10 
CASP3 caspase 3 
CASP4 caspase 4 
CASP5 caspase 5 
CASP8 caspase 8 
CAV1 caveolin 1 
CBLB Cbl proto-oncogene B 
CCDC138 coiled-coil domain containing 138 
CCL1 C-C motif chemokine ligand 1 
CCL11 C-C motif chemokine ligand 11 
CCL13 C-C motif chemokine ligand 13 
CCL14 C-C motif chemokine ligand 14 
CCL15 C-C motif chemokine ligand 15 
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CCL16 C-C motif chemokine ligand 16 
CCL17 C-C motif chemokine ligand 17 
CCL18 C-C motif chemokine ligand 18 
CCL19 C-C motif chemokine ligand 19 
CCL2 C-C motif chemokine ligand 2 
CCL20 C-C motif chemokine ligand 20 
CCL21 C-C motif chemokine ligand 21 
CCL22 C-C motif chemokine ligand 22 
CCL23 C-C motif chemokine ligand 23 
CCL24 C-C motif chemokine ligand 24 
CCL25 C-C motif chemokine ligand 25 
CCL26 C-C motif chemokine ligand 26 
CCL27 C-C motif chemokine ligand 27 
CCL28 C-C motif chemokine ligand 28 
CCL3 C-C motif chemokine ligand 3 
CCL4 C-C motif chemokine ligand 4 
CCL5 C-C motif chemokine ligand 5 
CCL7 C-C motif chemokine ligand 7 
CCL8 C-C motif chemokine ligand 8 
CCNA2 Cyclin A2 
CCNB1 Cyclin B1 
CCNB2 cyclin B2 
CCND1 cyclin D1 
CCND3 cyclin D3 
CCNE1 Cyclin E1 
CCNE2 Cyclin E2 
CCNF Cyclin F 
CCR1 C-C motif chemokine receptor 1 
CCR10 C-C motif chemokine receptor 10 
CCR2 C-C motif chemokine receptor 2 
CCR3 C-C motif chemokine receptor 3 
CCR4 C-C motif chemokine receptor 4 
CCR5 C-C motif chemokine receptor 5 (gene/pseudogene) 
CCR6 C-C motif chemokine receptor 6 
CCR7 C-C motif chemokine receptor 7 
CCR8 C-C motif chemokine receptor 8 
CCR9 C-C motif chemokine receptor 9 
CCRL2 C-C motif chemokine receptor like 2 
CCT5 chaperonin containing TCP1 subunit 5 
CD14 CD14 molecule 
CD160 CD160 molecule 
CD163 CD163 molecule 
CD180 CD180 molecule 
CD19 CD19 molecule 
CD1A CD1a molecule 
CD1B CD1b molecule 
CD1C CD1c molecule 
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CD1D CD1d molecule 
CD1E CD1e molecule 
CD2 CD2 molecule 
CD200 CD200 molecule 
CD209 CD209 molecule 
CD22 CD22 molecule 
CD226 CD226 molecule 
CD24 CD24 molecule 
CD244 CD244 molecule 
CD247 CD247 molecule 
CD27 CD27 molecule 
CD274 CD274 molecule 
CD276 CD276 molecule 
CD28 CD28 molecule 
CD33 CD33 molecule 
CD34 CD34 molecule 
CD37 CD37 molecule 
CD38 CD38 molecule 
CD3D CD3d molecule 
CD3E CD3e molecule 
CD3G CD3g molecule 
CD4 CD4 molecule 
CD40 CD40 molecule 
CD40LG CD40 ligand 
CD44 CD44 molecule (Indian blood group) 
CD47 CD47 molecule 
CD48 CD48 molecule 
CD5 CD5 molecule 
CD52 CD52 molecule 
CD53 CD53 molecule 
CD55 CD55 molecule (Cromer blood group) 
CD58 CD58 molecule 
CD59 CD59 molecule (CD59 blood group) 
CD5L CD5 molecule like 
CD6 CD6 molecule 
CD63 CD63 molecule 
CD68 CD68 molecule 
CD69 CD69 molecule 
CD7 CD7 molecule 
CD70 CD70 molecule 
CD72 CD72 molecule 
CD74 CD74 molecule 
CD79A CD79a molecule 
CD79B CD79b molecule 
CD80 CD80 molecule 
CD83 CD83 molecule 
CD84 CD84 molecule 
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CD86 CD86 molecule 
CD8A CD8a molecule 
CD8B CD8b molecule 
CD96 CD96 molecule 
CD99 CD99 molecule (Xg blood group) 
CDC20 Cell division cycle 20 
CDC25A Cell division cycle 25A 
CDC25C cell division cycle 25C 
CDC45 Cell division cycle 45 
CDC6 Cell division cycle 6 
CDC7 cell division cycle 7 
CDCA2 Cell division cycle associated 2 
CDCA3 Cell division cycle associated 3 
CDCA5 Cell division cycle associated 5 
CDCA8 Cell division cycle associated 8 
CDH1 cadherin 1 
CDH15 cadherin 15 
CDH5 cadherin 5 
CDK1 cyclin dependent kinase 1 
CDK4 cyclin dependent kinase 4 
CDK6 cyclin dependent kinase 6 
CDKN1A cyclin dependent kinase inhibitor 1A 
CDKN1B cyclin dependent kinase inhibitor 1B 
CDKN2A cyclin dependent kinase inhibitor 2A 
CDKN3 cyclin dependent kinase inhibitor 3 
CDT1 Chromatin licensing and DNA replication factor 1 
CEACAM1 carcinoembryonic antigen related cell adhesion molecule 1 
CEACAM5 carcinoembryonic antigen related cell adhesion molecule 5 
CEACAM6 carcinoembryonic antigen related cell adhesion molecule 6 
CEACAM8 carcinoembryonic antigen related cell adhesion molecule 8 
CEBPB CCAAT/enhancer binding protein beta 
CENPA Centromere protein A 
CENPE Centromere protein E, 312kDa 
CENPF centromere protein F 
CENPH Centromere protein H 
CENPI Centromere protein I 
CENPL Centromere protein L 
CENPU centromere protein U 
CENPW Centromere protein W 
CEP250 centrosomal protein 250 
CEP55 Centrosomal protein 55kDa 
CES1 carboxylesterase 1 
CGREF1 cell growth regulator with EF-hand domain 1 
CHDH choline dehydrogenase 
CHGA chromogranin A 
CHIT1 chitinase 1 
CHMP4B charged multivesicular body protein 4B 
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CHRM2 cholinergic receptor muscarinic 2 
CHRM3 cholinergic receptor muscarinic 3 
CHST10 carbohydrate sulfotransferase 10 
CHUK conserved helix-loop-helix ubiquitous kinase 
CIITA class II major histocompatibility complex transactivator 
CIP2A cell proliferation regulating inhibitor of protein phosphatase 2A 
CKAP2 Cytoskeleton associated protein 2 
CKAP2L Cytoskeleton associated protein 2-like 
CKLF chemokine like factor 
CLCA2 chloride channel accessory 2 
CLDN3 claudin 3 
CLEC12A C-type lectin domain family 12 member A 
CLEC2B C-type lectin domain family 2 member B 
CLEC4A C-type lectin domain family 4 member A 
CLEC4C C-type lectin domain family 4 member C 
CLEC5A C-type lectin domain family 5 member A 
CLEC6A C-type lectin domain containing 6A 
CLEC7A C-type lectin domain containing 7A 
CLEC9A C-type lectin domain containing 9A 
CLSPN Claspin 
CMA1 chymase 1 
CMKLR1 chemerin chemokine-like receptor 1 
CNNM1 cyclin and CBS domain divalent metal cation transport mediator 1 
CNTLN centlein 
COCH cochlin 
COL1A1 collagen type I alpha 1 chain 
COL1A2 collagen type I alpha 2 chain 
COL3A1 collagen type III alpha 1 chain 
CORO1A coronin 1A 
CPA3 carboxypeptidase A3 
CPE carboxypeptidase E 
CR1 complement C3b/C4b receptor 1 (Knops blood group) 
CR2 complement C3d receptor 2 
CREB1 cAMP responsive element binding protein 1 
CREB5 cAMP responsive element binding protein 5 
CREBBP CREB binding protein 
CRISPLD1 cysteine rich secretory protein LCCL domain containing 1 
CRMP1 collapsin response mediator protein 1 
CRP C-reactive protein 
CRTAM cytotoxic and regulatory T-cell molecule 
CSF1 colony stimulating factor 1 
CSF1R colony stimulating factor 1 receptor 
CSF2 colony stimulating factor 2 
CSF2RA colony stimulating factor 2 receptor alpha subunit 
CSF2RB colony stimulating factor 2 receptor beta common subunit 
CSF3 colony stimulating factor 3 
CSF3R colony stimulating factor 3 receptor 
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CSK C-src tyrosine kinase 
CT45_family cancer testis antigen family 45 
CT47_family cancer testis antigen family 47 
CTAG1A_1B cancer/testis antigen 1A and 1B 
CTAG2 cancer/testis antigen 2 
CTBP1 C-terminal binding protein 1 
CTLA4 cytotoxic T-lymphocyte associated protein 4 
CTNNB1 catenin beta 1 
CTRC chymotrypsin C 
CTSG cathepsin G 
CTSH cathepsin H 
CTSL cathepsin L 
CTSS cathepsin S 
CX3CL1 C-X3-C motif chemokine ligand 1 
CX3CR1 C-X3-C motif chemokine receptor 1 
CXCL1 C-X-C motif chemokine ligand 1 
CXCL10 C-X-C motif chemokine ligand 10 
CXCL11 C-X-C motif chemokine ligand 11 
CXCL12 C-X-C motif chemokine ligand 12 
CXCL13 C-X-C motif chemokine ligand 13 
CXCL14 C-X-C motif chemokine ligand 14 
CXCL16 C-X-C motif chemokine ligand 16 
CXCL2 C-X-C motif chemokine ligand 2 
CXCL3 C-X-C motif chemokine ligand 3 
CXCL5 C-X-C motif chemokine ligand 5 
CXCL6 C-X-C motif chemokine ligand 6 
CXCL8 C-X-C motif chemokine ligand 8 
CXCL9 C-X-C motif chemokine ligand 9 
CXCR1 C-X-C motif chemokine receptor 1 
CXCR2 C-X-C motif chemokine receptor 2 
CXCR3 C-X-C motif chemokine receptor 3 
CXCR4 C-X-C motif chemokine receptor 4 
CXCR5 C-X-C motif chemokine receptor 5 
CXCR6 C-X-C motif chemokine receptor 6 
CYBB cytochrome b-245 beta chain 
CYLD CYLD lysine 63 deubiquitinase 
CYP27A1 cytochrome P450 family 27 subfamily A member 1 
DAPK2 death associated protein kinase 2 
DAPL1 death associated protein like 1 
DBF4 DBF4 homolog (S. cerevisiae) 
DCLRE1A DNA cross-link repair 1A 
DCN decorin 
DDIAS DNA damage induced apoptosis suppressor 
DDX5 DEAD-box helicase 5 
DDX58 DExD/H-box helicase 58 
DEFB1 defensin beta 1 
DEPDC1 DEP domain containing 1 
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DGAT2 diacylglycerol O-acyltransferase 2 
DGKA diacylglycerol kinase alpha 
DHX40 DEAH-box helicase 40 
DIAPH3 Diaphanous homolog 3 (Drosophila) 
DLAT dihydrolipoamide S-acetyltransferase 
DLD dihydrolipoamide dehydrogenase 
DLGAP5 Discs, large (Drosophila) homolog-associated protein 5 
DLX6 distal-less homeobox 6 
DMBT1 deleted in malignant brain tumors 1 
DNAH14 dynein axonemal heavy chain 14 
DNMT1 DNA methyltransferase 1 
DOCK9 dedicator of cytokinesis 9 
DONSON Downstream neighbor of SON 
DPP4 dipeptidyl peptidase 4 
DPYSL4 dihydropyrimidinase like 4 
DSC3 desmocollin 3 
DSE dermatan sulfate epimerase 
DSG3 desmoglein 3 
DST dystonin 
DTL Denticleless E3 ubiquitin protein ligase homolog (Drosophila) 
DUSP4 dual specificity phosphatase 4 
DUSP6 dual specificity phosphatase 6 
E2F2 E2F transcription factor 2 
E2F7 E2F transcription factor 7 
EBF4 early B-cell factor 4 
EBI3 Epstein-Barr virus induced 3 
ECT2 Epithelial cell transforming sequence 2 oncogene 
EEF1G eukaryotic translation elongation factor 1 gamma 
EEF2 eukaryotic translation elongation factor 2 
EFNA4 ephrin A4 
EFNB3 ephrin B3 
EGFR epidermal growth factor receptor 
EGR1 early growth response 1 
EGR2 early growth response 2 
EGR3 early growth response 3 
EHD2 EH domain containing 2 
EIF2A eukaryotic translation initiation factor 2A 
EIF2AK2 eukaryotic translation initiation factor 2 alpha kinase 2 
ELK1 ETS transcription factor 
ELL3 Elongation factor RNA polymerase II-like 3 
EME1 Essential meiotic endonuclease 1 homolog 1 (S. pombe) 
EMP1 epithelial membrane protein 1 
EMX2 empty spiracles homeobox 2 
ENG endoglin 
ENO1 enolase 1 




EP300 E1A binding protein p300 
EPCAM epithelial cell adhesion molecule 
EPHX3 epoxide hydrolase 3 
EPSTI1 epithelial stromal interaction 1 
ERBB2 erb-b2 receptor tyrosine kinase 2 
ERBB3 erb-b2 receptor tyrosine kinase 3 
ERCC6L 
Excision repair cross-complementing rodent repair deficiency, 
complementation group 6-like 
ESCO2 Establishment of cohesion 1 homolog 2 (S. cerevisiae) 
ESPL1 extra spindle pole bodies like 1, separase 
ESYT2 extended synaptotagmin 2 
ETS1 ETS proto-oncogene 1, transcription factor 
ETS2 ETS proto-oncogene 2, transcription factor 
ETV1 ETS variant 1 
ETV4 ETS variant 4 
EWSR1 EWS RNA binding protein 1 
EXO1 Exonuclease 1 
EYS eyes shut homolog (Drosophila) 
EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunit 
F13A1 coagulation factor XIII A chain 
F2RL1 F2R like trypsin receptor 1 
FABP4 fatty acid binding protein 4 
FADD Fas associated via death domain 
FAM111B Family with sequence similarity 111, member B 
FAM122B family with sequence similarity 122B 
FAM161A family with sequence similarity 161 member A 
FAM222A family with sequence similarity 222 member A 
FAM69B family with sequence similarity 69 member B 
FAM72_family family with sequence similarity 72 (family probe) 
FAM83B family with sequence similarity 83 member B 
FANCA Fanconi anemia, complementation group A 
FANCD2 Fanconi anemia, complementation group D2 
FANCI Fanconi anemia, complementation group I 
FAP fibroblast activation protein alpha 
FAS Fas cell surface death receptor 
FASLG Fas ligand 
FBLN1 fibulin 1 
FCAR Fc fragment of IgA receptor 
FCER1G Fc fragment of IgE receptor Ig 
FCER2 Fc fragment of IgE receptor II 
FCGR1A_FCGR1
B Fc fragment of IgG receptor Ia and 1b 
FCGR2A_2C Fc fragment of IgG receptor IIa and IIc 
FCGR2B Fc fragment of IgG receptor IIb 
FCGR3A_3B Fc fragment of IgG receptor IIIa and IIIb 
FCMR Fc fragment of IgM receptor 
FCRL2 Fc receptor like 2 
FCRLA Fc receptor like A 
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FEN1 Flap structure-specific endonuclease 1 
FEZ1 fasciculation and elongation protein zeta 1 
FGD6 FYVE, RhoGEF and PH domain containing 6 
FGFR3 fibroblast growth factor receptor 3 
FICD FIC domain containing 
FLI1 Fli-1 proto-oncogene, ETS transcription factor 
FLT1 fms related tyrosine kinase 1 
FLT3 fms related tyrosine kinase 3 
FLT3LG fms related tyrosine kinase 3 ligand 
FLVCR1 feline leukemia virus subgroup C cellular receptor 1 
FMO5 flavin containing monooxygenase 5 
FN1 fibronectin 1 
FOLH1 folate hydrolase 1 
FOS Fos proto-oncogene, AP-1 transcription factor subunit 
FOXA1 forkhead box A1 
FOXG1 forkhead box G1 
FOXJ1 forkhead box J1 
FOXM1 forkhead box M1 
FOXO1 forkhead box O1 
FOXP1 forkhead box P1 
FOXP3 forkhead box P3 
FOXRED2 FAD dependent oxidoreductase domain containing 2 
FPR1 formyl peptide receptor 1 
FPR2 formyl peptide receptor 2 
FRYL FRY like transcription coactivator 
FUT4 fucosyltransferase 4 
FUT5 fucosyltransferase 5 
FXYD5 FXYD domain containing ion transport regulator 5 
FYB1 FYN binding protein 1 
FYN FYN proto-oncogene, Src family tyrosine kinase 
FZD3 frizzled class receptor 3 
G6PD glucose-6-phosphate dehydrogenase 
GABRA5 gamma-aminobutyric acid type A receptor alpha5 subunit 
GAD1 glutamate decarboxylase 1 
GADD45GIP1 GADD45G interacting protein 1 
GAGE_family G antigen (family probe) 
GATA2 GATA binding protein 2 
GATA3 GATA binding protein 3 
GBP1 guanylate binding protein 1 
GBP5 guanylate binding protein 5 
GCK_liver_T2 glucokinase (liver specific) 
GCK_Pan_T2 glucokinase (pancreas specific) 
GCK glucokinase (all isoforms) 
GDF15 growth differentiation factor 15 
GGT7 gamma-glutamyltransferase 7 
GINS4 GINS complex subunit 4 (Sld5 homolog) 
GLB1L2 galactosidase beta 1 like 2 
154 
 
GLIPR1 GLI pathogenesis related 1 
GNLY granulysin 
GPI glucose-6-phosphate isomerase 
GPR18 G protein-coupled receptor 18 
GPR19 G protein-coupled receptor 19 
GPRIN1 G protein regulated inducer of neurite outgrowth 1 
GRAP2 GRB2-related adaptor protein 2 
GSDME gasdermin E 
GTF3C1 general transcription factor IIIC subunit 1 
GTSE1 G-2 and S-phase expressed 1 
GUSB glucuronidase beta 
GZMA granzyme A 
GZMB granzyme B 
GZMH granzyme H 
GZMK granzyme K 
GZMM granzyme M 
H2AFZ H2A histone family member Z 
HASPIN histone H3 associated protein kinase 
HAVCR2 hepatitis A virus cellular receptor 2 
HCAR1 hydroxycarboxylic acid receptor 1 
HCAR2 hydroxycarboxylic acid receptor 2 
HDC histidine decarboxylase 
HELLS helicase, lymphoid specific 
HERC6 
HECT and RLD domain containing E3 ubiquitin protein ligase family 
member 6 
HES1 hes family bHLH transcription factor 1 
HES5 hes family bHLH transcription factor 5 
HEXIM2 hexamethylene bisacetamide inducible 2 
HEY1 hes related family bHLH transcription factor with YRPW motif 1 
HEY2 hes related family bHLH transcription factor with YRPW motif 2 
HEYL hes related family bHLH transcription factor with YRPW motif-like 
HGF hepatocyte growth factor 
HHLA2 HERV-H LTR-associating 2 
HIF1A hypoxia inducible factor 1 alpha subunit 
HIST1H2BH Histone cluster 1, H2bh 
HJURP Holliday junction recognition protein 
HK1 hexokinase 1 
HK2 hexokinase 2 
HLA-A major histocompatibility complex, class I, A 
HLA-B major histocompatibility complex, class I, B 
HLA-C major histocompatibility complex, class I, C 
HLA-DMA major histocompatibility complex, class II, DM alpha 
HLA-DMB major histocompatibility complex, class II, DM beta 
HLA-DOA major histocompatibility complex, class II, DO alpha 
HLA-DOB major histocompatibility complex, class II, DO beta 
HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 
HLA-DPB1 major histocompatibility complex, class II, DP beta 1 
HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 
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HLA-DQA2 major histocompatibility complex, class II, DQ alpha 2 
HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 
HLA-DQB2 major histocompatibility complex, class II, DQ beta 2 
HLA-DRA major histocompatibility complex, class II, DR alpha 
HLA-DRB1 major histocompatibility complex, class II, DR beta 1 
HLA-E major histocompatibility complex, class I, E 
HLA-F major histocompatibility complex, class I, F 
HLA-G major histocompatibility complex, class I, G 
HLF HLF, PAR bZIP transcription factor 
HMBS hydroxymethylbilane synthase 
HMGB1 high mobility group box 1 
HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 
HMMR Hyaluronan-mediated motility receptor 
HMOX1 heme oxygenase 1 
HMX2 H6 family homeobox 2 
HNF1A HNF1 homeobox A 
HNF1B HNF1 homeobox B 
HORMAD1 HORMA domain containing 1 
HORMAD2 HORMA domain containing 2 
HPDL 4-hydroxyphenylpyruvate dioxygenase like 
HPN hepsin 
HRAS HRas proto-oncogene, GTPase 
HSD11B1 hydroxysteroid 11-beta dehydrogenase 1 
HSP90B1 heat shock protein 90 beta family member 1 
HSPA1A heat shock protein family A (Hsp70) member 1A 
IBSP integrin binding sialoprotein 
ICAM1 intercellular adhesion molecule 1 
ICAM2 intercellular adhesion molecule 2 
ICAM3 intercellular adhesion molecule 3 
ICAM4 intercellular adhesion molecule 4 (Landsteiner-Wiener blood group) 
ICOS inducible T-cell costimulator 
ICOSLG inducible T-cell costimulator ligand 
ID2 inhibitor of DNA binding 2 
ID3 inhibitor of DNA binding 3, HLH protein 
ID4 inhibitor of DNA binding 4, HLH protein 
IDH1 isocitrate dehydrogenase (NADP(+)) 1, cytosolic 
IDH2 isocitrate dehydrogenase (NADP(+)) 2, mitochondrial 
IDO1 indoleamine 2,3-dioxygenase 1 
IDO2 indoleamine 2,3-dioxygenase 2 
IFI16 interferon gamma inducible protein 16 
IFI27 interferon alpha inducible protein 27 
IFI35 interferon induced protein 35 
IFI44L interferon induced protein 44 like 
IFI6 interferon alpha inducible protein 6 
IFIH1 interferon induced with helicase C domain 1 
IFIT1 interferon induced protein with tetratricopeptide repeats 1 
IFIT2 interferon induced protein with tetratricopeptide repeats 2 
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IFIT3 interferon induced protein with tetratricopeptide repeats 3 
IFIT5 interferon induced protein with tetratricopeptide repeats 5 
IFITM1 interferon induced transmembrane protein 1 
IFITM2 interferon induced transmembrane protein 2 
IFITM3 interferon induced transmembrane protein 3 
IFNA_Family interferon alpha (family probe) 
IFNAR1 interferon alpha and beta receptor subunit 1 
IFNAR2 interferon alpha and beta receptor subunit 2 
IFNB1 interferon beta 1 
IFNG interferon gamma 
IFNGR1 interferon gamma receptor 1 
IFNL1 interferon lambda 1 
IFNL2 interferon lambda 2 
IFNL3 interferon lambda 3 
IFNL4 interferon lambda 4 (gene/pseudogene) 
IFNLR1 interferon lambda receptor 1 
IGF1R insulin like growth factor 1 receptor 
IGF2R insulin like growth factor 2 receptor 
IGFBP3 insulin like growth factor binding protein 3 
IGSF6 immunoglobulin superfamily member 6 
IHH indian hedgehog 
IKBKB inhibitor of nuclear factor kappa B kinase subunit beta 
IKBKG inhibitor of nuclear factor kappa B kinase subunit gamma 
IKZF1 IKAROS family zinc finger 1 
IKZF2 IKAROS family zinc finger 2 
IKZF3 IKAROS family zinc finger 3 
IKZF4 IKAROS family zinc finger 4 
IL10 interleukin 10 
IL10RA interleukin 10 receptor subunit alpha 
IL10RB interleukin 10 receptor subunit beta 
IL11 interleukin 11 
IL11RA interleukin 11 receptor subunit alpha 
IL12A interleukin 12A 
IL12B interleukin 12B 
IL12RB1 interleukin 12 receptor subunit beta 1 
IL12RB2 interleukin 12 receptor subunit beta 2 
IL13 interleukin 13 
IL13RA1 interleukin 13 receptor subunit alpha 1 
IL13RA2 interleukin 13 receptor subunit alpha 2 
IL15 interleukin 15 
IL15RA interleukin 15 receptor subunit alpha 
IL16 interleukin 16 
IL17A interleukin 17A 
IL17B interleukin 17B 
IL17C interleukin 17C 
IL17D interleukin 17D 
IL17F interleukin 17F 
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IL17RA interleukin 17 receptor A 
IL17RB interleukin 17 receptor B 
IL18 interleukin 18 
IL18BP interleukin 18 binding protein 
IL18R1 interleukin 18 receptor 1 
IL19 interleukin 19 
IL1A interleukin 1 alpha 
IL1B interleukin 1 beta 
IL1R1 interleukin 1 receptor type 1 
IL1R2 interleukin 1 receptor type 2 
IL1RAP interleukin 1 receptor accessory protein 
IL1RL1 interleukin 1 receptor like 1 
IL1RL2 interleukin 1 receptor like 2 
IL1RN interleukin 1 receptor antagonist 
IL2 interleukin 2 
IL20 interleukin 20 
IL20RA interleukin 20 receptor subunit alpha 
IL20RB interleukin 20 receptor subunit beta 
IL21 interleukin 21 
IL21R interleukin 21 receptor 
IL22 interleukin 22 
IL22RA1 interleukin 22 receptor subunit alpha 1 
IL22RA2 interleukin 22 receptor subunit alpha 2 
IL23A interleukin 23 subunit alpha 
IL23R interleukin 23 receptor 
IL24 interleukin 24 
IL25 interleukin 25 
IL26 interleukin 26 
IL27 interleukin 27 
IL2RA interleukin 2 receptor subunit alpha 
IL2RB interleukin 2 receptor subunit beta 
IL2RG interleukin 2 receptor subunit gamma 
IL3 interleukin 3 
IL31 interleukin 31 
IL32 interleukin 32 
IL33 interleukin 33 
IL34 interleukin 34 
IL3RA interleukin 3 receptor subunit alpha 
IL4 interleukin 4 
IL4R interleukin 4 receptor 
IL5 interleukin 5 
IL5RA interleukin 5 receptor subunit alpha 
IL6 interleukin 6 
IL6R interleukin 6 receptor 
IL6ST interleukin 6 signal transducer 
IL7 interleukin 7 
IL7R interleukin 7 receptor 
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IL9 interleukin 9 
IL9R interleukin 9 receptor 
IMPG2 interphotoreceptor matrix proteoglycan 2 
INSM1 INSM transcriptional repressor 1 
IQGAP3 IQ motif containing GTPase activating protein 3 
IRAK1 interleukin 1 receptor associated kinase 1 
IRAK2 interleukin 1 receptor associated kinase 2 
IRAK3 interleukin 1 receptor associated kinase 3 
IRAK4 interleukin 1 receptor associated kinase 4 
IRF1 interferon regulatory factor 1 
IRF2 interferon regulatory factor 2 
IRF3 interferon regulatory factor 3 
IRF4 interferon regulatory factor 4 
IRF5 interferon regulatory factor 5 
IRF7 interferon regulatory factor 7 
IRF8 interferon regulatory factor 8 
IRF9 interferon regulatory factor 9 
IRGM immunity related GTPase M 
IRS1 insulin receptor substrate 1 
ISG15 ISG15 ubiquitin-like modifier 
ISG20 interferon stimulated exonuclease gene 20 
ITGA1 integrin subunit alpha 1 
ITGA2 integrin subunit alpha 2 
ITGA3 integrin subunit alpha 3 
ITGA4 integrin subunit alpha 4 
ITGA5 integrin subunit alpha 5 
ITGA6 integrin subunit alpha 6 
ITGAE integrin subunit alpha E 
ITGAL integrin subunit alpha L 
ITGAM integrin subunit alpha M 
ITGAX integrin subunit alpha X 
ITGB1 integrin subunit beta 1 
ITGB2 integrin subunit beta 2 
ITGB3 integrin subunit beta 3 
ITGB4 integrin subunit beta 4 
ITGB7 integrin subunit beta 7 
ITK IL2 inducible T-cell kinase 
ITLN2 intelectin 2 
ITPKC inositol-trisphosphate 3-kinase C 
JAK1 Janus kinase 1 
JAK2 Janus kinase 2 
JAK3 Janus kinase 3 
JAKMIP3 Janus kinase and microtubule interacting protein 3 
JAML junction adhesion molecule like 
JCHAIN joining chain of multimeric IgA and IgM 
KCNA1 potassium voltage-gated channel subfamily A member 1 
KCNH2 potassium voltage-gated channel subfamily H member 2 
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KCNK5 potassium two pore domain channel subfamily K member 5 
KDM5B lysine demethylase 5B 
KDR kinase insert domain receptor 
KHDRBS2 KH RNA binding domain containing, signal transduction associated 2 
KHK Ketohexokinase (fructokinase) 
KIF14 Kinesin family member 14 
KIF15 Kinesin family member 15 
KIF18B Kinesin family member 18B 
KIF20A Kinesin family member 20A 
KIF23 Kinesin family member 23 
KIF2C Kinesin family member 2C 
KIF4A Kinesin family member 4A 
KIF5C kinesin family member 5C 
KIFC1 Kinesin family member C1 
KIR2DL1 
killer cell immunoglobulin like receptor, two Ig domains and long 
cytoplasmic tail 1 
KIR2DL1_2DL2 
killer cell immunoglobulin like receptor, two Ig domains and long 
cytoplasmic tail 1 and 2 
KIR2DL3 
killer cell immunoglobulin like receptor, two Ig domains and long 
cytoplasmic tail 3 
KIR2DL4 
killer cell immunoglobulin like receptor, two Ig domains and long 
cytoplasmic tail 4 
KIR2DL5A_5B 
killer cell immunoglobulin like receptor, two Ig domains and long 
cytoplasmic tail 5A and 5B 
KIR2DS2_2DS4 
killer cell immunoglobulin like receptor, two Ig domains and short 
cytoplasmic tail 2 and 4 
KIR2DS4 
killer cell immunoglobulin like receptor, two Ig domains and short 
cytoplasmic tail 4 
KIR2DSx 
killer cell immunoglobulin like receptor, two Ig domains and short 
cytoplasmic tail (all isoforms) 
KIR3DL1 
killer cell immunoglobulin like receptor, three Ig domains and long 
cytoplasmic tail 1 
KIR3DL2 
killer cell immunoglobulin like receptor, three Ig domains and long 
cytoplasmic tail 2 
KIR3DL3 
killer cell immunoglobulin like receptor, three Ig domains and long 
cytoplasmic tail 3 
KIR3DS1 
killer cell immunoglobulin like receptor, three Ig domains and short 
cytoplasmic tail 1 
KIR-panL killer cell immunoglobulin like receptor, pan long forms 
KIR-panS killer cell immunoglobulin like receptor, pan short forms 
KIT KIT proto-oncogene receptor tyrosine kinase 
KLF2 Kruppel like factor 2 
KLHDC9 kelch domain containing 9 
KLRB1 killer cell lectin like receptor B1 
KLRD1 killer cell lectin like receptor D1 
KLRF1 killer cell lectin like receptor F1 
KLRG1 killer cell lectin like receptor G1 
KLRK1 killer cell lectin like receptor K1 
KNL1 kinetochore scaffold 1 
KPNA2 Karyopherin alpha 2 (RAG cohort 1, importin alpha 1) 
KREMEN1 kringle containing transmembrane protein 1 
KRT13 keratin 13 
KRT16 keratin 16 
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KRT17 keratin 17 
KRT18 keratin 18 
KRT19 keratin 19 
KRT34 Keratin 34 
KRT5 keratin 5 
KRT6A keratin 6A 
KRT7 keratin 7 
KRT8 keratin 8 
KRTCAP3 keratinocyte associated protein 3 
KSR2 Kinase suppressor of ras 2 
L1CAM L1 cell adhesion molecule 
LAG3 lymphocyte activating 3 
LAIR2 leukocyte associated immunoglobulin like receptor 2 
LAMC3 Laminin, gamma 3 
LAMP1 lysosomal associated membrane protein 1 
LAMP3 lysosomal associated membrane protein 3 
LAPTM5 lysosomal protein transmembrane 5 
LAT linker for activation of T cells 
LCK LCK proto-oncogene, Src family tyrosine kinase 
LCN2 lipocalin 2 
LCP1 lymphocyte cytosolic protein 1 
LEXM lymphocyte expansion molecule 
LGALS1 galectin 1 
LGALS3 galectin 3 
LGALS9 galectin 9 
LGSN lengsin, lens protein with glutamine synthetase domain 
LIF leukemia inhibitory factor 
LILRA4 leukocyte immunoglobulin like receptor A4 
LILRB1 leukocyte immunoglobulin like receptor B1 
LILRB2 leukocyte immunoglobulin like receptor B2 
LIMA1 LIM domain and actin binding 1 
LIPE lipase E, hormone sensitive type 
LMNA lamin A/C 
LMNB1 Lamin B1 
LOXL1 lysyl oxidase like 1 
LOXL2 lysyl oxidase like 2 
LRBA LPS responsive beige-like anchor protein 
LRG1 leucine rich alpha-2-glycoprotein 1 
LRP1 LDL receptor related protein 1 
LST1 leukocyte specific transcript 1 
LTA lymphotoxin alpha 
LTB lymphotoxin beta 
LTB4R leukotriene B4 receptor 
LTBP1 latent transforming growth factor beta binding protein 1 
LTBR lymphotoxin beta receptor 
LTK leukocyte receptor tyrosine kinase 
LY86 lymphocyte antigen 86 
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LY9 lymphocyte antigen 9 
LY96 lymphocyte antigen 96 
LYN LYN proto-oncogene, Src family tyrosine kinase 
LYVE1 lymphatic vessel endothelial hyaluronan receptor 1 
LYZ lysozyme 
M6PR mannose-6-phosphate receptor, cation dependent 
MAB21L2 mab-21 like 2 
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) 
MADCAM1 mucosal vascular addressin cell adhesion molecule 1 
MAF MAF bZIP transcription factor 
MAGEA1 MAGE family member A1 
MAGEA10 MAGE family member A10 
MAGEA12 MAGE family member A12 
MAGEA3_A6 MAGE family member A3/A6 
MAGEA4 MAGE family member A4 
MAGEB2 MAGE family member B2 
MAGEC1 MAGE family member C1 
MAGEC2 MAGE family member C2 
MAP2K1 mitogen-activated protein kinase kinase 1 
MAP2K2 mitogen-activated protein kinase kinase 2 
MAP2K4 mitogen-activated protein kinase kinase 4 
MAP2K6 Mitogen-activated protein kinase kinase 6 
MAP2K7 mitogen-activated protein kinase kinase 7 
MAP3K1 mitogen-activated protein kinase kinase kinase 1 
MAP3K5 mitogen-activated protein kinase kinase kinase 5 
MAP3K7 mitogen-activated protein kinase kinase kinase 7 
MAP4 Microtubule-associated protein 4 
MAP4K1 mitogen-activated protein kinase kinase kinase kinase 1 
MAPK1 mitogen-activated protein kinase 1 
MAPK11 mitogen-activated protein kinase 11 
MAPK14 mitogen-activated protein kinase 14 
MAPK3 mitogen-activated protein kinase 3 
MAPK8 mitogen-activated protein kinase 8 
MAPKAPK2 mitogen-activated protein kinase-activated protein kinase 2 
MARCO macrophage receptor with collagenous structure 
MBL2 mannose binding lectin 2 
MCM10 Minichromosome maintenance complex component 10 
MCM2 minichromosome maintenance complex component 2 
MCM6 Minichromosome maintenance complex component 6 
MCM7 minichromosome maintenance complex component 7 
MECOM MDS1 and EVI1 complex locus 
MEF2C myocyte enhancer factor 2C 
MELK maternal embryonic leucine zipper kinase 
MERTK MER proto-oncogene, tyrosine kinase 
MGA MAX dimerization protein 
MICA MHC class I polypeptide-related sequence A 
MICB MHC class I polypeptide-related sequence B 
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MIF macrophage migration inhibitory factor (glycosylation-inhibiting factor) 
MKI67 marker of proliferation Ki-67 
MLANA melan-A 
MLF1 myeloid leukemia factor 1 
MME membrane metalloendopeptidase 
MMP11 matrix metallopeptidase 11 
MMP12 matrix metallopeptidase 12 
MMP2 matrix metallopeptidase 2 
MMP9 matrix metallopeptidase 9 
MND1 Meiotic nuclear divisions 1 homolog (S. cerevisiae) 
MNDA myeloid cell nuclear differentiation antigen 
MOB3A MOB kinase activator 3A 
MPO myeloperoxidase 
MPPED1 metallophosphoesterase domain containing 1 
MR1 major histocompatibility complex, class I-related 
MRAP2 melanocortin 2 receptor accessory protein 2 
MRC1 mannose receptor C-type 1 
MS4A1 membrane spanning 4-domains A1 
MS4A2 membrane spanning 4-domains A2 
MS4A4A membrane spanning 4-domains A4A 
MSH2 mutS homolog 2 
MSH3 mutS homolog 3 
MSH4 mutS homolog 4 
MSH5 mutS homolog 5 
MSH6 mutS homolog 6 
MSR1 macrophage scavenger receptor 1 
MST1R macrophage stimulating 1 receptor 
MT2A metallothionein 2A 
MTDH metadherin 
MTFR2 Mitochondrial fission regulator 2 
MTOR mechanistic target of rapamycin kinase 
MUC1 mucin 1, cell surface associated 
MX1 MX dynamin like GTPase 1 
MXD3 MAX dimerization protein 3 
MYBL2 V-myb myeloblastosis viral oncogene homolog (avian)-like 2 
MYC v-myc avian myelocytomatosis viral oncogene homolog 
MYD88 myeloid differentiation primary response 88 
MYH10 myosin heavy chain 10 
MYH11 myosin heavy chain 11 
MYH9 myosin heavy chain 9 
MYO1B Myosin IB 
MYO5C myosin VC 
MYOCD myocardin 
MYOF myoferlin 
NCAM1 neural cell adhesion molecule 1 
NCAPG Non-SMC condensin I complex, subunit G 
NCAPG2 Non-SMC condensin II complex, subunit G2 
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NCAPH Non-SMC condensin I complex, subunit H 
NCF1 neutrophil cytosolic factor 1 
NCK1 NCK adaptor protein 1 
NCL nucleolin 
NCR1 natural cytotoxicity triggering receptor 1 
NCR3 natural cytotoxicity triggering receptor 3 
NCR3LG1 natural killer cell cytotoxicity receptor 3 ligand 1 
NDC1 NDC1 transmembrane nucleoporin (also called TMEM48) 
NDC80 NDC80 kinetochore complex component 
NECTIN2 nectin cell adhesion molecule 2 
NEFL neurofilament light 
NEIL3 nei like DNA glycosylase 3 
NEK2 NIMA-related kinase 2 
NFATC1 nuclear factor of activated T-cells 1 
NFATC3 nuclear factor of activated T-cells 3 
NFATC4 nuclear factor of activated T cells 4 
NFKB1 nuclear factor kappa B subunit 1 
NFKB2 nuclear factor kappa B subunit 2 
NFKBIA NFKB inhibitor alpha 
NGFR nerve growth factor receptor 
NKG7 natural killer cell granule protein 7 
NKX2-1 NK2 homeobox 1 
NLRC5 NLR family CARD domain containing 5 
NLRP3 NLR family pyrin domain containing 3 
NMRAL1 NmrA like redox sensor 1 
NOD1 nucleotide binding oligomerization domain containing 1 
NOD2 nucleotide binding oligomerization domain containing 2 
NOS2 nitric oxide synthase 2 
NOS3 nitric oxide synthase 3 
NOTCH1 notch 1 
NOTCH3 notch 3 
NOX1 NADPH oxidase 1 
NPM1 nucleophosmin 1 
NPR3 natriuretic peptide receptor 3 
NRL neural retina leucine zipper 
NRP1 neuropilin 1 
NT5E 5'-nucleotidase ecto 
NTN3 netrin 3 
NTRK2 neurotrophic receptor tyrosine kinase 2 
NUDT1 Nudix (nucleoside diphosphate linked moiety X)-type motif 1 
NUF2 NUF2, NDC80 kinetochore complex component, homolog (S. cerevisiae) 
NUP107 nucleoporin 107 
NUSAP1 Nucleolar and spindle associated protein 1 
OAS1 2'-5'-oligoadenylate synthetase 1 
OAS2 2'-5'-oligoadenylate synthetase 2 
OAS3 2'-5'-oligoadenylate synthetase 3 




OIP5 Opa interacting protein 5 
OLR1 oxidized low density lipoprotein receptor 1 
OPTN Optineurin 
ORC1 Hs.17908 
ORC6 Origin recognition complex, subunit 6 
OSM oncostatin M 
PAGE1 PAGE family member 1 
PAGE2 PAGE family members 2 and 2B 
PAGE3 PAGE family member 3 
PAGE4 PAGE family member 4 
PAGE5 PAGE family member 5 
PATZ1 POZ (BTB) and AT hook containing zinc finger 1 
PAX5 paired box 5 
PBK PDZ binding kinase 
PBX1 PBX homeobox 1 
PCLAF PCNA clamp associated factor 
PCNA proliferating cell nuclear antigen 
PDCD1 programmed cell death 1 
PDCD1LG2 programmed cell death 1 ligand 2 
PDGFC platelet derived growth factor C 
PDGFRB platelet derived growth factor receptor beta 
PDHA1 pyruvate dehydrogenase E1 alpha 1 subunit 
PDHA2 pyruvate dehydrogenase E1 alpha 2 subunit 
PDHB pyruvate dehydrogenase E1 beta subunit 
PDHX pyruvate dehydrogenase complex component X 
PDK1 pyruvate dehydrogenase kinase 1 
PDK2 pyruvate dehydrogenase kinase 2 
PDK3 pyruvate dehydrogenase kinase 3 
PDK4 pyruvate dehydrogenase kinase 4 
PDLIM1 PDZ and LIM domain 1 
PDLIM3 PDZ and LIM domain 3 
PDP1 pyruvate dehyrogenase phosphatase catalytic subunit 1 
PECAM1 platelet and endothelial cell adhesion molecule 1 
PF4 platelet factor 4 
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 
PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 
PGF placental growth factor 
PHF10 PHD finger protein 10 
PIF1 PIF1 5'-to-3' DNA helicase homolog (S. cerevisiae) 
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha 
PIK3CD phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta 
PIK3CG phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma 
PIMREG PICALM interacting mitotic regulator 
PKLR pyruvate kinase L/R 
PKM pyruvate kinase M1/2 
PKMYT1 Protein kinase, membrane associated tyrosine/threonine 1 
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PKP1 plakophilin 1 
PLA2G6 phospholipase A2 group VI 
PLA2G7 phospholipase A2 group VII 
PLAU plasminogen activator, urokinase 
PLAUR plasminogen activator, urokinase receptor 
PLEKHG4 pleckstrin homology and RhoGEF domain containing G4 
PLEKHG6 pleckstrin homology and RhoGEF domain containing G6 
PLK1 Polo-like kinase 1 
PLK4 Polo-like kinase 4 
PMCH pro-melanin concentrating hormone 
PMEL premelanosome protein 
PML Promyelocytic leukemia 
PNOC prepronociceptin 
POC1A POC1 centriolar protein homolog A (Chlamydomonas) 
PODXL2 podocalyxin like 2 
POLQ Polymerase (DNA directed), theta 
POLR2A RNA polymerase II subunit A 
POU2AF1 POU class 2 associating factor 1 
POU2F2 POU class 2 homeobox 2 
POU5F1 POU class 5 homeobox 1 and 1B 
PPARD peroxisome proliferator activated receptor delta 
PPARG peroxisome proliferator activated receptor gamma 
PPBP pro-platelet basic protein 
PPIA peptidylprolyl isomerase A 
PPM1E Protein phosphatase, Mg2+/Mn2+ dependent, 1E 
PRAME preferentially expressed antigen in melanoma 
PRC1 Protein regulator of cytokinesis 1 
PRDM1 PR/SET domain 1 
PRDM6 PR/SET domain 6 
PRF1 perforin 1 
PRG2 proteoglycan 2, pro eosinophil major basic protein 
PRKCD protein kinase C delta 
PRKCE protein kinase C epsilon 
PRR11 Proline rich 11 
PRR15L proline rich 15 like 
PSEN1 presenilin 1 
PSEN2 presenilin 2 
PSMB10 proteasome subunit beta 10 
PSMB5 proteasome subunit beta 5 
PSMB6 proteasome subunit beta 6 
PSMB7 proteasome subunit beta 7 
PSMB8 proteasome subunit beta 8 
PSMB9 proteasome subunit beta 9 
PSMD7 proteasome 26S subunit, non-ATPase 7 
PSRC1 Proline/serine-rich coiled-coil 1 
PTEN phosphatase and tensin homolog 
PTGDR2 prostaglandin D2 receptor 2 
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PTGER1 prostaglandin E receptor 1 
PTGER2 prostaglandin E receptor 2 
PTGER3 prostaglandin E receptor 3 
PTGER4 prostaglandin E receptor 4 
PTGS1 prostaglandin-endoperoxide synthase 1 
PTGS2 prostaglandin-endoperoxide synthase 2 
PTK7 protein tyrosine kinase 7 (inactive) 
PTPN11 protein tyrosine phosphatase, non-receptor type 11 
PTPN6 protein tyrosine phosphatase, non-receptor type 6 
PTPN7 protein tyrosine phosphatase, non-receptor type 7 
PTPRC protein tyrosine phosphatase, receptor type C 
PTPRCAP protein tyrosine phosphatase, receptor type C associated protein 
PVR poliovirus receptor 
PVT1 Pvt1 oncogene (non-protein coding) 
PXYLP1 2-phosphoxylose phosphatase 1 
PYCARD PYD and CARD domain containing 
PYCR1 pyrroline-5-carboxylate reductase 1 
PYGL glycogen phosphorylase L 
RAC1 Rac family small GTPase 1 
RACGAP1 Rac GTPase activating protein 1 
RAD51 RAD51 homolog (S. cerevisiae) 
RAD51AP1 RAD51 associated protein 1 
RAD54L RAD54-like (S. cerevisiae) 
RAG1 recombination activating 1 
RB1 RB transcriptional corepressor 1 
RBM24 RNA binding motif protein 24 
RBX1 ring-box 1 
RDM1 RAD52 motif 1 
REL REL proto-oncogene, NF-kB subunit 
RELA RELA proto-oncogene, NF-kB subunit 
RELB RELB proto-oncogene, NF-kB subunit 
REPS1 RALBP1 associated Eps domain containing 1 
REV3L REV3 like, DNA directed polymerase zeta catalytic subunit 
RFC4 replication factor C subunit 4 
RGS20 regulator of G protein signaling 20 
RHOG ras homolog family member G 
RIC8A Resistance to inhibitors of cholinesterase 8 homolog A (C. elegans) 
RIPK2 receptor interacting serine/threonine kinase 2 
RMI2 RMI2, RecQ mediated genome instability 2, homolog (S. cerevisiae) 
RNASEH2A ribonuclease H2 subunit A 
RND2 Rho family GTPase 2 
RNF149 ring finger protein 149 
RNF4 ring finger protein 4 
RNFT2 Ring finger protein, transmembrane 2 
ROR2 receptor tyrosine kinase like orphan receptor 2 
RORC RAR related orphan receptor C 
RPL38 ribosomal protein L38 
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RPL6 ribosomal protein L6 
RPS19 ribosomal protein S19 
RPS6 ribosomal protein S6 
RPS7 ribosomal protein S7 
RPSA ribosomal protein SA 
RRAD Ras related glycolysis inhibitor and calcium channel regulator 
RRAS2 Related RAS viral (r-ras) oncogene homolog 2 
RRM1 Ribonucleotide reductase M1 
RRM2 Ribonucleotide reductase M2 
RTN1 reticulon 1 
RUNX1 runt related transcription factor 1 
RUNX3 runt related transcription factor 3 
S100A12 S100 calcium binding protein A12 
S100A8 S100 calcium binding protein A8 
S100A9 S100 calcium binding protein A9 
S100B S100 calcium binding protein B 
SALL2 spalt like transcription factor 2 
SAMD12 sterile alpha motif domain containing 12 
SAMD9 sterile alpha motif domain containing 9 
SAMHD1 
SAM and HD domain containing deoxynucleoside triphosphate 
triphosphohydrolase 1 
SCAMP5 secretory carrier membrane protein 5 
SCG3 secretogranin III 
SDHA succinate dehydrogenase complex flavoprotein subunit A 
SELE selectin E 
SELL selectin L 
SELPLG selectin P ligand 
SEMA4D semaphorin 4D 
SERINC2 serine incorporator 2 
SERPINA1 serpin family A member 1 
SERPINB2 serpin family B member 2 
SERPINB5 serpin family B member 5 
SERPINB7 serpin family B member 7 
SERPINE1 serpin family E member 1 
SGO1 shugoshin 1 
SGO2 shugoshin 2 
SH2D1A SH2 domain containing 1A 
SH2D1B SH2 domain containing 1B 
SHCBP1 SHC SH2-domain binding protein 1 
SIGIRR single Ig and TIR domain containing 
SIGLEC5 sialic acid binding Ig like lectin 5 
SIT1 signaling threshold regulating transmembrane adaptor 1 
SKA1 Spindle and kinetochore associated complex subunit 1 
SKA3 Spindle and kinetochore associated complex subunit 3 
SKAP2 src kinase associated phosphoprotein 2 
SKP2 S-phase kinase-associated protein 2, E3 ubiquitin protein ligase 
SLAMF1 signaling lymphocytic activation molecule family member 1 
SLAMF6 SLAM family member 6 
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SLAMF7 SLAM family member 7 
SLAMF8 SLAM family member 8 
SLC11A1 solute carrier family 11 member 1 
SLC25A3 solute carrier family 25 member 3 
SLC25A5-AS1 SLC25A5 antisense RNA 1 
SLC27A2 solute carrier family 27 member 2 
SLC2A1 solute carrier family 2 member 1 
SLC31A2 solute carrier family 31 member 2 
SLC35B1 solute carrier family 35 member B1 
SLFN11 schlafen family member 11 
SMAD2 SMAD family member 2 
SMAD3 SMAD family member 3 
SMAD7 SMAD family member 7 
SMPD3 sphingomyelin phosphodiesterase 3 
SMPDL3B sphingomyelin phosphodiesterase acid like 3B 
SNAI1 snail family transcriptional repressor 1 
SNAI2 snail family transcriptional repressor 2 
SOCS1 suppressor of cytokine signaling 1 
SOCS3 suppressor of cytokine signaling 3 
SOCS5 suppressor of cytokine signaling 5 
SOD1 superoxide dismutase 1 
SOX2 SRY-box 2 
SOX9 SRY-box 9 
SP100 SP100 nuclear antigen 
SP110 SP110 nuclear body protein 
SPANXACD 
sperm protein associated with the nucleus, X-linked, family members A1, 
A2, C, and D 
SPANXB1 SPANX family member B1 
SPANXN1 SPANX family member N1 
SPANXN3 SPANX family member N3 
SPANXN4 SPANX family member N4 
SPANXN5 SPANX family member N5 
SPC24 SPC24, NDC80 kinetochore complex component, homolog (S. cerevisiae) 
SPC25 SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae) 
SPDL1 Spindle apparatus coiled-coil protein 1 
SPI1 Spi-1 proto-oncogene 
SPIB Spi-B transcription factor 
SPIN4 Spindlin family, member 4 
SPINK1 serine peptidase inhibitor, Kazal type 1 
SPINK5 serine peptidase inhibitor, Kazal type 5 
SPN sialophorin 
SPOP speckle type BTB/POZ protein 
SPP1 secreted phosphoprotein 1 
SPTLC3 serine palmitoyltransferase long chain base subunit 3 
SRGN serglycin 
SSX1 synovial sarcoma X (SSX) breakpoint protein 
SSX2 SSX family member 2 and 2B 
ST6GAL1 ST6 beta-galactoside alpha-2,6-sialyltransferase 1 
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STAT1 signal transducer and activator of transcription 1 
STAT2 signal transducer and activator of transcription 2 
STAT3 signal transducer and activator of transcription 3 
STAT4 signal transducer and activator of transcription 4 
STAT5A signal transducer and activator of transcription 5A 
STAT5B signal transducer and activator of transcription 5B 
STAT6 signal transducer and activator of transcription 6 
STIL SCL/TAL1 interrupting locus 
STK32A serine/threonine kinase 32A 
STOX2 storkhead box 2 
SUSD3 sushi domain containing 3 
SUZ12 SUZ12 polycomb repressive complex 2 subunit 
SV2A synaptic vesicle glycoprotein 2A 
SVIL supervillin 
SYCP1 synaptonemal complex protein 1 
SYK spleen associated tyrosine kinase 
SYT17 synaptotagmin 17 
SYT4 synaptotagmin 4 
TAB1 TGF-beta activated kinase 1 (MAP3K7) binding protein 1 
TACC3 Transforming, acidic coiled-coil containing protein 3 
TACSTD2 tumor associated calcium signal transducer 2 
TAGAP T-cell activation RhoGTPase activating protein 
TAGLN transgelin 
TAGLN3 transgelin 3 
TAL1 TAL bHLH transcription factor 1, erythroid differentiation factor 
TAP1 transporter 1, ATP binding cassette subfamily B member 
TAP2 transporter 2, ATP binding cassette subfamily B member 
TAPBP TAP binding protein 
TARP TCR gamma alternate reading frame protein 
TBK1 TANK binding kinase 1 
TBX21 T-box 21 
TCF12 transcription factor 12 
TCF19 Transcription factor 19 
TCF7 transcription factor 7 (T-cell specific, HMG-box) 
TCL1A T-cell leukemia/lymphoma 1A 
TCL1B T cell leukemia/lymphoma 1B 
TDO2 tryptophan 2,3-dioxygenase 
TEDC2 tubulin epsilon and delta complex 2 
TEK TEK receptor tyrosine kinase 
TESC tescalcin 
TEX14 testis expressed 14, intercellular bridge forming factor 
TFF1 trefoil factor 1 
TFRC transferrin receptor 
TGFB1 transforming growth factor beta 1 
TGFB2 transforming growth factor beta 2 
TGFBI transforming growth factor beta induced 
TGFBR1 transforming growth factor beta receptor 1 
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TGFBR2 transforming growth factor beta receptor 2 
TGIF2 TGFB induced factor homeobox 2 
THAP11 THAP domain containing 11 
THBD thrombomodulin 
THBS1 thrombospondin 1 
THY1 Thy-1 cell surface antigen 
TICAM1 toll like receptor adaptor molecule 1 
TICAM2 toll like receptor adaptor molecule 2 
TIGIT T-cell immunoreceptor with Ig and ITIM domains 
TIMP1 TIMP metallopeptidase inhibitor 1 
TIRAP TIR domain containing adaptor protein 
TK1 Thymidine kinase 1, soluble 
TLDC1 TBC/LysM-associated domain containing 1 
TLR1 toll like receptor 1 
TLR10 toll like receptor 10 
TLR2 toll like receptor 2 
TLR3 toll like receptor 3 
TLR4 toll like receptor 4 
TLR5 toll like receptor 5 
TLR6 toll like receptor 6 
TLR7 toll like receptor 7 
TLR8 toll like receptor 8 
TLR9 toll like receptor 9 
TMBIM1 transmembrane BAX inhibitor motif containing 1 
TMEM173 transmembrane protein 173 
TMEM246 transmembrane protein 246 
TMPO Thymopoietin 
TNF tumor necrosis factor 
TNFAIP3 TNF alpha induced protein 3 
TNFAIP8 TNF alpha induced protein 8 
TNFRSF10A TNF receptor superfamily member 10a 
TNFRSF10B TNF receptor superfamily member 10b 
TNFRSF10C TNF receptor superfamily member 10c 
TNFRSF10D TNF receptor superfamily member 10d 
TNFRSF11A TNF receptor superfamily member 11a 
TNFRSF11B TNF receptor superfamily member 11b 
TNFRSF12A TNF receptor superfamily member 12A 
TNFRSF13B TNF receptor superfamily member 13B 
TNFRSF13C TNF receptor superfamily member 13C 
TNFRSF14 TNF receptor superfamily member 14 
TNFRSF17 TNF receptor superfamily member 17 
TNFRSF18 TNF receptor superfamily member 18 
TNFRSF19 TNF receptor superfamily member 19 
TNFRSF1A TNF receptor superfamily member 1A 
TNFRSF1B TNF receptor superfamily member 1B 
TNFRSF21 TNF receptor superfamily member 21 
TNFRSF25 TNF receptor superfamily member 25 
171 
 
TNFRSF4 TNF receptor superfamily member 4 
TNFRSF8 TNF receptor superfamily member 8 
TNFRSF9 TNF receptor superfamily member 9 
TNFSF10 tumor necrosis factor superfamily member 10 
TNFSF11 TNF superfamily member 11 
TNFSF12 TNF superfamily member 12 
TNFSF13 TNF superfamily member 13 
TNFSF13B tumor necrosis factor superfamily member 13b 
TNFSF14 tumor necrosis factor superfamily member 14 
TNFSF15 TNF superfamily member 15 
TNFSF18 tumor necrosis factor superfamily member 18 
TNFSF4 tumor necrosis factor superfamily member 4 
TNFSF8 tumor necrosis factor superfamily member 8 
TNFSF9 TNF superfamily member 9 
TOLLIP toll interacting protein 
TOP2A DNA topoisomerase II alpha 
TP53 tumor protein p53 
TP63 tumor protein p63 
TPSAB1 tryptase alpha/beta 1 
TPX2 TPX2, microtubule nucleation factor 
TRABD2A TraB domain containing 2A 
TRAF2 TNF receptor associated factor 2 
TRAF3 TNF receptor associated factor 3 
TRAF6 TNF receptor associated factor 6 
TRAP1 TNF receptor associated protein 1 
TRAT1 T cell receptor associated transmembrane adaptor 1 
TREM1 triggering receptor expressed on myeloid cells 1 
TREM2 triggering receptor expressed on myeloid cells 2 
TRIM21 tripartite motif containing 21 
TRIM22 tripartite motif containing 22 
TRIM29 tripartite motif containing 29 
TRIM59 tripartite motif containing 59 
TRIP13 thyroid hormone receptor interactor 13 
TROAP trophinin associated protein 
TSG101 tumor susceptibility 101 
TTK TTK protein kinase 
TUBB tubulin beta class I 
TWIST1 twist family bHLH transcription factor 1 
TWIST2 twist family bHLH transcription factor 2 
TXLNA taxilin alpha 
TXNIP thioredoxin interacting protein 
TYK2 tyrosine kinase 2 
TYMS Thymidylate synthetase 
TYROBP TYRO protein tyrosine kinase binding protein 
UBA6 ubiquitin like modifier activating enzyme 6 
UBE2C Ubiquitin-conjugating enzyme E2C 
UBE2T ubiquitin conjugating enzyme E2 T 
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UBE3A ubiquitin protein ligase E3A 
UHRF1 Ubiquitin-like with PHD and ring finger domains 1 
ULBP1 UL16 binding protein 1 
UNC5D unc-5 netrin receptor D 
UPK2 uroplakin 2 
UPK3A uroplakin 3A 
USP9Y ubiquitin specific peptidase 9, Y-linked 
VAV1 vav guanine nucleotide exchange factor 1 
VCAM1 vascular cell adhesion molecule 1 
VEGFA vascular endothelial growth factor A 
VEGFC vascular endothelial growth factor C 
VSIR chromosome 10 open reading frame 54 
VSNL1 visinin like 1 
VTCN1 V-set domain containing T-cell activation inhibitor 1 
VWDE von Willebrand factor D and EGF domains 
VWF von Willebrand factor 
WARS tryptophanyl-tRNA synthetase 
WASHC4 WASH complex subunit 4 
WDHD1 
multiple N-terminal WD40 domains and a C-terminal high mobility group 
(HMG) box 
WDR60 WD repeat domain 60 
WDR76 WD repeat domain 76 
WNK2 WNK lysine deficient protein kinase 2 
WNT5A Wnt family member 5A 
WNT7B Wnt family member 7B 
XAF1 XIAP associated factor 1 
XAGE1B_1E X antigen family member 1B and 1E 
XAGE2 X antigen family member 1A 
XAGE3 X antigen family member 3 
XAGE5 X antigen family member 5 
XCL1 X-C motif chemokine ligand 1 
XCL1_XCL2 X-C motif chemokine ligand 1 and 2 
XCR1 X-C motif chemokine receptor 1 
YWHAZ 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein zeta 
ZAP70 zeta chain of T cell receptor associated protein kinase 70 
ZBTB46 zinc finger and BTB domain containing 46 
ZEB1 zinc finger E-box binding homeobox 1 
ZIC5 Zic family member 5 
ZNF14 zinc finger protein 14 
ZNF205 zinc finger protein 205 
ZNF74 zinc finger protein 74 
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